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FACTORS ASSOCIATED WITH THE INCIDENCE AND SEVERITY OF 
NEONATAL ABSTINENCE SYNDROME IN INFANTS BORN TO OPIOID 
DEPENDENT MOTHERS  
 
Neonatal abstinence syndrome (NAS), the constellation of withdrawal symptoms 
experienced by neonates exposed to opioids prenatally, is an epidemic affecting an 
estimated 23,580 infants each year with an annual cost of $720 million.  The purpose of 
this study was to examine factors associated with the incidence and severity of NAS as 
measured by the need for initiation of neonatal medication, peak medication dose, 
hospital length of stay (LOS), and hospital costs among newborns born to opioid-
dependent mothers. A retrospective review of medical records was conducted with two 
convenience samples: 204 infants born to mothers who used opioids during pregnancy; 
and 121 of these infants who required treatment with morphine to control symptoms of 
NAS. Data from April 2011 to September 2017 were collected from medical records of a 
large Midwestern hospital. Exploratory analysis and descriptive statistics were 
performed.  
Associations between independent variables and outcomes were examined using 
correlations, chi-square, t-tests, analyses of variance, and linear regression. Of the 204 
neonates who were exposed to opioids prenatally, 121 (59%) developed symptoms of 
NAS requiring treatment with morphine. Neonates requiring morphine had significantly 
higher gestational ages than those who did not (37.7 vs 36.4 weeks; p = < .001) and their 
mothers were present at the neonates’ bedside a lower proportion of their total hospital 
ix 
stay (mean = 0.5684 of days vs 0.7384 of days; p = < .001). Compared to maternal use of 
buprenorphine, maternal methadone use was associated with higher peak morphine doses 
needed to control the neonate’s withdrawal symptoms (0.089 mg/kg versus 0.054 mg/kg; 
p = .023), and with longer hospital length of stay when compared to maternal use of 
buprenorphine and other opioid analgesics (34.2 vs. 20.8 vs. 22.5 days, respectively; 
p=0.02).  Higher visitation time from the primary caregiver was correlated with lower 
hospital LOS (r = -0.421; p = < .001).  Future research is needed to examine these 
relationships prospectively in a larger and more diverse sample. An effective response to 
the epidemics of opioid use during pregnancy and the incidence of NAS requires ongoing 
coordinated research and intervention in clinical care, public health, and health policy. 
 
Susan Rawl, PhD, RN, FAAHB, FAAN, Chair  
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CHAPTER ONE 
Background and Significance 
The Opioid Epidemic and Its Impact on Maternal Child Health 
The use of opioids in the United States, both prescription and illicit, has increased 
significantly in the past 10 years (Ailes et al., 2015). There were several policy and 
regulatory factors which contributed to this increase. Relaxing of the restrictions on laws 
regulating prescribing of opioids for the treatment of chronic non-cancer pain which 
occurred in the 1990s, resulted in an increase in opioid prescriptions (Edlund et al., 2014; 
Hansen, Noe, & Racz, 2014; Kuehn, 2007; Volkow, McLellan, Cotto, Karitanom, & 
Weiss, 2011; Vowles et al., 2015). In 2000, the Joint Commission on the Accreditation of 
Health Care Organizations (JCAHO) introduced new pain management guidelines and 
encouraged providers to be aware of the patient’s right to effective pain relief (Olsen, 
Daumit, & Ford, 2006; Phillips, 2000a; Vowles et al., 2015). As a result, the use of 
opioids for managing both acute and chronic pain was encouraged.  
Other factors that contributed to increased opioid prescribing include aggressive 
marketing by the pharmaceutical industry, promotion of opioids to and by physicians for 
chronic pain management, and reports in medical and lay literature that the dangers of 
opioid use were exaggerated (Manchikanti, Helm, Janata, Pampati, & Grider, 2012; 
Phillips, 2000b; Vowles et al., 2015). This increase in opioid use has created a public 
health crisis with serious and fatal consequences including higher rates of opioid 
overdose, opioid dependence disorder, and blood-related infectious diseases (CDC, 2011; 
SAMHSA, 2014).  
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In 2008, drug overdoses in the United States were responsible for 36,450 deaths 
(Jones, Mack, & Paulozzi, 2013). In 2016, the total number of drug overdose deaths rose 
to over 63,600 in the United States (Seth, Scholl, Rudd, & Bacon, 2018).  From 2015 to 
2016, deaths increased across all drug categories examined. The largest increases 
involved cocaine (52.4%) and synthetic opioids (100 %) (Seth et al., 2018). The rate of 
drug overdose deaths reported involving synthetic opioids (such as fentanyl) doubled 
from 2015 to 2016 (Hedegaard, 2017). The overall rate of reported drug overdose deaths 
increased from 6.1 per 100,000 in 1999 to 19.8 in 2016 (Hedegaard, 2017). The rate of 
increase varied during this time increasing by 10% per year from 1999 to 2006, then by 
3% per year from 2006 to 2014, and up by 18% per year from 2014 to 2016 (Hedegaard, 
2017; Seth et al., 2018). The rate of overdose deaths reported has continued to increase in 
all categories of opioids; synthetic, natural and semi-synthetic, and heroin and across all 
demographics, states, and urbanization levels (Hedegaard, 2017; Seth et al., 2018). 
In 2011, the Drug Abuse Warning Network (DAWN) estimated that about 2.5 
million emergency department (ED) visits resulted from medical emergencies involving 
drug misuse or abuse, the equivalent of 790 ED visits per 100,000 population. Between 
2004 and 2011, the annual overall number of ED visits attributable to drug misuse or 
abuse rose steadily each year for a total increase of 52 percent, or about 844,000 visits 
(SAMHSA, 2011).  
The rate of infectious disease, such as HIV and Hepatitis-C, also increased with 
the growth of injectable opioid use (Grigoryan et al., 2009). Researchers estimate 
approximately 3.5 to 3.9 million persons in the general population of the United States 
have chronic hepatitis C infections (Degenhardt et al., 2016; Han et al., 2017). Among 
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patients with hepatitis C, 53% have a history of illicit drug use (Aceijas & Rhodes, 
2007). The hepatitis C positivity rate among people who inject drugs is estimated to be as 
high 80-90% (Amon et al., 2008; Lavanchy, 2009; Smith, Combellick, Jordan, & Hagan, 
2015). Local infections such as abscesses and cellulitis are also extremely common 
among persons misusing intravenous drugs (Del Giudice, 2004). A small town in rural 
Indiana experienced one of the most notable infectious disease outbreaks associated with 
opioid addiction. Austin, Indiana (population 4,200) in rural Scott County made national 
news in March, 2015, after reporting 185 cases of HIV related to sharing of hypodermic 
needles and the widespread use of the synthetic opioid, Opana ER (Conrad et al., 2015; 
Ungar, 2015). 
 Opioid medications are obtained in two ways, through prescription or through 
illicit sources. These two avenues can be inter-related because as the number of 
prescriptions increase, drugs available for diversion to illicit use also increase (Compton 
& Volkow, 2006; Manchikanti, 2012). Chronic use of opioids and subsequent physical 
dependence leads to misuse or addiction in an estimated 14-35% of people who use 
opioids regardless of whether opioids were introduced through prescription or illicit use 
(Compton & Volkow, 2006; Couto, Romney, Leider, Sharma, & Goldfarb, 2009; 
Manchikanti, 2010; Vowles et al., 2015). 
Treatment of Opioid Use Disorder in the General Population 
Opioid Use Disorder (OUD) is classified by the Institute of Medicine (IOM) and 
the National Institutes of Health (NIH) as a chronic medical disorder. OUD is defined in 
the DSM V as a  problematic pattern of opioid use which leads to clinically significant 
impairment or distress and involving behaviors such as taking larger amounts than 
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intended, unsuccessful efforts to control opioid use, cravings or strong desire to use 
opioids, use of opioids interfering with role obligations, a great deal of time spent in 
activities necessary to obtain the opioid, taking opioids to relieve or avoid withdrawal 
symptoms, and recurrent opioid use in situations in which it is physically hazardous 
(Hasin et al., 2016).  
Guidelines for effective treatment of OUD recommend medication-assisted 
treatment (MAT). MAT is the use of FDA-approved medications, in combination with 
counseling and behavioral therapies, to provide a “whole-patient” approach to the 
treatment of substance use disorders (Kampman & Jarvis, 2015; SAMHSA, 2015; Soyka 
et al., 2011; Volkow, Frieden, Hyde, & Cha, 2014). The FDA has approved several 
different medications to treat opioid use disorder. A common misconception associated 
with MAT is that it simply substitutes one drug for another. However, the purpose of 
these medications is to relieve withdrawal symptoms and restore chemical imbalances in 
the body. Research on treatment efficacy has shown that when provided at the proper 
dose, medications used in MAT do not adversely affect the individual’s intelligence, 
mental capability, or physical function. Methadone, buprenorphine and naltrexone are 
medications which are recommended in MAT programs (SAMHSA, 2015). 
The history of identifying affordable and effective care and integrating this care 
model into public health policy began more than 40 years ago. In the early 1970s, under 
the leadership of Dr. Jerome Jaffe, director of the Special Action Office for Drug Abuse 
Prevention in the Executive Office of the White House, methadone maintenance 
programs, the most common MAT, became a major public health initiative to treat opioid 
addiction. Jaffe's office oversaw the creation of a nationwide, publicly-funded system of 
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treatment programs for opioid addiction (Center for Substance Abuse Treatment, 2005). 
The goal of these treatment programs was to move from addiction to maintenance to 
abstinence from all opioid drugs. This is usually achieved by a gradual weaning of the 
treatment medication (Kampman & Jarvis, 2015; Stotts, Dodrill, & Kosten, 2009). The 
treatment methods proven to be most effective for opioid addiction are often expensive 
and labor intensive in the short term. The extended length of treatment and need for 
quality support and supervision of patients can be difficult to accomplish due to funding 
shortages and difficulty ensuring treatment quality and proper oversight (Kolodny et al., 
2015; Lobmaier, Gossop, Waal, & Bramness, 2010). 
Methadone continues to be used today, but other medications have been added in 
the effective treatment of OUD. Buprenorphine is another approved medication used to 
treat OUD.  It is a partial opioid agonist. It has antagonistic properties as well which 
prevents euphoric effects. These qualities decrease abuse potential, increase safety, and 
cause fewer and less severe withdrawal symptoms with weaning and discontinuation 
(Gordon & Krumm, 2013; Lobmaier et al., 2010). It is being used increasingly as MAT, 
in part because it requires less supervision. Some studies indicate there may be concerns 
about retention in buprenorphine therapy, continued use of illicit drugs during treatment, 
and increased subsequent treatment needs (Bell, Trinh, Butler, Randall, & Rubin, 2009; 
Burns et al., 2015; Fiellin et al., 2008; Mattick & Hall, 1998)).  These issues may be 
resolved by adjusting the dosing regimen, as retention in a fixed dose program at a higher 
dose, rather than a flexible dose regime, is comparable to methadone for retention in the 
treatment program and suppression of illicit opioid use. (Mattick, Breen, Kimber, & 
Davoli, 2014). 
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There are four possible levels of care recommended for OUD which have varying 
levels of reimbursement provided by Medicaid and private insurers. Current available 
treatment for OUD includes short term (30 day) inpatient and outpatient abstinence-based 
programs; however, brief or extended period detoxification therapy has been shown to be 
less effective in the treatment of opioid addiction as compared to treatment and 
stabilization with MAT (Kampman & Jarvis, 2015; Sigmon et al., 2012; Stotts et al., 
2009). The addition of medication therapy serves a purpose in both biological and 
behavioral aspects of addiction, controlling symptoms of withdrawal with long-acting 
opioid agonist or partial agonist taken orally once daily and continuing a daily routine 
associated with drug administration (Bellg et al., 2004; Volkow, Frieden, Hyde, & Cha, 
2014). To better control the current nationwide problem of increasing opioid addiction, 
the IOM and NIH recommended relaxing the strict regulation of MAT and expansion of 
availability of treatment (Rudd, 2016; Volkow et al., 2014).  
Access to effective evidence-based treatment for OUD is often difficult to obtain. 
The current state of available services is inadequate in quality and quantity (Grogan et al., 
2016; Martin, Longinaker, & Terplan, 2015a; Stein et al., 2015; White House, 2016). 
Substance use disorder (SUD) is categorized as a chronic illness with the need for 
ongoing treatment and relapse prevention (Han, Compton, Jones, & Cai, 2015; Kampman 
& Jarvis, 2015). However, reimbursement for SUD has always been less than payment 
for other chronic diseases in both private and public health insurance plans (Andrews et 
al., 2015; Grogan et al., 2016). Addiction, and other substance-related disorders, are 
misunderstood and stigmatized conditions leading to policies which produce an 
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inadequate benefit structure, and restrictions on access to affordable and effective care 
(Andrews et al., 2015; Grogan et al., 2016; McLellan & Woodworth, 2014). 
Substance use disorder has never been viewed, treated, or insured like other 
illnesses. Many private insurance plans have never included addiction treatment in their 
coverage and most of addiction treatment financing has come from government sources, 
such as State Block grants and the Veteran’s Administration, with only a small portion 
from private insurance (McCabe, Cranford, & West, 2008; McLellan, Lewis, O'Brien, & 
Kleber, 2000). The Affordable Care Act does provide for a public health approach 
requiring health insurers to cover, and healthcare organizations to provide, prevention, 
screening and brief interventions for the full spectrum of substance use disorders, not just 
for the most severe (McLellan & Woodworth, 2014). 
It important to note there are wide disparities between US states in both coverage 
and availability for substance use disorder treatment. Many states do not cover all levels 
of care required for effective treatment which limits providers’ ability to make optimal 
choices for treatment (Grogan et al., 2016). Researchers conducted a recent survey on the 
increasing need for OUD treatment and the number of providers (Jones, Campopiano, 
Baldwin, & McCance-Katz, 2015).  They found the number of available services and 
providers continues to be deficient despite a marked increase in licensed providers 
between 2003 and 2012. The growth of providers did not keep pace with the increase in 
patients affected by OUD, leaving an estimated gap of nearly 1 million people nationally. 
The researchers’ findings demonstrate significant variation between states in treatment 
need and capacity, but with a majority of states still having higher rates of treatment need 
than treatment capacity (Jones et al, 2015). 
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Special Considerations for Treatment in Women 
Studies indicate women and men differ in both their substance abuse etiology and 
their access to addiction treatment (Greenfield et al., 2007; Hayes et al., 2011; CDC, 
2009; Tuchman, 2010; Winklbaur et al., 2008). Although men and women demonstrate 
similar rates of misuse of opioids, gender differences are found in their risk factors for 
misuse of prescription opioids (Jamison, Butler, Budman, Edwards, & Wasan, 2010). 
Women with opioid use disorder have different demographic, social, and health profiles 
than men with OUD. Women are more likely than men to report their first exposure to 
opioids was physician prescribed pain medications (52% versus 38%) (Bawor et al., 
2014; McHugh, Nielsen, & Weiss, 2015). Women are more likely than men to have 
experienced adverse childhood experiences such as childhood physical and sexual abuse 
(Jamison et al., 2010). Women who develop substance use disorders more frequently 
have antecedent comorbidities of major depression and other mental health disorders than 
men (Helmbrecht & Thiagarajah, 2008; Jamison et al., 2010)). Women are also more 
likely to have physical health problems, family history of mental illness, and greater 
childcare responsibilities (Bawor et al., 2014). Substance abuse treatment services that 
are gender-specific and tailored to the common barriers and facilitators described by 
women could enhance their entry into treatment (Grella, 2008; Tuchman, 2010). Very 
few programs offer specialized services for women and additional research is needed on 
the comparative effectiveness of programs of this type (Greenfield, Back, Lawson, & 
Brady, 2010; Messina, Grella, Cartier, & Torres, 2010).  
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Opioid Use during Pregnancy 
Pregnant women who misuse opioids present unique and concerning health risks 
to both themselves and their unborn children. The incidence of pregnancy complications, 
such as premature labor, poor fetal growth during pregnancy, complications at delivery, 
and infant and fetal loss is higher among women with OUD compared to the general 
population (Pinto et al., 2010); (Ordean, Kahan, Graves, Abrahams, & Kim, 2015). 
Women who use all types of illicit drugs have a preterm birth rate of 25% compared to 
9.6 % in the general population (Goel, Beasley, Rajkumar, & Banerjee, 2011; March of 
Dimes, 2015). The incidence of poor fetal growth or low birth weight (LBW) is 
significantly higher among women who use or misuse opioids during pregnancy than 
pregnant women in a control group (31% among women with OUD versus 5-8% in the 
general population) (Pinto et al., 2010). Mother’s use of opioids in pregnancy is also 
associated with complications during labor and delivery such as postpartum hemorrhage 
(OR 3.02), and operative or wound complications (OR 4.85) and for the infant metabolic 
acidosis with an increased risk of umbilical arterial pH less than 7.0 (OR 2.65) (Losso, 
Friedman, & Whitten, 2017). 
A mother’s use of opioids not only increases complications during pregnancy and 
delivery but also is associated with complications after birth such as inadequate maternal-
infant bonding, insecure infant attachment, and lack of maternal responsiveness to infant 
cues (Keegan, Parva, Finnegan, Gerson, & Belden, 2010; Mirick & Steenrod, 2016). 
Complications such as re-hospitalization of the infant, abuse, and neglect, and sudden 
unexplained infant death are also increased with maternal opioid use (Foulkes, 2015; 
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Friedman, Heneghan, & Rosenthal, 2009b; Nørgaard, Nielsson, & Heide-Jørgensen, 
2015).  
Substance use has been cited as one of the most common reasons to not seek 
adequate prenatal care (Friedman, Heneghan, & Rosenthal, 2009a; Phillippi, 2009).  
Inadequate or late prenatal care is often associated with a history of illicit substance use 
(Goettler & Tschudin, 2014). Barriers that inhibit pregnant women who use opioids from 
seeking prenatal care include fear that their substance use will be discovered, fear of 
losing custody of their child or child protective services involvement, stigma attached to 
use of drugs during pregnancy, lack of access to needed treatment and mental health 
programs, and lack of family or partner support (Ordean et al., 2015;  Ordean & Kahan, 
2011; Stone, 2015a). In a qualitative study of 36 women examining help-seeking 
behaviors, results indicate many women who used drugs during pregnancy did seek 
prenatal care but identified barriers which prevented follow through, such as fear of 
punitive actions from health care providers, or social service agencies. Other barriers 
identified included lack of access to substance abuse treatment programs and 
unsupportive partners (Jessup, Humphreys, Brindis, & Lee, 2003). 
Women who use opioids have a complex set of needs related to pregnancy care, 
including SUD treatment, behavioral evaluation and treatment, and social support which 
are frequently not being met by the conventional prenatal care system (Jones & 
Kaltenbach, 2013; Scott, Shieh, Umoren, & Conard, 2017; Winklbaur-Hausknost et al., 
2013). Early and comprehensive prenatal care are known to be crucial factors in 
improving pregnancy outcomes (Heaman, Newburn-Cook, Green, Elliott, & Helewa, 
2008; Hoyert, Mathews, Menacker, Strobino, & Guyer, 2006; Partridge, Balayla, 
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Holcroft, & Abenhaim, 2012). This is true for all women, including those using opioids, 
if the programs properly address the many specific needs of this population. Women with 
OUD have higher rates of co-morbidities such as psychiatric illness, trauma, and prior 
abuse and need treatment for these integrated into a comprehensive approach for prenatal 
care (Haug, Duffy, & McCaul, 2014). Pregnancy may serve as a sentinel event that 
motivates all mothers with substance use or misuse issues to modify their behavior in the 
interest of improved outcomes for their infants as well as themselves (Goettler & 
Tschudin, 2014). 
Treatment of Opioid Use Disorder during Pregnancy 
Pregnancy adds another layer of complexity to treating women with OUD 
(McLellan & Woodworth, 2014). Programs that provide comprehensive and coordinated 
treatment involving prenatal care, SUD services, behavioral health, and social support 
provide more complete treatment and achieve more consistent participation. Recent 
reviews of the literature examining prenatal care models used for women with substance 
use disorders indicated that a collaborative approach in a high-risk specialty clinic using a 
standard protocol for care may decrease stigma, improve attendance, and improve 
outcomes for both mothers with OUD and their infants (Goettler & Tschudin, 2014; 
Lewis, Wu, Prasad, & Locke, 2017; Milligan et al., 2010; Tarasoff, Milligan, Le, Usher, 
& Urbanoski, 2018). Women enrolled in programs integrating maternity care and 
treatment for SUD have improved outcomes such as attending more prenatal visits and 
less use of illicit drugs at the time of birth (Goler, Armstrong, Taillac, & Osejo, 2008; 
Jones et al., 2008; Jones, O’Grady, & Tuten, 2011). However prenatal clients with OUD 
often do not receive either adequate prenatal care or comprehensive OUD treatment 
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services (Goettler & Tschudin, 2014; Goler et al., 2012). There is a shortage of OUD 
treatment providers willing and able to accept pregnant women (Grella, 2008; Jackson & 
Shannon, 2012b). The lack of available services causes resistance among obstetrical care 
providers to screen adequately for substance misuse during prenatal care when they are 
unable to facilitate proper referrals in light of a positive drug screen (ACOG, 2013).  
Possible barriers and facilitators to seeking OUD treatment during pregnancy 
have been explored. Qualitative researchers examined the possible facilitators and 
barriers in pregnant women with opioid dependence and found they were often denied 
access to residential treatment programs because their situation was found to be "too 
complex” (Jessup et al., 2003). Pregnancy can be a barrier to selection of appropriate 
treatment regimes, as drug dependence in pregnancy is attached to additional stigma and 
requires provision of additional health care services that some treatment programs do not 
feel they can provide (Jackson & Shannon, 2012a, 2012b; Jessup et al., 2003; Martin, 
Longinaker, & Terplan, 2015b). The enabling factors that cause women to seek treatment 
for SUD include the desire to retain child custody and their concern for fetal and child 
well-being. Researchers found that a punitive approach toward the mother with threats 
and warnings is not a motivating factor and causes additional barriers to seeking care by 
generating distrust and therapeutic ambivalence between the mother and health care 
providers (Jackson & Shannon, 2012b; Jessup et al., 2003).  
Women’s negative prenatal care-seeking experiences, fear of discovery, and 
stigma limit utilization of services (Chandler et al., 2013; Stone, 2015a). If opioid use 
during pregnancy was promptly identified through early prenatal care and appropriate 
screening, many medical and social complications of perinatal opioid use could be 
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prevented for both the women and their children. Negative prenatal care experiences will 
also influence care-seeking behaviors in future pregnancies, and potentially also with 
seeking needed behavioral health services and SUD treatment, increasing the risk of 
future morbidity related to maternal opioid use (Jessup et al., 2003; Stone, 2015a).  
Opioid-Related Neonatal Abstinence Syndrome 
Neonatal Abstinence Syndrome (NAS), also known as neonatal drug withdrawal, 
is a condition characterized by a group of symptoms that occur in a newborn (infant less 
than 4 weeks of age) exposed to opioids via the placenta during gestation (Jansson, 
Velez, & Harrow, 2009; Jansson, 2012). Opioids cross the placenta and can cause 
dependency and subsequent withdrawal symptoms in newborns (McQueen, Murphy-
Oikonen, & Desaulniers, 2015). Maternal prenatal substance use of opioids places the 
infant at risk for developing opioid-related NAS (Murphy-Oikonen, Montelpare, 
Southon, Bertoldo, & Persichino, 2010). Symptoms of NAS include tremors, 
sleeplessness, irritability, high-pitched cry, excoriated skin, excessive sucking, poor 
feeding, diarrhea, sneezing, vomiting, and seizures (Nelson, 2013).   
 NAS was first recognized as a public health problem and named as a syndrome in 
the 1970s (Finnegan & MacNew, 1974). At that time there was a national problem of 
heroin addiction (Berridge & Mars, 2004; Kolodny et al., 2015). Biological research 
conducted in the 1970s focused on newborn infant’s reaction to prenatal heroin exposure, 
as well as reactions to methadone that was utilized in treatment of heroin addiction 
(Zelson, Lee, & Casalino, 1973). NAS is broadly defined with the essential attributes of 
1) opioid drug discontinuation 2) followed by appearance of specific physical withdrawal 
symptoms related to gastrointestinal, metabolic, and neurological systems (Finnegan, 
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Connaughton, Kron, & Emich, 1975; Hodding, Jann, & Ackerman, 1980; Kocherlakota, 
2014; Lall, 2008).  
The literature on NAS provides a general consensus for specific criteria used to 
identify the syndrome, such as prenatal exposure to opioids and the constellation of 
symptoms. There are two variations in the use of the term NAS, the first, which is the 
focus of this study, is related to prenatal substance exposure. The second is acquired 
dependence from analgesia and sedation provided during neonatal medical treatment. 
Iatrogenic opioid and benzodiazepine dependence may require medication to control 
symptoms and prolong hospital stays (Hudak & Tan, 2012) however, the two types are 
best examined separately because of the variations in context, etiology, biology, and 
social implications. In this study, newborns with iatrogenic NAS will not be included. 
The increasing incidence of NAS and related expenses has become a major public 
health concern. Between 2000 and 2009, the national incidence of NAS increased from 
1.2 per 1000 live births to 3.4 per 1000 births (Patrick et al., 2012). During the same time, 
prenatal opioid use increased 1.19 per 1000 births to 5.63 per 1000 (Patrick, Davis, 
Lehmann, & Cooper, 2015). The reason for this increase in maternal opioid use is varied 
and includes many of the same factors described in the general population, such as an 
increase in general opioid prescribing (Volkow, McLellan, Cotto, Karithanonom, & 
Weiss, 2011), steadily increasing use of illicit narcotics (Hayes & Brown, 2012), and 
mothers in opioid use disorder programs with opioid medication substitution (McCabe et 
al., 2008). These circumstances make opioid-related NAS the most significant problem in 
prenatal substance exposure. 
15 
Between 55% and 95% of infants prenatally exposed to opioids will experience 
symptoms of NAS severe enough to require treatment with medication, such as morphine 
solution (MacMullen, Dulsk, & Blobaum, 2014). Medication is needed by many infants 
with NAS due to potential life-threatening complications of seizures, poor oral feeding, 
and dehydration. Weaning from these opioid medications is often a protracted process 
requiring slow incremental weaning of medication. This process leads to extended NICU 
stays, disruption of family attachment, and altered developmental experience for these 
newborns (Logan, Brown, & Hayes, 2013; Welle-Strand, Skurtveit, Jones, et al., 2013).  
Neonatal abstinence syndrome is responsible for a significant and growing portion 
of the financial resources utilized in neonatal care. Rates of admission to NICU for 
diagnosis of NAS increased from 7 per 1000 admissions in 2004 to 27 per 1000 in 2013 
(Tolia et al., 2015). Length of hospital stay for NAS infants range from 7 to 42 days, 
creating substantial social and economic costs. The percentage of total NICU days 
attributable to NAS patients increased from 0.6% to 4% between 2000 and 2009 (Tolia et 
al., 2015). The total cost of treatment of NAS in the US has risen from approximately 
$190 million in 2000 to $720 million in 2009 (Patrick et al., 2012). In 2009, the estimated 
number of newborns with NAS was 13,539 or approximately one infant born every 39 
minutes in the United States with symptoms of drug withdrawal (Patrick, Davis, Lehman, 
& Cooper, 2015). 
Infants diagnosed with NAS are more often insured by Medicaid as compared to 
other births (81.5% vs 46.4%; p <0.001) (Patrick et al., 2015). Over 73% of NAS births 
in 2004 and 82.0% of NAS births in 2014 were insured by Medicaid (Winkelman, 
Villapiano, Kozhimannil, Davis, & Patrick, 2018). Among infants insured by Medicaid, 
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the incidence of NAS rose to 14.4 per 1000 births in 2014 (Winkelman et al., 2018). The 
estimated total hospital costs for NAS births insured by Medicaid was $462 million in 
2014 (Winkelman et al., 2018). The increased burden on public resources is a concern for 
health care providers, policymakers, and elected officials and has increased attention and 
urgency in developing clinical care and health policies, which will reduce the incidence 
of maternal opioid use, reduce the occurrence of NAS, and decrease related costs (GAO, 
2015; Warren, Miller, Traylor, Bauer, & Patrick, 2015). 
Identifying Infants at Risk for NAS 
Agreement on the most effective methods for identifying infants at risk for NAS 
is difficult to achieve because of the many biological and psychosocial factors that 
potentially act as mediators and moderators (Hall et al., 2014; L. M. Jansson & Velez, 
2011). Components include universal screening of mothers during prenatal care to 
ascertain exposure to opioids and obtaining a thorough history to determine the infant’s 
potential risk factors.  
Identification of risk for NAS begins with identifying opioid use during 
pregnancy. Intrauterine exposure to opioids is the essential component which places a 
neonate at risk for developing NAS, but the severity and length of treatment can vary 
significantly, even between infants exposed to the same opioid (Abrahams, Chase, 
Desmoulin, Roukema, & Uddin, 2012; Lind et al., 2015; Murphy-Oikonen et al., 2010). 
Current guidelines from the American Academy of Obstetrics and Gynecology (ACOG) 
recommend screening all pregnant women for opioid use disorder by history (ACOG, 
2013). Universal screening is felt to decrease stigma associated with selected or risk-
based screening (Hotham, Ali, White, Sullivan, & Robinson, 2013; Seib et al., 2012). The 
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addition of urine drug testing can be used to detect or confirm suspected substance use 
but must be done only with the patient’s consent and according to state laws (ACOG, 
2013). 
Identification of opioid use in pregnancy is important for other reasons besides 
predicting risk of NAS. It facilitates the mother’s entry into appropriate services, 
addiction treatment and behavioral therapy if needed, and facilitates preparation for 
parenting and management of neonate (WHO, 2014). Prenatal care provides a unique 
entry point to coordinate services for addiction therapy and behavioral health because of 
additional maternal motivation of protecting fetal well-being.  Additional needed services 
can be incorporated into routine prenatal care and specialized treatment coordinated 
throughout pregnancy and into the postpartum period (Jones et al., 2014).  
Toxicology screening of the neonate at birth is another strategy for identifying 
infants at risk. Toxicology screening in not intrusive; it can be done with urine, 
meconium, or umbilical cord tissue samples. Screening at birth augments maternal 
screening and increases the likelihood of attaining accurate information regarding 
substance exposure of the infant (Murphy-Oikonen et al., 2010). 
Assessing Severity of NAS and Need for Treatment 
Two areas of neonatal abstinence care, assessment of symptoms, screening, and 
neonatal medication treatment guidelines have achieved improved consistency in the past 
decade through meta-analysis, integrative review, and the subsequent development of 
consensus and expert opinion-based clinical guidelines. Professional guidelines have 
been developed in assessing severity of symptoms and need for treatment. The American 
Academy of Pediatrics (AAP) published formal practice guidelines first in 1993 (AAP, 
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1993) and then revised recommendations in 2012 (Hudak & Tan, 2012). The committee’s 
report included information on the scope of the problem, clinical presentation, and 
recommendations for identification and treatment of opioid withdrawal. Key 
recommendations for use in clinical practice included the use of valid and reliable 
screening tools to guide treatment (Hudak & Tan, 2012; AAP, 2012). 
Various diagnostic tests of the neonate can be utilized to detect the presence of 
opioids or other illicit drugs including blood sampling, urine drug screen, umbilical cord 
tissue sample, and meconium drug testing. Unfortunately, all these diagnostic tests have 
limitations in their ability to help identify NAS. Toxicology screening can be negative in 
the presence of exposure and exposure alone does not guarantee development of the 
symptoms of NAS (Kuschel, Austerberry, Cornwell, Couch, & Rowley, 2004). 
Standardized instruments are necessary for assessing the severity of NAS symptoms and 
guiding treatment with an opioid substitute, as well as non-pharmacologic comfort 
measures (Ebner et al., 2007; Murphy-Oikonen et al., 2010). Choosing a valid and 
reliable measure, training staff adequately, and monitoring consistency of measurement 
are important considerations when establishing a screening method (Jensen, 2014; 
Retskin & Wright, 2014). NAS is comprised of constellation of opioid withdrawal signs 
that involve multiple body systems, CNS, gastrointestinal, and metabolic/autonomic (Bio, 
Siu, & Poon, 2011). Comprehensive screening tools should reflect symptoms related to 
each of these systems and provide a basis of uniform, objective criteria for the assessment 
and treatment of the neonate (Finnegan, 2010). 
The first published scoring instrument for severity of NAS was developed by 
Loretta Finnegan and associates in the 1970s, in response to the increasing use of heroin 
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and subsequent identification of neonatal drug withdrawal (Finnegan, Kron, 
Connaughton, & Emich, 1975). The term neonatal abstinence syndrome was first defined 
by Dr. Finnegan and used exclusively to refer to infants exposed prenatally to heroin 
(Finnegan & MacNew, 1974). A scoring system was developed as a clinical and 
investigative tool. The score was designed to monitor opioid exposed infants in a more 
comprehensive and objective manner than clinical judgement alone (Finnegan, Kron, et 
al., 1975). The tool was also used to evaluate the efficacy of different treatments and the 
progression of withdrawal symptoms before, during, and after therapy. The Modified 
Finnegan Scoring Tool has become the gold standard and is widely used in clinical care. 
It had a high inter-rater reliability coefficient of 0.82 when initially developed (Finnegan, 
1976; Finnegan, Connaughton, Kron, & Emich, 1975). The instrument’s use over a long 
period of time has provided an opportunity for modification and improvement, as well as 
increased familiarity and consistency among providers (Kocherlakota, 2014; Kron, 
Finnegan, Kaplan, Litt, & Phoenix, 1975). 
The Lipsitz score is also used in some clinical settings (Lejeune, Simmat-Durand, 
Gourarier, & Aubisson, 2006; Lipsitz, 1975). It covers symptoms in multiple areas but 
has fewer items than the Finnegan scale and so is felt to be easier to use (Colombini et al., 
2008). The decreased number of scoring items does decrease the time involved and ease 
of use, however issues with consistency among raters has brought questions of reliability 
with the instrument (O'Grady, Hopewell, & White, 2009).  
There are several instruments currently in development with testing at individual 
clinical sites, but no other tools widely used. The subjectivity of the current instruments is 
controversial and some advocate using objective measures alone, such as adequate oral 
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feeding and weight gain (Hunseler, Bruckle, Roth, & Kribs, 2013). An instrument using 
an additional objective measure of sucking quality, measured by an electronic pacifier 
that provides data on strength, consistency, and length of sucking burst, is a novel 
approach (Kron, Litt, Phoenix, & Finnegan, 1976). Although the addition of more 
objective measurement will likely improve consistency of scoring between caregivers, 
the equipment necessary is not commonly available in clinical settings (Bagley, 
Wachman, Holland, & Brogly, 2014). 
Unfortunately, the sensitivity and specificity of current objective instruments of 
assessment of withdrawal intensity are only slightly more reliable when compared to 
subjective clinical judgment (Bagley et al., 2014). The most common difficulties reported 
with their use by clinical staff, are the need for detailed and consistent training and 
regular continuing education and updates to insure inter-rater reliability (Zahorodny et 
al., 1998).  
Another limitation to current tools is their focus on behaviors of the newborn in 
the first few days of life. During prolonged hospitalizations for treatment, tools become 
developmentally obsolete for older neonates. Clinicians often use untested variations, 
such as dropping items from the tool that are no longer developmentally appropriate, such 
as sleeping three hours between feeding, or weighting gastrointestinal symptom items 
more heavily in their treatment and weaning decisions (Retskin & Wright, 2014). Some 
facilities report switching to a basic pediatric pain assessment tool rather than an 
instrument specific to NAS (D'Apolito, 2014). 
In clinical practice there is a high degree of variability in assessment of NAS 
symptoms that range from use of published abstinence tools to inconsistent clinical 
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assessment strategies (Bagley, Wachman, Holland, & Brogly, 2014). Infants are typically 
scored every 3-4 hours with feedings and decisions on increasing and weaning 
medication are based on these scores. Treatment decisions based on these scoring 
strategies make this a crucial area for improvement to reduce length of stay. The 
American Academy of Pediatrics (AAP) recommends use of a standardized tool such as 
the gold-standard modified Finnegan abstinence assessment for evaluation of NAS (AAP, 
2012). They also recommend an ongoing inter-observer reliability program to improved 
consistency and quality.  
Guidelines for Treatment of NAS 
Infants who experience clinically significant symptoms, as identified by a 
standardized screening tool, should be treated with appropriate pharmacotherapy. The 
amount and type of medication which best controls symptoms and reduces length of stay 
has been the primary research question in several studies (Bagley et al., 2014; Jones & 
Fielder, 2015). National recommendations to guide practice and treatment have been 
developed by professional organizations (AAP, 2012; SAMSHA, 2014). These 
guidelines, and the increased use of institutional protocols, have improved consistency in 
medication regimes, but there remains a great deal of variability in practice. There are 
still many questions and inconsistencies surrounding choice of opioid, dosing schedule, 
and weaning protocols (Jensen, 2014).  
The most efficacious treatment for NAS cannot be easily determined, because of 
the lack of sufficient controlled studies comparing medications (Ebner et al., 2007). 
Recent reviews and meta-analysis warn there is a lack of high-quality evidence to support 
specific treatments. Current guidelines are based on expert opinion and clinical consensus 
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and recommend the use of an opioid to control symptoms (Osborn & Cole, 2010; 
Kuschel, 2007). 
Initial treatment protocols for NAS favored sedation with a medication such as 
phenobarbital and these sedatives are still used, particularly when infants are exposed to 
multiple substances in utero (Osborn & Cole, 2005). The increased number of infants 
diagnosed with NAS brought increased experience for care providers in caring for these 
infants and problem areas were identified with this approach.  First, sedative medications 
controlled CNS symptoms only and had no effect on metabolic/autonomic, or 
gastrointestinal effects of opioid withdrawal. Also, it was difficult to be certain these 
sedative medications were even effectively managing the CNS symptoms since infants 
cannot describe their experience. Medications other than opioids could potentially be 
masking, but not controlling, discomfort (Osborn, & Cole, 2010). In addition, 
collaboration with adult addiction specialists confirmed these potential problems based 
on their experiences with patients who were able to communicate directly about the 
experience and side effects of various agents used for MAT (Greenfield et al., 2007). 
Using an opioid medication for neonatal treatment was also found to decrease symptoms 
and shorten length of hospitalization when compared to phenobarbital (Ebner et al., 
2007). In their 2012 consensus statement on opioid exposed neonates, the AAP 
confirmed opioid medications as the recommended pharmacotherapy for NAS (AAP, 
2012; Osborn et al., 2010). 
For NAS there are several possible choices for opioid medication: methadone, 
tincture of opium, oral morphine preparations, and buprenorphine are the recommended 
treatment options. Methadone is the most common choice for opioid therapy in adults and 
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also has been utilized for treatment of NAS. Methadone has the advantage of over three 
decades of patient use and testing for opioid dependence (Cleary et al., 2013; Inturrisi, 
Colburn, Kaiko, Houde, & Foley, 1987; Mattick et al., 2014; Mattick & Hall, 1998). It is 
known to be effective in adults, has low patient drop-out rates when used in OUD 
therapy, and its pharmacokinetics have been well-studied. However, there are several 
limitations to its use in infants with NAS. The long half-life of methadone, 26 hours in 
neonates, make timely dose adjustments and weaning difficult. This long half-life may 
also contribute to dose stacking and drug accumulation in the infant (Hudak & Tan, 2012; 
Madden et al., 1977).  
Morphine-containing, tincture of opium provided the first alternative to 
methadone. Tincture of opium has been used safely and effectively in neonates for the 
treatment of NAS (Ebner et al., 2007; Sarkar & Donn, 2005; Lifshitz, Gavrilov, Galil, & 
Landau, 2001). Tincture of opium was the drug recommended for NAS by the AAP in 
their 1998 position statement (AAP, 1998). It was preferred to other available opioid 
preparations at that time because it contained less alcohol and other potentially harmful 
additives (Bio et al., 2011). There are some concerns about the formulation of tincture of 
opium. It is a combination medication with other alkaloid components (such as alcohol), 
which have effects and the alkaloid content is not standardized, so there is a question of 
the consistency and amount of active substance per dose. 
Another alternative for neonatal opioid medication is oral morphine solution. Oral 
morphine solution is a feasible option with no questionable additives or alcohol (Jackson, 
Ting, McKay, Galea, & Skeoch, 2004). It has been shown to be effective in controlling 
central nervous system/ autonomic and gastrointestinal symptoms in comparisons to 
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phenobarbital and methadone without excessive sedation (Bada et al., 2015; Hudak & 
Tan, 2012; Kokotajlo, Robinson, & Presti, 2013). The half-life of morphine solution in a 
neonate is 6-8 hours, allowing for flexibility with dosing amount and frequency if 
indicated by NAS scoring tools (Bio et al., 2011; Colombini et al., 2008). In a 
comparison of tincture or opium and morphine solution, researchers showed similar 
Finnegan scores and length of stay between the two medications, with improved weight 
gain in the morphine group (Langenfeld et al., 2005). 
Buprenorphine recently has been investigated as an option for treatment of NAS. 
Its use in the treatment of adults with opioid dependence has increased significantly in the 
past few years. It has desirable properties in addiction treatment, as it is long acting and 
has pharmacokinetics properties which are abuse deterrents. Buprenorphine is a partial 
mu opioid receptor agonist/antagonist, which binds to the mu opioid receptor with high 
affinity but has low intrinsic activity resulting in milder analgesia and euphoria, and it 
also blocks the binding of other mu agonists such as morphine (Brogly, Saia, Walley, Du, 
& Sebastiani, 2012; Metz et al., 2011). Buprenorphine is beginning to be examined as an 
alternative treatment for NAS. A randomized, open-label, control study of buprenorphine 
for the treatment of NAS was done comparing the agent to standard treatment with 
tincture of opium (Kraft et al., 2008). Dosing decisions for both groups were made by a 
standardized and reliable instrument (modified Finnegan scoring system). The infants 
assigned to the buprenorphine group had a shorter length of treatment and a shorter 
hospital stay (Kraft et al., 2008). The clinical group involved in the study has continued 
to use buprenorphine for treatment of NAS on their units and has further revised their 
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clinical guidelines and dosing based on continued experience with the medication (Kraft 
et al., 2011; Kraft & van den Anker, 2012). 
Adjunctive therapy with phenobarbital and clonidine may be used with opioid 
medication for NAS, particularly when there is a maternal history of polysubstance use 
(Bio et al., 2011). Clonidine is used in pain management for adults and children, both as a 
primary medication and an adjunct with an opioid (Cox & Pappagallo, 2001). Clonidine 
also is used in combination with an opioid substitute to treat withdrawal symptoms in 
older children and adults (Cox & Pappagallo, 2001). Researchers compared addition of 
clonidine with standard therapy of an opioid and found reduced length of treatment and 
reduced peak doses of opioid were needed (Agthe et al., 2009). In a case study review of 
neonates treated with clonidine as a primary agent for opioid withdrawal infants had 
Finnegan scores < 8 (mean 6) and length of treatment average at 6.4 days. However, this 
study is limited in generalizability to all NAS patients, as the subjects were mostly 
preterm neonates with a mean gestational age of 30.1 weeks (range 24 to 40) and eleven 
of fourteen were iatrogenic exposure from treatment in the intensive care unit with a 
fentanyl drip. Only three infants were born to mothers who used opioids throughout 
pregnancy (Leikin et al., 2009). Both decreased gestational age and exposure to opioids 
after birth are known to decrease severity of NAS symptoms and length of treatment. The 
lack of current information is reflected in the AAP Committee on Drugs statement which 
recommends that larger clinical trials and additional pharmacologic data are needed 
before the routine use of clonidine can be recommended for treatment of NAS (AAP, 
2012).  
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Phenobarbital, although decreased in use as a primary treatment, is still 
recommended as an adjunct therapy, particularly in infants exposed to maternal 
polysubstance use. A meta-analysis of phenobarbital use in NAS from the Cochrane 
group found reduced length of stay, reduced treatment failure and decreased NAS scores 
on standardized measures when compared to supportive care or opioid use alone (Osborn 
et al., 2005). The group does recommend further studies on safety and efficacy, as well as 
investigation of possible long-term effects of use on infants’ developmental outcomes 
(Osborn et al., 2005). 
Non-pharmacological Treatment Strategies of NAS 
Recently several studies examined non-pharmacologic treatments such as 
acupuncture, acupressure, and rocking beds, as well as other non-opioid medications, for 
treatment of NAS but thorough discussion of these interventions is beyond the scope of 
review undertaken for this project (Boucher, 2017; Cox & Pappagallo, 2001; D'Apolito, 
1999; Hall et al., 2014).  
Currently in the United States, the most common model for environment of care 
in NAS patients is transfer to a neonatal intensive care unit (NICU) for observation and 
treatment.  Kaiser Family Foundation estimates the cost per day of all diagnoses for 
inpatient care including physician billing, hospital costs, and ancillary services to be 
$2212 for the US and $ 2240 for the state of Indiana (http://kff.org/other/state-
indicator/expenses-per-inpatient-day). In contrast, the average cost for a NICU stay for 
all diagnoses is about $10,000 (Phibbs, Williams, & Phibbs, 1981).  
The hospital in which the data for study of maternal, infant, and environmental 
factors affecting medication use and length of hospital stay was conducted has a 26-bed 
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NICU and a 15-bed pediatric inpatient unit. A survey of case management records for the 
facility over the past six years, using cases identified for this study indicated an average 
cost for infants with a diagnosis of NAS of $4238 per day when cared for in the NICU. 
Daily costs for infants transferred to the inpatient pediatric unit for weaning of 
medication after initial treatment in NICU was lower at $2852. The charge for newborn 
nursery/ post-partum days was much lower at about $750 per day. The excessive cost of 
inpatient care makes reducing length of stay a priority, even 2-6 days results in a 
significant cost savings. There are other potential deleterious factors related to transfer of 
the newborn to the NICU such as separation from mother, difficulty maintaining 
breastfeeding, and interruption of maternal infant bonding (Brenneman & Price, 2014). 
There are significant gaps in knowledge concerning many factors that may 
aggravate or ameliorate the illness course of infants with NAS. There are several factors, 
other than choice of medication substitution and weaning protocol, which have been 
identified in literature as possible contributors to the onset and severity of symptoms of 
NAS and subsequently to length of stay and hospital cost. These are typically not the 
focus of the study but mentioned as possible confounding factors and have received 
minimal attention. These factors include maternal history and demographics, exposure to 
other drugs, maternal tobacco use, feeding method, social support, family involvement, 
non-pharmacologic treatment measures, and experience of caregivers.  
A more thorough examination of such non-pharmacologic factors could direct 
future research and facilitate development of more innovative and effective interventions 
related to care delivery for NAS patients. Maternal and infant screening and clinical care 
guidelines that have potential to decrease infant illness, decrease medication needs, limit 
28 
inpatient hospital stay, and costs are priorities for this population. The purpose of this 
study was to examine several of these factors which may be associated with severity of 
NAS, as measured by need for medication treatment and peak medication dose, length of 
hospital stay, and hospital cost in infants exposed to opioids prenatally. 
A retrospective review of electronic and paper medical records was conducted 
with a convenience sample of 204 infants born to mothers who used opioids during 
pregnancy and 121 infants who then received medication treatment with morphine 
solution for symptoms of NAS from April 2011 to September 2017 at a large Midwestern 
hospital. Exploratory analysis and descriptive statistics were performed using IBM-SPSS 
statistical software package. Associations were analyzed related to the independent 
variables and the outcomes of interest.  
Purpose and Aims 
The purpose of this study was to examine factors associated with severity of NAS 
as measured by the outcome variables of use of neonatal medication (yes/no), peak 
medication dose (morphine solution in mg/), hospital length of stay (LOS), and calculated 
total hospital costs among newborns born to opioid-dependent mothers. Specific aims are 
to:  
Aim 1. Identify what proportion of all infants prenatally exposed to opioids will 
develop symptoms that require initiation of neonatal medication to control symptoms 
during their first week of life. 
Aim 2. Identify what maternal, infant, and environmental factors are associated 
with initiation of neonatal medication for treatment of NAS. 
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Aim 3. Among infants who receive medication, examine maternal factors (e.g. 
age, parity, race, reason for opioid use, type of opioid used during pregnancy, tobacco 
use) that are associated with level of peak morphine dose, hospital stay length of stay and 
hospital cost.  
Aim 4. Among infants who receive medication, examine infant factors (e.g. 
gestational age, birthweight, and sex) that are associated level of peak morphine dose, 
hospital length of stay, and hospital costs. 
Aim 5. Among infants who receive medication, examine environmental factors 
(e.g. type of inpatient unit, type of feeding method: breastmilk/formula, presence of 
primary caregiver, and use of non-pharmacologic interventions) that are associated with 
level of peak morphine dose, hospital length of stay, and hospital costs. 
Conceptual Framework 
Based on the review of literature a conceptual model was developed to reflect 
possible factors associated with the immediate outcomes of initiation of neonatal 
medication, hospital length of stay, and hospital costs. Research which formed the basis 
for the current care model for post-partum mothers and normal newborns was guided by 
attachment theory (Bretherton, 1992). More recently, regulation theory (Schore, 2001; 
Schore & Schore, 2008) was developed based on attachment theory. It is a more detailed 
examination of the neurobehavioral reactions developed during attachment. Regulation 
Theory examines potential causes of the positive effects observed from secure attachment 
and positive interaction. The theory has been utilized in other infants who experience 
prolonged separation due to admission in the NICU, such as premature infants (Weber, 
Harrison, & Steward, 2012). Many concerns related to infant behavior and development 
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that are felt to be improved by close maternal contact, such as improved feeding, infant 
emotional stability, and improved sleep, are closely related to the symptoms of NAS 
patients.  Neurobehavioral and biochemical reactions facilitated by secure attachment 
influence the development of the infant’s mood regulation and coping capacity (Schore, 
2001). Influences of secure attachment on structural development of the right brain, 
dopamine release, endogenous opiate release, and sensory control (Schore, 2001) provide 
a mechanism for amelioration of many NAS symptoms. A comprehensive illustration of 
the model is contained in Appendix B.  Figure 1 below illustrates the factors that were 
addressed in this study. 
 
 
 
 
Figure 1:  NAS Conceptual Model 
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Review of Literature: Factors that Affect the Severity of Neonatal Abstinence 
Syndrome 
The increasing incidence and cost of neonatal abstinence syndrome (NAS) make 
it imperative to develop evidence-based practice guidelines for assessment and care of 
these neonates. An evaluation of current literature for best practice of management of 
neonates with NAS was undertaken which focused on three areas: identification of 
neonates at risk for developing NAS, valid and reliable instruments for assessing severity 
of symptoms and determining need for treatment, and guidelines for effective treatment. 
This study will concentrate on factors that may affect the development and severity of 
symptoms and environment of treatment components that may affect the severity of NAS 
and hospital course. Several key factors in each of these categories that are included in 
the complete conceptual model will not be examined in this study because either it is not 
possible to retrieve adequate information from the medical record to evaluate the factor, 
or there is not enough variability among the patient sample. These factors will be 
discussed briefly in each of the sections to illustrate their importance in future research. 
Potential mediators that may contribute to the exposed infant’s risk of developing 
clinically significant symptoms of withdrawal are also important in assessing risk. The 
relationship of these factors to outcomes is not well explored but they are often discussed 
as an incidental finding in studies with a primary research question that focus on 
medication regimens for the mother or the infant (Johnson, Jones, & Fischer, 2003; Jones 
et al., 2012; Kaltenbach et al., 2012). These influencing factors can be distributed in three 
categories: maternal, infant, and environmental. Maternal factors include issues related to 
mother’s current drug use, such specific opioid drugs used, prescription of illicit use, use 
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of other prescription or illicit drug outside the opioid family, and use of tobacco. Infant 
factors examined are gender, birthweight, and gestational age.  
Potential moderators of NAS severity related to potential treatment are the 
medication choices and environment of treatment factors that may influence the amount 
and severity of symptoms. Environment of treatment factors include non-pharmacologic 
treatments, such as swaddling, sleep promotion, use of rocking beds, location and 
atmosphere of treatment. The course of NAS can also be impacted by healthcare provider 
characteristics, such as inter-observer reliability in the NAS scoring and experience and 
training. A care environment of rooming-in with mother as compared to transfer to a 
neonatal intensive care unit, choice of breastmilk feeding, and infant care by a consistent 
family or primary caretaker involvement also are potential factors that influence the 
severity of NAS. Other pharmacologic treatment components include choice of 
medication for the neonate and use of adjunct medication to control symptoms when the 
primary medication is not sufficient.  
Maternal Factors 
The maternal factors examined in this study were: 1) source of opioid use 2) 
primary type of opioid used 3) use of other drugs/ medications 4) Tobacco use. 
The largest portion of current research on these potential mediators involves 
maternal factors. These include comparisons of outcomes with different drugs chosen for 
maternal MAT (Jones, Kaltenbach, Heil, Stine, Coyle, Arria, O'Grady, et al., 2010; Patel 
et al., 2013; Welle-Strand, Skurtveit, Jansson, Bakstad, Bjarko, et al., 2013; Wiegand et 
al., 2015) and the influence of exposure to other drugs, such as selective serotonin 
reuptake inhibitors (SSRIs) and benzodiazepines (Jansson et al., 2012; Wachman, 2011) 
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(Cleary et al., 2012; McQueen et al., 2015). Maternal tobacco use has also been 
mentioned as a potential risk factor for NAS (Chisolm et al., 2011; Jones et al., 2013).  
Recommended prenatal treatment for the women with opioid addiction is 
medication-assisted treatment (MAT) with an opioid replacement (ACOG, 2012). This 
provides consistency in fetal medication exposure, better compliance with prenatal care, 
and MAT is more effective in preventing relapse than abstinence treatment programs as it 
addresses both biologic and behavioral aspects of withdrawal (Baker, Japuntich, Hogle, 
McCarthy, & Curtin, 2006). Methadone is currently the recommended drug of choice for 
maternal MAT (Kraft & van den Anker, 2012).  
Recently, additional drugs have become available for medication maintenance 
therapy (buprenorphine and buprenorphine+ naloxone) (Winklbaur et al., 2008). Three 
studies compared buprenorphine (BMT) versus methadone (MMT) for maternal MAT 
(Jones, Kaltenbach, Heil, Stine, Coyle, Arria, O’Grady, et al., 2010; Welle-Strand, 
Skurtveit, Jansson, Bakstad, Bjarko, et al., 2013; Wiegand et al., 2015). One study 
compared buprenorphine versus non-buprenorphine opiate substitution, or non-opiates 
(Patel et al., 2013). All four studies found improved short-term perinatal outcomes such 
as increased GA, birthweight, and OFC with BMT. Two studies (Jones, Kaltenbach, Heil, 
Stine, Coyle, Arria, O'Grady, et al., 2010; Wiegand et al., 2015) also found significantly 
lower length of stay for the BMT exposed infants. In one study, treatment for neonates 
was completed as outpatients so length of stay was known but there was significant 
missing data for length of treatment (Patel et al., 2013). Maximum morphine doses were 
higher in the non-buprenorphine group in this study. There was no difference in need for 
medication treatment or peak NAS scores in three of the studies. However, Wiegand 
34 
(2015) did show a decreased incidence of NAS diagnosis and need for treatment. Three 
study designs were retrospective chart review but the study by Jones et al (2010) was a 
blinded randomized controlled study assigning women to MMT or BMT. An aspect 
worth consideration in this study was a higher maternal dropout rate that was statistically 
significant in the BMT group (33% versus 18% in MMT; P <.02) (Jones, Kaltenbach, 
Heil, Stine, Coyle, Arria, O'Grady, et al., 2010). 
Benzodiazepines are often prescribed as an adjunct therapy for opioid use 
disorder to limit increases in opioid dose. Illicit use of benzodiazepines is also common 
both with persons using illicit opioids and also with clients in treatment for OUD 
(Winklbaur et al., 2008). Mothers who have used benzodiazepines during pregnancy have 
an increased rate of preterm birth, low birthweight, and hypoglycemia (Wikner, Stiller, 
Bergman, Asker, & Källén, 2007). Neonates exposed to benzodiazepines prenatally have 
associated withdrawal symptoms which overlap opioid withdrawal symptoms, such as 
increased muscle tone, jitteriness, and poor feeding (Wikner et al., 2007; Winklbaur et 
al., 2008).  
Four studies provided information on the influence of exposure to other drugs, 
such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. In all these 
studies, the population included was mothers in treatment with methadone. Two studies 
found that both benzodiazepines and SSRIs increased length of stay in infants with NAS 
(Cleary et al., 2012; Wachman, 2011). Two studies utilized categories for drug exposure. 
Forty-nine women were categorized into three groups: methadone and poly drug use; 
methadone only; or non-methadone treatment (Jansson et al., 2012). Infants exposed to 
other drugs, that included benzodiazepines, barbiturates, and cocaine, had an increased 
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incidence of NAS requiring medication treatment, however there was no difference in 
length of treatment. In another study, four groups were used; methadone only, methadone 
and other substances, a single non-methadone drug exposure (that included 95% other 
opioid and 5% non-opioid drugs), and polysubstance non-methadone (McQueen et al., 
2015). A retrospective chart review was conducted that obtained 137 eligible infants. In 
both methadone groups, the need for treatment was higher and the length of stay longer. 
The methadone and polysubstance group had the longest length of stay. The number of 
different drugs included in the polysubstance group (10 classifications) was diverse with 
very small numbers in some categories. Researchers in a study comparing mothers who 
were concomitantly taking antidepressants and MAT with buprenorphine found the time 
to resolution of NAS symptoms was significantly longer in infants exposed to both 
buprenorphine and antidepressants when compared to those exposed to buprenorphine 
alone (129.8 h versus 70.2 h, p = 0.042) (O’Connor, O’Brien, Alto, & Wong, 2016).  
It is difficult to compare tobacco effects because concomitant tobacco use is so 
high in addiction disorders. Cigarette smoking is reported in as much as 95% of mothers 
in addiction treatment (Jones et al., 2013). Researchers in two studies found an 
association between increased amounts of tobacco consumption and increased need for 
medication treatment for NAS (Chisolm et al., 2011; Jones et al., 2013). These studies 
included 119 and 131 subjects respectively. The remaining study which included 23 
participants did not indicate relationship between increased tobacco consumption and 
need for treatment (O'Connor et al., 2011). All researchers mentioned an increase in 
adverse perinatal outcomes such as low birthweight among tobacco exposed infants. 
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Researchers explored incidence of NAS with maternal prescription opioid use, as 
opposed to illicit use (Desai et al., 2015). They used a broad review technique, which 
examined opioid prescriptions from Medicaid data. They concluded overall prescription 
opioid use was associated with a minimal risk of NAS. The design of the study limited 
the usefulness of this conclusion. The population included all women who filled an 
opioid prescription at any time during pregnancy. Infants in the groups that would be 
suspected of being at risk for NAS, women using prescription opioids late in pregnancy 
or using opioids long term (greater than 30 days) showed an increased risk for NAS. 
Mothers included in this study had a variety of sources for opioid use. Some were 
on prescribed analgesics, some were in outpatient MAT treatment with an opioid 
substitute, and others were taking illicit opioids. Another possibility for prenatal opioid 
exposure which will not be explored is a rapid detoxification program, rather than 
maintenance on MAT throughout pregnancy. The possibility of rapid weaning of opioid 
use during pregnancy is an area of increased attention because this approach has the 
possibility of greatly decreasing the incidence of NAS and subsequently the cost of care 
(Haabrekke, Slinning, Walhovd, Wentzel-Larsen, & Moe, 2014; Stewart et al., 2013). 
However, the utilization of a rapid detoxification program during pregnancy is 
controversial. The crucial issues cited are safety of the infant without adequate means for 
assessing fetal well-being during rapid weaning and high incidence of potential relapse to 
illicit substances for the mother (Unger & Fischer, 2012; Ward, Hall, & Mattick, 1999).  
The other potential maternal factors influencing severity of NAS for which there 
was inadequate information available in the medical record include the impact of 
maternal drug dose or cumulative exposure (Cleary et al., 2012; de Castro et al., 2011; 
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Jones et al., 2014; O'Connor et al., 2011; Seligman et al., 2010), use of prescription as 
compared to illicit opioids (Desai et al., 2015), and maternal treatment with rapid 
detoxification as compared to maintenance MAT throughout pregnancy (Haabrekke et 
al., 2014; Stewart et al., 2013).  
Infant Factors 
The infant factors examined in this study were:  1) Sex 2) Gestational age 3) 
Birthweight and 4) Other Health Complications. 
Gestational age is frequently discussed as a factor based on anecdotal evidence 
and clinical experience. Preterm infants do not exhibit the same incidence or symptoms 
of opioid withdrawal (Dabek, Poeschl, Englert, & Ruef, 2013; Liu, Jones, Murray, Cook, 
& Nanan, 2010). Different physiological responses to opioids are observed in premature 
animals and humans (Dysart, Hsieh, Kaltenbach, & Greenspan, 2007). This may be due 
to metabolism, as the systems responsible for opioid metabolism in the liver are immature 
in a preterm infant. Another possible cause is the length and amount of exposure is 
decreased when an infant of an opioid dependent woman is born prior to term (de Castro 
et al., 2011). Differences in placental transfer also are seen closer to term with increasing 
amounts of opioid transfer occurring in the third trimester (Dysart et al., 2007). 
Researchers in a large multi-center study examined the influence of several perinatal 
factors including gestational age (Liu et al., 2010). Records of 232 infants exposed 
prenatally to methadone were analyzed by logistic regression to identify risk factors for 
NAS requiring treatment. Results confirmed risk was lower for younger gestational ages 
(Liu et al., 2010). 
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The effect of birthweight is often included when researchers are examining 
multiple maternal and infant characteristics that may influence severity of NAS. 
Researchers found birth weight was helpful in predicting incidence of NAS (Liu et al., 
2010).  Birthweight is also associated with increased risk of NAS which requires 
medication. A secondary analysis of a large placebo controlled RCT made comparisons 
about many factors, including birthweight. Researchers concluded increased infant 
weight was associated with increased NAS scores and greater risk of medication 
treatment. (Kaltenbach et al., 2012).  
Several researchers have examined the influence of gender (O'Connor, O'Brien, & 
Alto, 2013; Holbrook & Kaltenbach, 2010; Jansson, Dipietro, Elko, & Velez, 2010; 
Unger et al., 2011).  There is some evidence of gender related differences in opioid 
receptors in both animals and humans. There are indications of both quantitative and 
qualitative differences in opioid effects for males and females (Bawor et al., 2014). These 
changes are apparent in both therapeutic reaction and side effects (Dahan, Kest, Waxman, 
& Sarton, 2008). In a secondary analysis of data from the Maternal Opioid Treatment: 
Human Experimental Research (MOTHER) study, researchers evaluated data from 131 
infants who were born to mothers maintained on either buprenorphine or methadone for 
MAT in pregnancy (Unger et al., 2011). They compared differences between males and 
females in perinatal outcomes, such as gestational age (GA), birthweight, head 
circumference, birth mode, and Apgar scores. They also examined NAS outcomes such 
as peak NAS score, peak morphine dose, and duration of treatment. They found 
differences in birthweight and OFC with males having increased birthweight and head 
circumference; this is consistent with typical fetal and neonatal growth patterns. They 
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found no difference in any of the NAS related outcomes (Jones et al., 2012; Welle-
Strand, Skurtveit, Jones, et al., 2013). 
Jansson (2010) found support for the possibility of sex differences in relation to 
markers of changes in vagal tone and course of NAS. There were 65 infants included in 
the study. Findings showed males had increased peak NAS scores, there was no 
difference in incidence of treatment but there was increased duration of treatment and 
hospital stay in male infants. The study was controlled for potential confounding variable 
of maternal methadone dose. There was no discussion of correlation for other factors, 
which might affect morphine dose and length of stay such as birthweight, gestational age, 
and Apgar score. There was no discussion of relationship of GA, but all infants are 
described as term or > 37 weeks. These factors were compared in treated versus untreated 
infants but treated male versus treated female was not described (Jansson et al., 2010). 
O’Connor also compared male versus female outcomes in mothers maintained on 
buprenorphine during pregnancy (O'Connor et al., 2013). The study included 90 infants. 
They found an increase in peak NAS score and an increase with number of males treated 
with medication. No difference in length of stay was found but infant medication used 
was phenobarbital and infants were discharged prior to weaning off medication. This 
treatment approach is somewhat unusual as current guidelines recommend treatment with 
medication of exposure. However, the author cited an unusually high rate of multi-drug 
exposure as their reason for using phenobarbital as the first line medication. The average 
GA was 37 weeks, but the range was not specified. Length of treatment also was 
increased with maternal toxicology screen positive for benzodiazepines, increased infant 
birthweight, and higher maternal methadone dose. 
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In the current study, information was also collected on the infant’s other 
diagnoses or health complications during the initial inpatient stay. These factors could be 
confounding factors that influence length of stay and hospital cost (Berry, Shah, 
Brouillette, & Hellmann, 2008; Pritham, Paul, & Hayes, 2012). Other complications 
which may extend hospitalization include prematurity, congenital anomalies, and 
respiratory distress syndrome. 
NAS Treatment Components 
The institution of a standardized protocol for identification and treatment of NAS 
is recommended and is associated with a decreased LOS (Lucas & Knobel, 2012; 
Murphy-Oikonen, Montelpare, Bertoldo, Southon, & Persichino, 2012; Stephen W 
Patrick et al., 2016). The clinical facility for this study uses standard screening and 
treatment guidelines for infants diagnosed with NAS. These guidelines include a standard 
screening tool (the modified Finnegan), the use of neonatal morphine solution as the 
primary medication, an algorithm to direct weaning of medication, and the use of adjunct 
medications of either clonidine or phenobarbital. However, the use of consistent 
guidelines reduces the variability related to these factors in the study sample so NAS 
screening tools, selection of primary medication, dosing and weaning of opioid 
medication, routine non-pharmacologic treatments, and healthcare provider 
characteristics, such as experience and training could not be examined in this study. 
Information was collected on the use of adjunct medications, clonidine and 
phenobarbital, to assist in controlling symptoms as these can reflect severity of symptoms 
since they are recommended when symptoms are not well controlled using morphine 
solution.  
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Environmental Factors  
The environmental factors examined in this study were: 1) Breastmilk feeding 2) 
Primary caregiver involvement 3) Location/ Inpatient unit of care (using neonatal 
intensive care unit versus mother infant or pediatric unit). 
There were eight articles reviewed which apply to the category of environmental 
factors. The potential impact of breastfeeding as a possible confounding variable in 
severity of NAS and in treatment outcomes was discussed in three articles (O'Connor, 
Collett, Alto, & O'Brien, 2013; Welle-Strand, Skurtveit, Jansson, Bakstad, Bjarko, et al., 
2013; Isemann, Meinzen-Derr, & Akinbi, 2011). One study detailed effects of the 
implementation of standardized clinical guidelines. In four studies, researchers examined 
location of care; rooming-in versus transfer to a neonatal intensive care unit, or inpatient 
versus outpatient weaning of medication (Abrahams et al., 2007’ Backes et al., 2012; 
Hunseler et al., 2013; Metz et al., 2011). 
Several studies have explored the impact of feeding method and type and describe 
decreased NAS scores and reduced need for medication treatment in infants who were 
breastfed, as compared to bottle-fed, or combination of breast and bottle, and in infants 
fed breastmilk. Findings in two studies indicated a shorter duration of medication therapy 
in breastmilk fed infants (Isemann et al., 2011; Welle-Strand, Skurtveit, Jansson, 
Bakstad, Bjarko, et al., 2013). Breastfeeding was associated with reduced odds of 
requiring neonatal medication (OR 0.55, 95% CI 0.34-0.88) in a study of 450 neonates 
prenatally exposed to methadone (Dryden, Young, Hepburn, & Mactier, 2009). Infants 
who were predominately breastfed had statistically significant lower mean NAS scores as 
measured by a modified Finnegan scale (p < 0.0001) when compared to infants who were 
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combination fed or predominately formula fed (McQueen, Murphy-Oikonen, Gerlach, & 
Montelpare, 2011). The use of breastmilk versus formula, regardless of feeding method 
may also affect NAS severity as measured by Finnegan scores and need for medication 
treatment. In a retrospective chart review of 190 drug-dependent mother and infant pairs, 
breast milk intake was associated with reduced neonatal abstinence syndrome severity, 
regardless of the gestation age of the neonate and the type of prenatal drug exposure 
(Abdel-Latif et al., 2006). 
Current research indicates one factor which may ameliorate the severity of NAS 
and decrease the need for medication is a consistent primary caregiver, or maternal-
newborn couplet care, rather than separation of mother and newborn (Hodgson & 
Abrahams, 2012; Hunseler et al., 2013). Most newborns treated for NAS are separated 
from their mother shortly after birth and cared for in a separate neonatal intensive care 
unit, potentially increasing length of stay, limiting maternal involvement, and affecting 
maternal attachment (Bagley et al., 2014). The problem with this care model is two-fold, 
mothers are not prepared to participate in care and the arrangement discourages 
participation. The separation further alters the developmental environment of the 
newborn during a critical period. Maintaining a traditional maternity care model of 
rooming-in for mothers and infants dependent on opioids with the mother or primary 
caregiver providing the majority of infant’s care may decrease severity of NAS and 
length of stay, as well as provide additional benefits to the family for bonding and early 
infant development (Abrahams et al., 2007; Bagley et al., 2014; Dumas et al., 2013; 
Hodgson & Abrahams, 2012; McKnight et al., 2015; Metz et al., 2011; Norr, Roberts, & 
Freese, 1989; O'Connor, Vietze, Sherrod, Sandler, & Altemeier Iii, 1980). For the current 
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study, information about primary caregiver involvement was limited. The number of days 
the mother or caregiver visits is recorded in the infant’s chart. The percentage of days the 
mother or primary caregiver was present at the infant’s bedside during the entire hospital 
stay was used as a proxy for primary caregiver involvement. 
In this study, we had an opportunity to compare outcomes for neonates with NAS 
who were cared for in the NICU and those who were cared for on the pediatric ward. 
Infants are initially transferred to the NICU, but some are subsequently transferred to the 
pediatric ward for weaning off medication and eventual discharge. The customary 
practice of transferring infants to a neonatal intensive care unit is receiving increased 
attention recently and several researchers have examined alternative approaches 
(Grossman et al., 2017; Holmes et al., 2016; Loudin et al., 2017; Metz et al., 2011). 
These include continuing in a traditional post-partum and newborn model of rooming-in 
on the maternity ward or a transfer to an alternative inpatient ward, either a pediatric 
ward, or a specialty unit specifically for infants diagnosed with NAS. Outcomes such as 
need for medication, length of medication treatment, and hospital LOS may be affected 
by differences in location of care (Grossman et al., 2017). In one study of 287 
methadone-exposed infants who were admitted from post-partum unit to a pediatric ward, 
rather than transferred to NICU, LOS decreased from 22.4 to 5.9 days. Infants treated 
with morphine decreased from 98% to 14% and costs decreased from $44 824 to $10 289 
(p < .01). No infants were readmitted for treatment of NAS and no other adverse 
outcomes were reported (Grossman et al., 2017).  
One clinical facility created a specialized therapeutic unit for NAS patients. The 
environment was designed to address the needs of NAS patients including low-light, low 
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noise, parent involvement was encouraged, and specially trained staff and volunteers with 
expertise in therapeutic and support techniques were used for these neonates. A 
retrospective chart review identified 1023 infants with prenatal exposure to drugs as 
confirmed by cord tissue sample and comparisons were made between infants cared for 
in the NICU and those cared for in the diagnosis specific specialty unit. The creation of 
the new unit reduced the average daily census in the NICU, but there was no significant 
difference in LOS between the two groups (median stay 24 days NICU; 26 days specialty 
unit). There was a significant cost reduction with median cost in NICU of $90,601 and 
specialty unit $17,688 (p < 0.0001) (Loudin et al., 2017). 
An environment of care model not explored in this study was the possibility of 
outpatient weaning of MAT. This is of interest due to potential of cost savings. Concerns 
about safety and medication diversion have resulted in the prevalence of inpatient 
weaning models. Researchers who were able to compare these two care models found 
that infants treated as outpatients had a longer length of treatment but a shorter length of 
stay. There were significantly lower hospital costs in the outpatient group (Backes et al., 
2012). Although this is a critical area for future research, there are several potential 
problems that warrant caution. Increased length of treatment does translate to increased 
exposure time to methadone. Long term outcomes for the infant, such as adverse 
behavioral and developmental effects may be associated with cumulative methadone 
exposure. The other concern is screening and proper patient selection of candidates for 
outpatient weaning is very important. This model of care requires dependable attendance 
at follow-up visits which can be very challenging among the patient population with of 
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substance abuse disorder. Proper screening and support to navigate barriers is essential in 
this model of care delivery. 
Summary of Literature 
There has been considerable progress over the past decade on consistent 
recognition and appropriate medication substitution treatment for NAS. NAS is a 
complex problem that is multi-factorial and there are many potential influences that need 
to be examined to improve care and outcomes. Despite the growing scope of the problem 
of neonatal opioid exposure and ongoing research, there are still gaps in knowledge 
concerning mediating factors and the optimal treatment strategy for infants with NAS. 
There has been a substantial amount of research in recent years concerning which 
medications are best used to treat NAS and what weaning protocol should be followed 
although this has not lead to consistency of treatment between centers and regions (AAP, 
2012; Asti, Magers, Keels, Wispe, & McClead, 2015; Kelly, Knoppert, & Koren, 2015; 
Kokotajlo et al., 2013).  
There are gaps in current knowledge concerning risk factors for developing 
symptoms of NAS, proper identification and screening, and best practices in clinical care. 
Further exploration of potential mediators such as maternal history and demographics, 
exposure to other drugs, maternal tobacco use, feeding method, social support, and family 
involvement, have potential to help with early identification, and perhaps even prevention 
of clinically significant NAS requiring medication treatment. Further study in the areas of 
environment of care, non-pharmacologic treatment measures, moving primary care 
responsibilities back to parents or a primary caregiver, and strategies to insure adequate 
experience and preparation of health care providers all have potential to guide the 
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development of innovative and effective care delivery in NAS patients and to shorten 
inpatient hospitalization and decrease hospital costs. 
Operational Definitions of Variables in the Conceptual Model 
The variables measured in this study were maternal characteristics (maternal 
opioid use: medication used for MAT and/or other opioid use, use of other drugs, tobacco 
use), infant characteristics (sex, birthweight, gestational age, health complications), 
environment of treatment components (primary care giver involvement, location of 
treatment, and health care providers) and outcome variables of initiation and peak dose of 
neonatal morphine solution, hospital length of stay, and cost of hospital stay. The 
variables examined in this study are also defined and described in the table in Appendix 
C. The table includes operational definitions and the source used to obtain the data. 
Outcome Variables. Outcome variables to be examined in this study are: 1) the incidence 
and severity of NAS as measured by the initiation of neonatal opioid medication, 2) peak 
total daily dose of neonatal opioid medication, 3) hospital LOS, and 4) hospital cost of 
stay. The measures used for need for neonatal medication were the initiation of 
medication (yes/no) and the peak dosage (in milligrams per kilogram and in total 
milligrams). Peak Finnegan scores were also collected as the clinical guidelines utilized 
at the facility recommend the use of Finnegan scores as a means to quantify severity of 
NAS symptoms and guide the initiation and weaning of medication.  Hospital LOS is 
also affected by the Finnegan scores since recommendations for weaning of medication 
and when to discontinue medication are based on Finnegan scores. Hospital LOS was 
collected in days from the electronic and paper chart records. Hospital costs were 
collected from the case management review reports used for hospital billing. Information 
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contained total dollar amount billed by hospital. It does not include medical provider 
billing. Actual cost was only obtained for 35% of patients. A more complete estimate of 
cost for the entire sample was obtained using information supplied by the hospital 
administration and case management on the average cost per day for infants with the 
diagnosis of NAS. Estimates were provided for individual units of care (newborn nursery, 
neonatal intensive care unit, and pediatrics), but were de-identified and could not be 
connected to individual infants.  
Intrauterine Opioid Exposure and Neonatal Abstinence Syndrome. The operational 
definition for intrauterine drug exposure was an ICD-9 code of 760.7 (substance affecting 
newborn via the placenta) or ICD-10 codes of 099.320 (drug use complicating 
pregnancy) and P04.4 (newborn affected by maternal drug use) and intrauterine exposure 
to opioids confirmed by medical record review finding maternal or infant positive 
toxicology screen for opioids (urine, meconium, or umbilical cord) or opioid use 
confirmed by maternal report. The operational definition for NAS was an ICD-9 code of 
779.5 (neonatal drug withdrawal) or ICD-10 of P96.1 (neonatal abstinence syndrome 
neonatal drug withdrawal with symptoms) and medical record review confirming a 
modified Finnegan score of greater than eight or initiation of neonatal opioid medication 
for treatment of withdrawal symptoms.  
Peak Score Modified Finnegan Scale. The modified Finnegan scale has been the most 
common measure of presence and severity of NAS symptoms since 1974 (Finnegan, 
Connaughton, Jr., et al., 1975). The tool is an observation scale dividing symptoms in 
three broad categories of neurological, metabolic, and gastrointestinal. It has been widely 
tested and utilized in practice (Orlando, 2014; Retskin & Wright, 2014; Sarkar & Donn, 
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2006). The tool is used exclusively in the designated clinical sites for assessment of NAS, 
as well as to guide treatment decisions about neonatal MAT use and weaning. 
Information on the Finnegan score collected included peak score, and day of life of peak 
score. 
Maternal Characteristics. Opioid medications used by the mother during pregnancy 
collected by mother’s report on prenatal history and hospital admission history, and by 
toxicology screen ( maternal urine, infant urine, infant meconium, infant cord tissue). 
Type of opioid medication used and dose in milligrams recorded from prenatal records or 
mother’s report. Other drugs used by the mother during pregnancy with information 
collected in the same ways. Tobacco use by the mother collected by mother’s report and 
by prenatal records. 
Infant Characteristics. Infant sex (male, female, indeterminate), birthweight (in 
kilograms), and gestational age (in weeks) was collected from electronic and paper chart 
birth records. The presence of other health complications which may be associated with 
increased hospital length of stay and hospital cost, such as prematurity, feeding disorders, 
genetic syndromes, and congenital anomalies was also collected. 
Treatment Components-Medication. The need for neonatal opioid medication is largely 
determined by the modified Finnegan Scale. The need for treatment of withdrawal with 
an opioid medication (morphine solution) is directed by established clinical guidelines 
utilized throughout the medical group for initiation of treatment. Clinical guidelines for 
the medical group recommend initiation of neonatal medication treatment with morphine 
for two consecutive Finnegan scores of greater than eight, three scores of greater than 
eight in a 12-hour period, or one score greater than or equal to 13. The peak of dose of 
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morphine solution parameter was measured in three ways, in milligrams per kilogram per 
dose as per dose variation occur between patients based on infant weight, and as total 
dose medication of medication in milligrams per dose and per day, as this can impact 
weaning time and length of stay. Ultimately the dose in milligrams per kilogram was 
used in the analysis for an accurate comparison of doses among infants of different 
weights. The highest Finnegan score recorded during the hospitalization was also 
collected as a reflection of severity of symptoms. There were clinical guidelines for 
beginning adjunct medications such as clonidine and phenobarbital, if symptoms of NAS 
were not well controlled with morphine solution. The use of adjunct medication was 
collected by occurrence and type. 
The health care provider group in the clinical facility used for this study has 
standardized clinical guidelines for assessment of treatment of NAS. The guidelines 
recommend morphine solution as the primary medication for neonatal treatment. 
Information about neonatal opioid medication use was collected including time to 
initiation of medication due to Finnegan scores in treatment range (two consecutive 
scores greater than 8 or one score greater than 13), peak dose of medication in milligrams 
per kilogram and total milligrams per day, date and time morphine solution was 
discontinued, any adjunctive medication in addition to morphine solution, time initiated 
and time discontinued. Adjunct medications were measured as yes and no, as there are 
standard doses for these medications and they are not adjusted. 
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Caregiver Involvement. Primary caregiver involvement data was collected from an 
observational log which is currently a standard part of charting in this patient population 
at the current clinical site. The bedside nurse records if the mother or primary caregiver is 
at the infant’s bedside at the time of assessment and care. The measurements of total 
number of days the caregiver was recorded as at the bedside was collected. The number 
of visit days was then divided by the total hospital LOS to obtain the percentage of the 
hospital days when the primary caregiver was recorded at the infant’s bedside as a way to 
quantify caregiver involvement.  
Feeding Method. The feeding method and type was collected from the EMR and 
available paper records. It is unclear whether the potential benefits of breastfeeding are 
related to opioid medication excreted in breastmilk or to the physical closeness and 
involvement with a primary caregiver which the act of breastfeeding encourages. The 
intention for this variable was to collect both method (direct breast vs bottle) and type 
(breast milk vs formula), however available medical record data did not contain sufficient 
information on feeding method, so only type of feeding was included. Feedings were 
categorized in three ways: exclusive breastmilk feeding, exclusive formula feeding, and 
combination of breastmilk and formula feeding. 
Unit of Care: Neonatal Intensive Care Unit and Inpatient Pediatric Unit.  The hospital 
unit of care (NICU and pediatric ward) in total number of days, was extracted from 
electronic medical record. The location of care may be important for several reasons. The 
unit of care may facilitate primary caregiver involvement as the design of the units and 
the facilities differ. The pediatric unit is designed to accommodate parents with larger 
rooms, sleeping couches in every room, increased privacy, and bathroom facilities. There 
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may be other factors which affect hospital LOS and hospital cost as well, such as 
different nursing/ ancillary staff and staffing patterns. 
Due to possible variation in clinical guideline adherence between individual 
providers which may affect the outcome variables of hospital LOS and hospital cost, the 
attending provider of record was also collected in days from progress notes in the EMR 
and from provider schedules. Additional details for conceptual and operational 
definitions of variables are included in Appendix C. The results of this study will be 
reported in chapter four. 
Summary 
Neonatal abstinence syndrome is a complex and challenging clinical and public 
health issue which will require a multi-pronged collaborative approach to improve 
outcomes. Multiple factors have contributed to the incidence and severity including social 
determinants of health, health policy and management, and clinical care for both women 
and infants. Research and interventions which go beyond identification and clinical care 
of the infant exposed to opioids prenatally have the potential for the greatest impact. Two 
additional complementary studies are included in this dissertation; one which explored 
the experience of the mothers with opioid use disorder (OUD), pregnancy, and fetal and 
infant loss (Chapter 2) and a second original study which assessed the United States 
public health and policy response to the increasing use of opioids during pregnancy 
(Chapter 3).   
Collaborative research which includes representatives from the disciplines of 
behavioral health, maternal child health, health policy and management, and law 
enforcement will be able to thoroughly examine the many aspects of the problem of 
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increasing opioid use. Assessment of the individual experiences of women with opioid 
use disorder, development of health policies for prevention and treatment of opioid 
dependence disorder, and clinical research to support clinical decision-making for mother 
and infant are all required to adequately address the current problem of maternal opioid 
use during pregnancy and neonatal abstinence syndrome.  
  
53 
CHAPTER TWO: Care Experiences of Women Who Used Opioids and 
Experienced Fetal or Infant Loss 
Introduction 
Use of prescription and illicit opioids in the United States has increased 
significantly in the past 10 years (Ailes et al., 2015; Patrick, Kaplan, Passarella, Davis, & 
Lorch, 2014; Tolia et al., 2015). This increase has created a public health crisis of 
increased opioid dependence and addiction, drug overdose, and corresponding infectious 
disease (Degenhardt & Hall, 2012; Jones, Mack, & Paulozzi, 2013; Paulozzi, 2006; Roy 
et al., 2011). Opioid dependence during pregnancy presents unique perinatal health risks 
for women and their infants, including intrauterine fetal demise, low birthweight, preterm 
labor, and fetal and infant loss (Goettler & Tschudin, 2011; Pinto et al., 2010; Whiteman 
et al., 2014). Women who use opioids during pregnancy have complex needs, including 
addiction therapy, behavioral evaluation and treatment, and social support that are 
frequently not available through conventional prenatal care approaches (Jones et al., 
2013; Jones & Kaltenbach, 2013; Winklbaur, Kopf, Ebner, Jung, Thau, & Fischer, 2008). 
Although coordinated care is critical for these women, little is known about care needs 
from the women’s perspectives. The purpose of our qualitative study was to explore care 
experiences of women who used opioids throughout pregnancy and experienced fetal or 
infant loss.  
Literature Review 
Needs for Prenatal and Drug Treatment Care 
From 2000 to 2009, the prevalence of opioid use in the prenatal period increased 
five-fold from 1.2 to 5.6 per 1,000 live births (Patrick, Davis, Lehmann, & Cooper, 
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2015). Compared to the general population, women who use opioids have higher rates of 
preterm birth (25% vs. 9.6%), low birth weight (31% vs. 5-8%), and intrauterine growth 
restriction (30% vs. 8% (Pinto et al., 2010).  In response to the rapid increase in the use 
and abuse of opioids, the federal government passed the Protecting Our Infants Act of 
2015. This legislation directed agencies to develop strategies to prevent and treat  opioid 
use during pregnancy and neonatal abstinence syndrome (NAS) by assessing the 
comprehensive health care needs of women who use opioids during pregnancy and the 
long-term consequences of prenatal opioid exposure on infants (Miller et al., 2016; 
Ruble, 2016). The American College of Obstetricians and Gynecologists (ACOG, 2012) 
has developed policy statements and clinical care recommendations to improve prenatal 
care, substance abuse treatment availability and accessibility, and reduce NAS. Prenatal 
care for women who use opioids includes assessment of substance use history; referral to 
tertiary obstetric services or drug treatment specialists; opioid substitution therapy during 
antenatal, birth, and postpartum stages; and management of relapse (Abrahams, Chase, 
Desmoulin, Roukema, & Uddin, 2012; Arunogiri, Foo, Frei, & Lubman, 2013; 
Winklbaur et al., 2008).  
Opioid use remains one of the most common reasons why women do not seek 
early prenatal care (Friedman, Heneghan, & Rosenthal, 2009; Schempf & Strobino, 
2009). The stigma attached to the use of drugs during pregnancy could be a barrier. 
Public discourse and media attention have focused on the dangers of fetal exposure 
without considering the history of each woman (Kennedy-Hendricks, McGinty, & Barry, 
2016).  Also, the complex physical, psychological, and social needs of this population 
make it difficult to design appropriate, comprehensive, and coordinated care. Women 
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who use opioids during pregnancy are at higher risk for perinatal complications and 
require high-risk pregnancy services. They have additional needs for substance abuse 
treatment, chronic pain treatment, behavioral health services, and social support.  
Attitudes of care providers toward pregnant women who use opioids may also deter the 
women from seeking care. Goodman and Wolff (2013) found that 46% to 95% of 
physicians believed that drug or alcohol use during pregnancy is a form of child abuse 
and favored compulsory treatment for the women. However, drug treatment, such as 
opioid substitution therapy (OST), may not always be viewed by the women as helpful. 
Chandler et al. (2013) found that some women perceived OST as a barrier to normal 
family life because substitute drugs (e.g., methadone) gave them “a kind of fuzzy feeling” 
and drug treatment required frequent trips to care centers and disclosure of their drug 
histories to more people. As suggested by Jones et al. (2008) advancing an evidence-
based approach to optimal care for women with opioid use is possible only when we 
know more about the needs of opioid-dependent pregnant women. 
Transition to Motherhood: Care and Support for Women Who Use Opioids 
In the Transitions Framework, Meleis (2000) described pregnancy, childbirth, and 
parenthood as lifespan transition and emphasized that a healthy transition enables an 
individual to feel connected, to better interact with others, and develop confidence and 
coping strategies. While many women easily transition to motherhood, women who use 
opioids may be challenged in this transition by difficulty in developing the maternal-
infant relationship, custody loss, or death of the infant. Prenatal opioid use was associated 
with insecurity in attachment to the infant, re-hospitalization, and child abuse and neglect 
(Foulkes, 2015; Friedman et al., 2009; Patrick & Wu, 2015; Terplan, Kennedy-
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Hendricks, & Chisolm, 2015; Worcel, Furrer, Green, Burrus, & Finigan, 2008). Mothers 
who use drugs may be less sensitive to infant cues and have inadequate infant care 
knowledge and skills. Removing an infant from a mother who uses opioids and placing 
the infant in a different family environment is often done to offer protection to the infant 
(Smith, Johnson, Pears, Fisher, & DeGarmo, 2007; Young, Boles, & Otero, 2007). 
However, this course of action could be viewed by the mother as punitive and can be 
detrimental to the mother’s recovery and treatment compliance (Krans & Patrick, 2016; 
Ordean, Kahan, Graves, Abrahams, & Kim, 2015; Stone, 2015; Worcel, 2008). 
Nevertheless, loss of parental rights or custody is common for mothers who use drugs 
and constitutes an involuntary loss which can cause a grief response with persistent anger 
and could result in the need to blame others to minimize the consequences attributable to 
substance abuse and allow the mother to manage guilt and maintain her maternal identity 
(Sykes, 2011; Wells, 2011). 
Another type of loss experienced by mothers who use opioids is perinatal or 
infant death. Women who abuse substances are 3-4 times more likely to experience fetal 
or infant death than the general population (King-Hele et al., 2009). Potential 
complications of opioid use that increase these risks are intrauterine growth restriction, 
premature labor, placental abruption, and sudden unexplained infant death (Jones, H. 
2013a; Whiteman, 2014). Research on the perinatal or infant death experiences of 
mothers who use opioids is limited. Fetal and infant loss or death was described as a 
painful and traumatic experience for all mothers during their transitions to motherhood 
(Gaudet, 2010; Kersting, 2012; Rubin, 1985; Rubin & Malkinson, 2001). Mothers with 
such loss experience numbness, yearning, disorientation and despair (Badenhorst, & 
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Hughes, 2007; Bennett, 2005). Unresolved grief reactions may contribute to initial 
addiction or relapse of substance abuse, and addiction can also hinder the resolution of 
the grieving process in subsequent losses (Denny, 1984; Smith, 2009).  
Substance use is a potential complication of the grief experience as bereaved mothers 
have as much as a two-fold increase in the need for hospitalization due to substance use 
over mothers who have not experienced a loss (Li, Laursen, Precht, Olsen, & Mortensen, 
2005; Zuckoff et al., 2006). Some mothers seek to maintain relationships with their 
deceased children by carrying photographs and observing anniversaries; others may 
withhold emotional attachment in subsequent pregnancies until the perceived threat of 
loss is resolved (Lewis, 2006). Even though rates of perinatal loss are increased with 
maternal opioid use and the number of women who use opioids during pregnancy is 
increasing, there is little information in current literature about the unique aspects of these 
mothers’ experiences. Our study, which was based on Fetal and Infant Mortality Review 
(FIMR) maternal interviews, was designed to explore the care experiences of women 
who used prescribed or illicit opioids during pregnancy and had fetal or infant loss.   
Methods 
Design 
We conducted a thematic analysis (Sandelowski, 2000; Vaismoradi, 2013) of 
qualitative maternal interview data from a FIMR program in a Midwest County 
Department of Public Health in the United States. Our study was approved by the 
Institutional Review Board of Indiana University. Only de-identified FIMR data were 
used and were stored in a password protected drive used specifically for research data. 
  
58 
Participants 
 Inclusion criteria required participants to be age 18 or older with known histories 
of prenatal opioid use and fetal or infant losses. Between the years 2007 and 2012, the 
local FIMR program reviewed a total of 381 infant mortality cases; 194 (51%) of the 
mothers participated in interviews. In the same period, 26 adult mothers experienced a 
fetal or infant loss and were also identified as opioid users (prescribed or illicit). Of the 
26 women, 11 (42.3%) participated in a semi-structured telephone or in-person maternal. 
Data from the 11 interviews were analyzed in this study. Interviews were conducted 3.5 – 
10 months after the death (average = 5.2 months). Nine participants were interviewed by 
five months after infant death).  
Data Collection 
  The 11 interviews were conducted by four FIMR program nurses who received 
the National FIMR Maternal Interview Training on how to conduct an interview, comply 
with public health and safety codes, and handle difficult encounters. Interview questions 
asked of each participant focused on their thoughts and perceptions of the care they and 
their infants received and their experiences throughout the pregnancy and loss (See Table 
1 for FIMR suggested questions). Interviewers took detailed written notes during the 
interviews. Audio or video recordings were not used in the interviews because of the 
sensitive nature of the subject. The interview notes were typed and saved in a FIMR 
database.  
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Table 1 
Fetal Infant Mortality Review (FIMR) Case Study Suggested Questions 
Perinatal Events Prenatal, Labor, and 
Delivery 
Infant’s Death 
Questions Please tell me about the 
last few days of your 
pregnancy, your labor, and 
when your baby was born. 
How satisfied were you 
with the prenatal care you 
received? 
How was your baby’s 
death explained to you? 
What is your understanding 
of your baby’s death? 
Share what happened after 
your baby’s death. 
 
Data Analysis 
Coding and thematic analysis were conducted in three phases using the thematic 
analysis process described by Vaismoradi (2013). The first author is a neonatal nurse 
practitioner and a Ph.D. student with experience in treating infants with NAS. The second 
author is a prenatal health behavior researcher with experience in qualitative data 
analysis. In the first phase, to familiarize ourselves with the data, the first two authors 
read interview documents several times along with abstracted medical, obstetric, and 
infant data. The second phase of data analysis consisted of organizing data, including 
generating initial codes, searching for themes, and reviewing and naming themes. 
Interview data were initially organized based on the experience of pregnancy, birth, and 
postpartum periods (including care of the newborn), and infant care (up to 1 year). First, 
the two authors coded interviews independently; codes with similar meaning were 
grouped into themes within each perinatal stage. Then, we met in person to resolve 
coding and theme naming discrepancies. In the third phase of analysis, two additional 
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authors reviewed codes and themes: a neonatologist with experience in qualitative 
research and the FIMR process and the coordinator of the local FIMR program. These 
two team members verified whether they could follow the analysis processes 
(dependability) and commented on whether the themes in each stage were meaningful to 
individuals in clinical and public health practice (transferability). Discrepancies in this 
phase were resolved by group discussion via email. Data saturation was reached in each 
theme.  
Results 
Participants 
The sample consisted of 11 participants (Table 2). The participants ranged in age 
from 18 to 36 years. Most were White (n = 8), single (n = 9), and with less than high 
school educations (n = 7). Nine participants used opioids exclusively, and two reported or 
tested positive for polysubstance abuse. Four participants used prescription opioids for 
chronic pain, one participant was in a drug rehabilitation program using methadone, and 
five participants used opioids illicitly. Three deaths occurred before birth (intrauterine 
fetal demise), three during the neonatal period (first month after birth), and the remaining 
five in infancy (one month to one year after birth). Six deaths were related to prematurity 
or congenital/genetic abnormalities, and five were caused by sudden unexpected death, 
pneumonia, placental abruption, or unknown causes. 
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Table 2 
 
Demographics, Drug Use History, and Obstetric History for Study Participants 
(N = 11) 
 
Variables N (%) 
 
Variables N (%) 
Age (years) 
Mean (SD) 
Range: 18 - 
36 
 
25 (7.27) 
 
Number of 
Pregnancies 
Mean (SD)  
Range: 1 - 6 
 
 
3.45 (1.97) 
 
Ethnicity 
African 
American 
    White 
 
3 (18) 
8 (72) 
First Pregnancy 
    No 
    Yes 
 
10 (77) 
3 (23) 
Education 
Less than 
high school 
High school 
   
Master/PhD 
 
 
7 (64) 
2 (18) 
2 (18) 
 
Timing of 
Perinatal/Infant 
Death                   
    Fetal stage 
    Neonatal stage 
    Infant stage 
  
         
 
3 (27) 
3 (27) 
5 (45) 
 
Marital 
Status  
    Married  
    Single  
   
 
 
2 (18) 
9 (82) 
 
 
This Pregnancy 
Planned 
    No 
    Yes 
    Unknown 
 
  
4(36) 
3 (27) 
4 (36) 
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Tobacco 
Use 
   Yes 
   No 
   Unknown 
 
8 (73) 
2 (18) 
1 (9) 
Health Insurance 
    Medicaid 
    Private 
    None 
     
 
9 (82) 
1 (9) 
1 (9) 
  
Maternal 
Opioid Use 
Prescription  
    Illicit 
 
 
 
 
 
 
 
6 (55) 
5 (45) 
 
 
 
 
 
Reasons for 
Fetal/Infant Death 
Prematurity 
Congenital 
Anomalies 
 SUIDS/ 
Suffocation/Apnea 
Genetic Syndrome 
Pneumonia 
IUFD (abruption) 
Unknown 
 
 
4 (36) 
1 (9) 
 
2 (18) 
1 (9) 
1 (9) 
1 (9) 
1 (9) 
 
Note. IUDF: intrauterine fetal demise; SUIDS: sudden unexpected infant death.  
Themes 
Five themes were identified that represented the experiences of participants. The 
themes were: frustration and anger related to not being heard, feeling minimalized, being 
overwhelmed with attempts to process and understand medical complications and 
outcomes, profound sense of grief and coping with loss, need to understand why and 
make difficult decisions, placing blame and guilt over death.    
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Frustration and anger related to not being heard, feeling minimalized 
Many participants voiced their frustration that care providers did not listen to their 
concerns during pregnancy or the infant’s illness. They wanted care providers to value 
their input and experiences. They also wanted care providers to “listen to” and “pay 
attention to” them:  
“My baby could have been saved if my prenatal doctor would’ve listened to me 
and paid attention to me.” “I think if they looked more into what I was going through my 
loss could have been prevented.” 
“I took her to the clinic multiple times…and the doctors kept saying she was fine 
and not to worry about it. Then in May, I took her to get her shots and the next thing I 
know she’s dead.” 
Some participants stated that providers did not ask what they wanted regarding 
their infant’s care. Some participants felt they knew something was wrong, but care 
providers did not listen to their concerns: “I knew something was wrong. They never 
listened to me. They were all against me, and never asked what I wanted.” “If my 
prenatal doctor would've listened to me and paid attention to my extremely high blood 
pressure; took my son… when I begged her to because I had pre-eclampsia and my son's 
heartbeat was only 118.” 
Some participants felt “upset” because they were not adequately informed about 
complications and medical treatment. They were not allowed to fully participate in care 
decisions. If explanations were offered, they did not facilitate the participant’s 
understanding. The lack of information and communication frustrated the participants 
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and contributed to their feelings of being ignored and marginalized in making care 
decisions: 
“Everything was going okay, not great, but okay. Then one day they told me that 
they removed the breathing tube, without my permission. He didn’t like it, and they had 
to put it back in. When they put it back in, they punctured a lung and messed everything 
up. We had no idea what was going on, and all of sudden they handed me my son and 
said he was dead. I called the father, he was driving home from work, and I told him I 
was holding our dead baby. We had no idea what happened. I was so upset. I needed to 
get out of there.” 
Being overwhelmed with attempts to process and understand medical complications 
and outcomes 
Some participants had preexisting medical problems (e.g., hypertension, obesity, 
sexually transmitted infection, hypothyroidism, sickle cell trait) and pregnancy 
complications, such as vaginal bleeding, placental insufficiency, or chorioamnionitis. 
Some participants also reported behavioral health issues such as bipolar disorder, anxiety, 
depression, and schizophrenia. These medical and behavioral comorbidities added 
complexity to their prenatal care and often required referrals. “I went from jail to the 
mental hospital, and they put me on a medication called Lurasidone that killed my baby. 
With my other children, I wasn’t taking no medication, and nothing like that happened.” 
“My OB saw me while I was in the hospital and decided to transfer me to another 
hospital because they didn’t know what else to do. I had two blood transfusions, and they 
stopped the magnesium.” 
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  It was sometimes difficult for participants to identify physical signs of 
complications such as preterm labor. Some were seen and evaluated and sent home. As a 
result, they did not know whether they were actually in labor when the pain recurred. “I 
was having pains in my side and didn’t realize I was having contractions until I got to the 
hospital.” “I stayed home until the pain became unbearable and then went back to the 
hospital.” 
Other complications during pregnancy were also common in the participants. 
Thoughts about hemorrhage, placental problems, and pregnancy-induced hypertension 
worried some mothers and increased their anxiety levels. The participants reported being 
anxious about their treatment, being transferred to another hospital, being told of the need 
for a cesarean birth, and uncertainty of the baby’s survival. “She was born two weeks 
before that time she could live. Her heart and lungs were underdeveloped. They said she 
might make it and might not.” “I went to the hospital and was bleeding everywhere. Pool 
of blood. They said my daughter swallowed it.” 
Profound sense of grief and coping with loss 
Participants struggled to deal with grief. They expressed “how lost I feel about 
losing him” and “this is a very hard thing to go through.” Some participants wished 
“there was something you can do” to bring back their infants. Others thanked God for 
having other children who were alive. “Do you know how hard it is to deal with this after 
having him inside you all these months and then touching his hands and feet? This has 
been the worst 5 months of my life.” “That is a very hard thing to go through, and you 
still wish there was something you could do.” “…just how lost I feel about losing him 
and how lost I am without him! I just thank God for my other sons.” 
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Participants talked about the support they received during the experience with 
grief. Some expressed appreciation for bereavement services, such as booklets on 
bereavement, molds of handprints and footprints, or photographs. Others experienced 
frustration and disappointment because they did not receive enough support or resources. 
Participants also expressed receiving various degrees of professional bereavement 
support. Some had begun counseling with a psychiatrist or were considering grief support 
groups. “Everyone at the hospital was excellent. They made molds [of my baby’s hands 
and feet]. I was worried that I couldn’t afford to bury her, so they let me talk to the 
trustee.” 
“I am seeing [a] psychiatrist right now for my grief. I think it is helping. I am not ready to 
talk to people about it in a group or talk to other people. It’s just too hard, and I am not 
ready.” 
Some participants had difficulty managing their grief and others actively made 
plans for closure through a “memorial service” for their baby, spirituality, and family 
support. They sought validation for their feelings of grief and loss but sometimes felt 
pushed by family and friends to move on. “We had a memorial service for him and 
buried him at the cemetery…We are doing okay with the loss; we have a lot of family.” 
“Can I ask you something? People tell me the more I talk about her, or keep wanting to 
celebrate her birthday; I will never get over her …Do you think it is okay to celebrate her 
birthday?” 
Need to understand why and make difficult decisions 
Participants expressed that they were adept at recognizing changes in their 
infant’s health status (e.g., coughing and throwing up or not breathing) particularly after 
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hospital discharge. They sought medical attention and explanations. However, there were 
times some participants had to make difficult decision about care and treatment. “My 
baby did good at first. When he was 3 and half or 4 months old I noticed he couldn’t open 
his hand or sit up straight.” “I took her to the hospital and clinic multiple times because 
she was coughing and throwing up.” “I called out for someone to call 911 and started 
CPR, but it was already too late.” “His father and I decided to take him off the machine.” 
 Participants wanted to understand and make sense of their infant’s death. 
Knowing how and why their infant died seemed to offer them a “closure.” Knowing the 
cause of infant death was also important for them to understand implications for future 
children. They also wanted reassurance that their care, as a parent, and the health care 
provided was sufficient as “they did what they could for her [infant].” “Well, at least now 
we have closure. I wish someone had told us sooner; we have been going nuts not 
knowing.” “Now I know he did die because of sleep apnea.” “They said she had a tube 
defect and it was an encephalocele, and she couldn’t live.” “I don’t remember the name 
of the condition he had, but the doctors said it was genetic.” 
Placing blame and guilt over death 
Participants responded to infant death with two reactions. Some blamed health 
care providers because “they are responsible for her [infant] death.” Others blamed 
themselves for the infant’s death and believed that if they had done something to help the 
baby, the death would not have occurred. “I believe the OB doctors should be checked 
out. My baby could have been saved …” “I wanted to sue the hospital and clinic because 
they are responsible for her death.” 
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At times, pressure from family and friends precipitated feelings of self-blame and 
guilt. Occasionally, participants turned the blame to themselves and searched for how 
they might have prevented the death. “If we had used the monitor he might be alive. I 
wish we had kept on using the machine anyway.” “When I woke up, I knew something 
was wrong. I freaked out. So I told everyone she dies in her crib. But she was in bed with 
me. I tell everyone I know, see with a baby, everyone- not to sleep with their baby.” “All 
my friends and family thought I killed my baby. They kept saying I smothered her and 
stuff. My mom was real angry, but she was also crying.” 
Discussion 
Our results indicate that women who used opioids and experienced infant/fetal 
loss had complex needs which were often unmet. Of note, participants in our study 
repeatedly voiced concerns about not being heard, being ignored, and being undervalued. 
These concerns may be related to the stigma of addiction; however, it is also likely that 
they may have been exacerbated by participants’ anxiety about their high-risk conditions 
and frequent urgent medical treatments. The perception that their feelings were 
minimalized could also reflect their frustration and helplessness over the deaths of their 
infants. In previous studies on addiction, women expressed feelings of stigmatization 
from family, friends, society, and health care providers (Chandler et al., 2013; Earnshaw, 
Smith, & Copenhaver, 2013; McGinty, Goldman, Pescosolido, & Barry, 2015). If 
allowed to develop, these perceptions of stigma can create a lack of trust in individual 
health care providers and the health care system and serve as barriers to accessing care 
(Casper & Arbour, 2013; Winklbaur et al., 2008).  
Many participants in our study had difficulty understanding why devastating 
medical complications occurred for them and their infants and often felt the 
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communication from health care providers was inadequate, incomplete, or difficult to 
understand. This problem of incomplete understanding may be caused partially by the 
stress and uncertainty of the situation itself, but also may reflect a lack of communication 
skills among health care providers (Pozzo, Brusati, & Cetin, 2010). Several previous 
studies conducted with patient populations facing high stress and complex medical 
situations, such as cancer or high-risk pregnancy, have indicated the need for standard 
protocols and practice in delivering bad news (Pozzo et al., 2010). In the context of 
maternal opioid users experiencing fetal and infant complications, providers could also be 
helped in their regular communication by training on how to deal with the mothers’ 
emotional reactions and the mother’s need to be well informed. Communication would be 
enhanced if health care providers created illustrations and provided information in clear 
and simple terms. Mothers who report satisfaction with the information they receive are 
better prepared to take action and make good decisions (Makary, 2015).  
Dealing with grief, guilt, and blame was an ongoing process for participants from 
the first time infant complications were identified through the infant’s death and months 
later. Although every mother grieves in her own way, lack of support may prolong grief 
(Badenhorst, 2007; Cacciatore, Schnebly, & Froen, 2009; Kersting & Wagner, 2012). 
Moreover, the perinatal loss can be a trigger for addiction relapse (Smith, 2009). 
Bereavement support can help mothers with fetal/infant loss acknowledge their feelings 
of guilt over blame and the added burden of stigmatizing addiction (Bennett, Litz, Lee, & 
Maguen, 2005; Murphy, Shevlin, & Elklit, 2014).  
Anger and blame towards others, or self is a typical reaction after a perinatal loss, 
particularly when mothers feel unsupported or uninformed (Badenhorst, 2007; McCright, 
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2008; Cacciatore, Frøen, & Killian, 2013). Providers need to recognize that grief may be 
expressed in many ways, including blaming others. Blame is a normal aspect of grief in 
perinatal loss and many mothers blame themselves for their loss which may be a barrier 
to resolution of grief (Cacciatore, 2013). However, our participants turned blame toward 
themselves with less frequency than in general perinatal grief studies (Badenhurst, 2007; 
Kersting, 2012)). Blaming others may represent an abnormal grief reaction related to the 
need to minimize implications of substance use. Regardless of the reason, providing 
support and counseling is essential. 
Limitations 
The use of secondary data analysis provided only a narrow window into the care 
experience of the mothers. The FIMR interview was constructed for a specific purpose of 
identifying multiple maternal and infant healthcare, social, and community service issues. 
We were unable to clarify participants’ care experience with additional interview 
questions. We were also unable to explore specific care experiences regarding methadone 
use or other drug treatment during pregnancy. The interviews were not recorded on audio 
or visual media. Although extensive written notes were completed based on the FIMR 
protocols, written notes might not have captured all information given by each 
interviewed mother. The range of time between the loss and the interview (3.5 to 10 
months) is also a possible limitation. Grief is an individual experience and mothers 
interviewed soon after their infant’s death may report a very different experience than 
those interviewed several months later.  Unique perspectives related to opioid use and 
dependence may also affect the grief experience.  
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The secondary data analysis also prevented us from conducting member checks. 
Member checks reviewing the themes identified with the participants would have helped 
validate our findings. Our study was limited to a small number of women in one local 
FIMR program. Further study is needed to determine whether findings our similar with 
other similar women.  
Implications for Practice 
Our findings indicate that health care providers need to partner with women who 
use opioids designing care and making treatment decisions that acknowledge their needs, 
perceptions, and satisfaction are important (Wolf, Lehman, Quinlin, Zullo, & Hoffman, 
2008). Such a partnership fosters respect, shared decision making, and a caring 
environment where mothers who use opioids concerns can be addressed. This partnership 
focus also encourages care providers to be sensitive to the needs of these women to help 
reduce the perception of stigmatization and increase the perception of being valued.   
The need for health care provider education and training in effective and sensitive 
communication is evident from this study. The participants’ perception was that 
caregivers who did not listen to them, minimized their feelings, and were unsupportive, 
contributed to their pain, guilt, and bereavement experience. Projecting acceptance, 
accessibility, and readiness to listen is essential, as well as providing understandable 
medical information about the care provided and procedures performed (Fleischer, Berg, 
Zimmermann, Wüste, & Behrens, 2009). It is important to understand communication is 
bidirectional and the patient’s interpretation of the message may be very different than 
the nurse’s intended message (Kourkouta & Papathanasiou, 2014). It is also necessary to 
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continually assess the mother’s knowledge and confirm understanding of health 
information given. 
Comprehensive multidisciplinary care models may provide opportunities for care 
providers from different disciplines to develop coordinated care plans for opioid-using 
mothers and their infants, as well as to enhance communication among care providers. 
Continuing education programs or conferences could emphasize multidisciplinary aspects 
of care for the mothers with opioid use. 
Bereavement support and counseling is particularly important for the mothers 
who use opioids and experience perinatal or infant death. Such support and counseling 
may need to be long-term in order to resolve the mothers’ reactions of guilt, anger, and 
blame. There is a need to improve patient-provider communication and to address both 
individual and systems failures which may lead to poor outcomes through formal review 
processes such as FIMR and Child Death Review programs. 
Recommendations for Future Research 
Further exploration of this topic could best be accomplished with a 
phenomenology approach using open-ended interviews. This would provide a richer and 
more complete description of the participants’ experience. More focused exploration 
divided by the timeframe of the loss (fetal, neonatal, or infant) may also aid in theory 
development, as well further defining guidelines for effective practice.   
Conclusions 
The rapid increase in opioid use among pregnant women has led federal agencies 
to demand more research to determine best practice for caring for affected women and 
infants. We examined the care experiences of women who used opioids throughout 
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pregnancy and experienced fetal or infant loss. Five themes were identified: not being 
heard, or feeling minimalized, being overwhelmed with attempts to process and 
understand medical complications and outcomes, a profound sense of grief and coping 
with loss, a need to understand why and make difficult decisions, a need to place blame 
and assign guilt over death. The study findings suggest interdisciplinary team care, 
partnership in decisions, provider training for skillful communication, and emotional 
support for mothers with opioid use and pregnancy or infant loss. These findings have 
been published prior to their presentation here (Scott, Shieh, Umoren, & Conard, 2017). 
A release of copyright is included (Appendix A). 
In thoroughly addressing the needs of mothers who use opioids during pregnancy 
and their newborn infants, a collaborative effort with families affected, healthcare 
providers, public health providers, and policymakers is vital. Policy decisions inform and 
reflect public opinion concerning mothers who use opioids during pregnancy. Gaps in 
research, availability of treatment, and coordination of services are closely related to 
health care policy decisions. The priorities set for legislation, public health policy, and 
funding of opioid use disorder treatment and prevention determine availability and 
reimbursement for treatment and ancillary services. An examination of current US state 
policies and services related to opioid use in pregnancy and NAS is an essential step in 
developing viable plans for optimal care of women and infants. 
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CHAPTER THREE: Survey of US States’ Policies Regarding Maternal Opioid Use 
and Neonatal Abstinence Syndrome 
 Introduction  
Opioid abuse and misuse among pregnant women have reached epidemic 
proportions and has influenced maternal child health policy at the federal, state, and local 
levels. The number of women taking opioids during pregnancy increased five-fold 
between 2000 and 2009 (1.2 per 1000 live births to 5.6 per 1000) (Patrick, Davis, 
Lehmann, & Cooper, 2015). Much of this increase is related to prescription opioid use 
and abuse. Between 1992 and 2012, the proportion of pregnant women admitted for 
substance abuse treatment that reported a history of prescription opioid abuse increased 
from 2% to 28% (Krans & Patrick, 2016). The rapid increase in the incidence of this 
problem, as well as the accompanying economic and societal costs, has attracted attention 
and research focus by many health care professionals and policymakers. It is essential 
that health care policy be informed by research and evidence-based guidelines which 
support optimal outcomes for both pregnant women and their infants. 
Background and Significance 
In 2015, the Government Accountability Office (GAO) published “Prenatal Drug 
Use and Newborn Health,” a report that discussed current gaps in research and programs 
related to services for mothers during pregnancy and services for their infants after birth.  
Research gaps focused on treatment of opioid use during pregnancy and the long-term 
effects of prenatal opioid exposure on children. The lack of available treatment programs 
for both pregnant women and newborns with neonatal abstinence syndrome (NAS) was 
identified as a service gap. Other gaps included a lack of guidance for and coordination 
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among behavioral health providers, prenatal care providers, public health professionals, 
and policymakers in their efforts to address prenatal opioid use or NAS. Experts also 
noted that the most effective treatment options were hindered by difficulties in 
identifying and retaining pregnant women with substance use disorders for research. 
Recruitment to studies is hampered by women’s reluctance to participate in such studies 
due to fear of criminal charges or other repercussions from discovery (GAO, 2015; 
Poland, Dombrowski, Ager, & Sokol, 1993; Stone, 2015).  
The purpose  of this study  was to examine current US state policies and services 
related to opioid use in pregnancy and NAS, specifically, how these policies have 
evolved recently related to the increased population of opioid use disorder and how well 
current policies align with the federal and state objectives for women and infants outlined 
in the Protecting Our Infants Act of 2015 and in the National Governor’s Association 
(NGA) statement on Priorities for Addressing the Nation’s Opioid Crisis (NGA, 2016) . 
Conceptual Framework 
The concepts of substance misuse and addiction have been approached from 
many different perspectives, all have contributed to understanding the causes, 
consequences, and potential development of effective interventions. However, all the 
approaches have some shortcomings in offering a comprehensive explanation for the 
behavior and success or failure of existing treatment models. Several broad categories of 
theory can be identified, individual susceptibility, addictive stimuli, motivational 
constructs, socioeconomic and environmental factors, bio-psychological factors, and 
pharmacokinetics (Köpetz, Lejuez, Wiers, & Kruglanski, 2013; West, 2001). Interesting 
approaches related to behavioral economics (Worley, Shoptaw, Bickel, & Ling, 2015) 
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and attachment theory (Flores, 2006) blend biological, motivational, and behavioral 
factors. The number of theories and conceptual models developed to describe substance 
use disorder illustrate the difficulty in developing a comprehensive theory to explain 
human behavior.  
Kovac (2012) attempts to integrate the many different theoretical frameworks by 
emphasizing these different approaches are not mutually exclusive, but rather 
complementary. The multi-sourced model of addiction (Kovac, 2013) acknowledges the 
complexity and synergy that exists between various explanations. This model focuses on 
the individual, but emphasizes the influence of pre-disposition, actions/choices, 
neurobiology, social, historical, and cultural context, and neurobiology (see Figure 2). 
This model does not favor a sole mechanism or a simple interactive effect but instead 
describes factors, which concurrently act to form a forceful behavioral pattern (Kovac, 
2013). 
 
Figure 2: Kovac (2012) A Multi-sourced Model of Addiction 
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Research Aims 
• Assess U.S. state legislatures current response to the public health and 
economic issue of increases in opioid use disorder and its impact on 
pregnant women and infants as reported by survey respondents. 
• Assess the impact of federal and state policy objectives (Protecting Our 
Infants Act of 2015 and NGA priorities statement) and professional 
guidelines concerning opioid use disorder in pregnancy on public health 
and legislative initiatives as reported by survey respondents. 
Review of Literature 
The rising incidence of opioid use disorder during pregnancy and the subsequent 
escalation of NAS, and its related expense, have brought increasing attention by health 
care providers, policymakers, and payers. Professional organizations, such as the 
American College of Obstetricians and Gynecologist (ACOG), the American Academy 
of pediatrics (AAP) and the American Society for Addiction Medicine (ASAM) have 
published guidelines or position statements concerning the treatment of substance abuse 
in pregnancy and NAS (Hudak & Tan, 2012; Kampman & Jarvis, 2015; Krans & Patrick, 
2016). Through the Protecting Our Infants Act of 2015 (S.799/H.R.1462) (Congress, 
2016), the federal government has described objectives for establishing and 
disseminating best practice strategies and recommendations for diagnosis and treatment 
of NAS (White House, 2016). State priorities have been described by the National 
Association of Governors (NGA) concerning prevention and treatment of opioid use 
disorder (Desai, Hernandez-Diaz, Bateman, & Huybrechts, 2014).  Private and public 
healthcare payers are also developing strategies to mitigate their costs and limit patient 
exposure to potentially addictive opioid medications (Katz et al., 2013).  
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The Protecting Our Infants Act of 2015 (Public Law 114-91/S.799/H.R.1462) is 
an ambitious directive which outlines priorities for research, education, and treatment. 
This bill requires the Department of Health and Human Services (HHS) to review current 
initiatives related to prenatal opioid use and NAS and develop a strategy to address gaps 
in research as well as gaps and duplication in programs. It directs the HHS to conduct a 
study and develop recommendations for preventing and treating prenatal opioid use 
disorders, including the effects of those disorders on infants. The bill also details the 
essential components of the HHS report on maternal opioid use and NAS, such as an 
assessment of existing research, best practice recommendation for treatment of women, 
an evaluation of the barriers to treatment for women, and recommendations on prevention 
of opioid use disorder in women. Further research is also recommended on the effects of 
prenatal opioid use on infants. In addition, this bill would require the Centers for Disease 
Control and Prevention (CDC) to expand data collection and surveillance activities and 
would require the Agency for Healthcare Research and Quality (AHRQ) to study and 
recommend treatments for prenatal opioid abuse and NAS (Senate, 2016). The 
Congressional Budget Office estimates the cost of implementing H.R. 1462 would be 
about $27 million over the 2016-2020 period (2016). No funding has yet been 
appropriated for the bill. 
The recent NGA statement addresses opioid use and abuse as a public health 
crisis and describes states priorities. Priorities can include preventing and identifying 
addiction, developing best practice guidelines for addiction treatment services, increasing 
access to treatment programs, and eliminating regulations on Medicaid funding which 
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restrict reimbursement for inpatient treatment for substance abuse and mental illness 
(NGA, 2016).   
Some previous surveys have been conducted to assess state policies and practices 
concerning opioid use disorder in pregnancy. A survey of policies regarding substance 
use in pregnancy was conducted to assess the impact of decreased federal oversight and 
the transfer of budget and regulatory control to the states which occurred in 1994 
(Chavkin, Breitbart, Elman, & Wise, 1998). Their survey of substance abuse directors 
and child protective services showed an increase between 1992 and 1995 in mandatory 
drug testing of pregnant women and neonates (2% to 12%; .05% to 7%), increased 
mandatory reporting of positive maternal toxicology screens (2% to 17%), and an 
increase in criminal prosecution of drug using women (45% to 71%). There was also a 
trend toward mandating or prioritizing drug treatment services for pregnant women (24% 
of states).  They found a general delay between the development of policy and the 
establishment of related services. There were gaps identified in policy, such as mandated 
treatment but lack of availability of services and eligibility for reimbursement (Chavkin 
et al., 1998). 
Another survey examining state policies concerned mandatory reporting of 
substance abuse during pregnancy and it found twenty states had laws requiring health 
care providers to report perinatal substance use to child protective authorities, and four 
states required reporting only when a health care provider thought child maltreatment was 
involved. Only about 50% of states with a mandatory reporting law had a provision 
facilitating substance use disorder treatment in the perinatal period (Jarlenski et al., 
2017). 
80 
In 2004, a review was published summarizing policy research findings in 
substance abuse during pregnancy (Lester, Andreozzi, & Appiah, 2004). Policy is usually 
shaped by elected officials so is dependent on social context and public perception. There 
are two competing discussions involving attitudes about maternal substance use which 
have shaped public perception and consequently informed policy. One approach is to 
view drug abuse as a mental health or medial illness. This leads to policies which 
emphasize treatment and prevention strategies. The competing approach is punitive and 
views pregnant women who misuse drugs as criminals who are placing their infants at 
risk. These perceptions both agree on the necessity of appropriate treatment, but many 
other points related to the formation of policy, such as the origin and clinical approach to 
treatment, women’s autonomy, the legal status of the fetus, and the usefulness of punitive 
measures are in conflict between the two groups (Lester et al., 2004).  
State policy around perinatal substance abuse is shaped through two objectives; 
the state has a concern for the welfare of its citizens, and then the overall cost to the state 
(medical care, child protective services, public assistance and foster care are some of the 
state budget areas impacted by opioid use disorder in pregnancy) (Bishop et al., 2017). 
State approaches include prosecutorial strategies with a variety of potential charges for 
the pregnant substance user (child abuse, delivery of controlled substances to a minor, 
manslaughter) (Flavin & Paltrow, 2010). At the time of this review, three states mandated 
universal screening of pregnant women for substance use, fifteen (30%) mandated 
reporting prenatal substance abuse as child abuse and more than 25% of states (13) had 
passed laws that define mother’s substance use as child abuse (Lester et al., 2004). 
Fifteen states provided treatment programs or coordination of services and four states 
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gave priority access for addiction treatment services to pregnant women (Lester et al., 
2004).  
This study will evaluate the impact of published federal and state objectives and 
professional organizations’ guidelines on current state programs and policies for pregnant 
women with opioid use disorder and infants with NAS. Our study was approved by the 
Institutional Review Board of Indiana University. Data were stored in a password 
protected drive used specifically for research data. 
Methods 
Sample   
Participants were a convenience sample of 145 representatives from individual 
U.S. state’s departments of child welfare/ child and family services and representatives of 
state health departments in the divisions of substance abuse and mental health. The 
sampling frame and contact information was obtained from departmental contact listing 
from the Child Welfare Information Gateway, SAMHSA’s state profiles on substance 
abuse services, and individual states.gov websites and later by a respondent’s referral to 
the National Association of State Alcohol and Drug Abuse Directors. Participants were 
invited to participate by email contact with link to the electronic survey. They initially 
contacted by email and were assured of confidentiality and given an opportunity to 
decline to participate in the study. 
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Design and Materials 
The design was a non-experimental descriptive study using an electronic survey 
with telephone follow-up for non-respondents.  A 19-question survey instrument with a 
total of 54 discrete answers and two items with free text was developed. The survey was 
formatted in REDcap and grouped on seven sequential screens to minimize transmission 
time. This also allowed questions to be displayed completely and prevented the need for 
participants to scroll through pages. A pilot study to assess clarity and accessibility was 
conducted with five volunteer respondents who work in similar positions as the 
designated participants, within state child protective services or as health care social 
workers. The survey was revised to address any technical issues or ambiguity noted by 
the pilot volunteers.  
Procedure 
The survey link and a brief email introduction describing the goals of the survey 
and allowing participants to decline to participate by responding to the email was sent to 
the selected agency representatives. The survey link remained open for two months, 
during which time reminders and telephone contacts were also being sent. No response to 
the email implied consent as stated in the letter. If no response was received within six 
weeks of the email with two reminder emails sent at two week intervals, a telephone 
contact was attempted to offer the individual the opportunity to complete the survey via 
telephone conversation, in this way individuals with technical or user problems could still 
participate reducing potential nonresponse error. Early returns of the survey were 
scrutinized for any patterns of missed responses, skipped questions, or technical 
difficulties.  Corrections of these problems was addressed in follow-up reminder surveys 
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to avoid an unnecessary number of non-respondents or increased measurement error due 
to technical issues.  
The initial survey was sent with a unique individual identifier and could not be 
forwarded to closely control and identify respondents. This proved too cumbersome for 
respondents, as it required contacting the study team by email or telephone to refer the 
survey to co-workers who they felt could provide more complete information. In 
subsequent electronic mailings, a public link was included and allowed recipients to 
forward the survey.  
Responses to surveys completed online, were downloaded into an electronic 
database spreadsheet (Excel) per REDCap. Responses to surveys conducted by telephone 
were manually entered into the database. There were a total of 145 survey invitations sent 
electronically. Total responses online and by telephone were 52 for 36%. There were a 
total of 30 surveys completed online, three returned as emails directly to the researcher, 
and 19 completed by follow up telephone interview for a total of 52 respondents 
representing 39 states for 78% of states represented.  Individual questions on two surveys 
were ultimately dropped from the analysis due to inconsistencies in answers between two 
respondents from the same state. 
Data Analysis 
The data were first reviewed to find and delete incomplete and duplicate 
responses. The two open-ended questions were analyzed with a qualitative descriptive 
approach. The researcher conducted a thematic analysis (Sandelowski, 2010; Vaismoradi, 
2013) of the two items requiring free text. Coding and thematic analysis were conducted 
using the thematic analysis process described by Vaismoradi (2013). The data analysis 
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consisted of organizing data, including generating initial codes, searching for themes, and 
reviewing and naming themes. Descriptive statistics and relative frequency statistics was 
calculated on the ordinal data using REDCap and the SPSS statistical package (IBM 
2016). 
Results 
Respondents’ Information and Demographics 
Of the 52 respondents, 31% were from children and family services and 46% 
were from behavioral health/ substance use/ addiction services and 23% chose other. 
Professional credentials included social workers 13.5%, nurses 13.5%, psychologists 2%, 
physicians 6%, and other 65%. The years of experience reported were 48% with > 5 
years, 23% with 3-4 years, 27% 1-2 years and 2% with less than 1 year. A summary of 
respondents’ information can be found in Table 3. 
Table 3 
Respondents Demographic Information 
Sample 
Composition 
N (%)     
Position Children/ 
Family 
Services 
Behavioral 
Health 
Other   
 16 (31) 24 (46) 12 (23) 
 
  
Credentials Social 
Worker 
Nurse Physician Psychologist Other 
 7 (13.5) 7 (13.5) 3 (6) 1(2) 34 (65) 
 
Years of 
Experience 
< 1 years 1-2 years 3-4 years +5 years  
 1 (2) 43 (27) 12 (23) 25 (48) 
 
 
 
 
85 
Screening and Services 
All participating states indicated they were responding in some way to the public 
health and economic impact of increases in opioid use disorder. These actions included a 
combination of public health initiatives, surveillance, and clinical treatment. Of 
individual respondents, 22% indicated universal toxicology screening of pregnant women 
was recommended or required in their state. Twenty-five percent of respondents indicated 
screening of infants was required in their state. Thirty-nine per cent of the states 
responding indicated their state required mandatory reporting of positive screen in 
pregnant women to child protective services. Seventy percent indicated their state 
required mandatory reporting of positive screen in newborn infants to child protective 
services, 7% to the state department of health, no states required or recommended 
reporting to law enforcement. A positive maternal or infant toxicology was categorized as 
child abuse or neglect in 34% of the states. Twenty percent indicted their state has 
criminally prosecuted women for using illicit drugs during pregnancy some of the time, 
80% responded their state never utilizes criminal prosecution for abuse, neglect or other 
charges. 
Enrollment in treatment services was mandatory in cases of positive toxicology 
screen during pregnancy most of the time in 24% of those responding, 47% indicated 
women were required to participate in treatment some of the time, and in 20% treatment 
was never mandatory. Only 10 % of respondents felt availability of treatment services 
was always adequate in their state, 47% felt service availability was sometimes adequate, 
24% responded most of the time, and 20% felt services were never adequate.  
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Treatment services, including medication assisted treatment with an opioid 
substitute was covered by state Medicaid programs and was always available according 
to 60% of respondents, 24% felt it was available most of the time, and 16% reported it 
was covered some of the time. Some additional services for pregnant women with opioid 
dependence were offered in 96% of states. Only 4% reported their state never offered 
additional services or prioritized pregnant women for opioid dependence programs. 
Forty-four percent reported additional services were available some of the time, 20% 
most of the time, and 32% always available. These additional services included 
prioritizing pregnant women for available treatment, additional funding which waived 
fees and co-pays, social support services including transportation and childcare, and 
coordinated services which combined prenatal care, behavioral health, and opioid 
dependence treatment. 
Routine developmental follow up for infants exposed to opioids during pregnancy 
was provided by 34 % of respondents’ states some of the time, 42% most of the time, 
14% always, and 10% responded developmental services were never available.  
Policy Changes and Funding 
The exact impact of federal and state policy objectives (Protecting Our Infants 
Act of 2015 and NGA priorities statement) and professional organizations’ guidelines on 
public health and legislative initiatives is difficult to assess. There are many instances 
where recent state policy changes, and plans align with recommendations from these 
documents. Eighty per cent of states had recently increased funding or added additional 
programs for opioid use disorder. These included changes in general programs for opioid 
dependence, as well as some which specifically targeted pregnant women and infants. 
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Focus areas for treatment for the general population included additional funding for 
detoxification services or medication assisted treatment services, expanded Medicaid 
coverage for treatment services, and liberalizing licensure practices for narcotic treatment 
programs. Other priority areas included establishing care coordination positions within 
the state and counties, expanded services to rural areas through primary care engagement 
in treatment, additional oversight and tracking of prescribing practices, and increased 
availability of naloxone for overdose treatment.  
Prevention, early intervention, and public health education were also mentioned 
as new areas with enhanced programs. Specifically, for women and children, recent 
enhancement of programs included increasing targeted outreach programs to engage 
women earlier in care, expansion of high-risk pregnancy services to include opioid 
dependence and increasing availability of drug rehabilitation and behavioral health 
treatment within obstetric services. Some states also reported establishing care 
coordination services for pregnant women to include opioid dependence treatment and 
behavioral health, and implementing specialized program designed to reduce the severity 
of neonatal abstinence syndrome. 
Respondents indicated recent increases in funding or plans for increasing funding 
or adding additional programs in 62% of the states. Some of these included increased 
access to naloxone, increased funding for medication assisted treatment programs, 
expanding to primary care-based programs with advanced providers in rural areas, 
expanding residential services, and enhancing community-based recovery support. 
Increasing education and prevention efforts was also mentioned including education to 
providers on safe opioid prescribing, as well as public education on safe use of opioids 
88 
and early identification of dependence. Most respondents indicated a general initiative to 
continue to enhance, expand, and integrate recovery support and services. Some 
respondents mentioned their planning is dependent on the future of the patient protection 
and affordable care act (ACA) which will determine available funding for OUD both at 
the federal and state level. A summary of the multiple-choice responses can be found in 
Table 4. A summary of the themes identified in the narrative responses can be found in 
Table 5. 
Table 4 
Summary of Multiple Choice Question Responses 
Question All of 
the 
Time 
Most 
of the 
time 
Most 
of the 
time 
Never 
Does your state criminally prosecute 
mothers for illicit drug use during 
pregnancy? 
0% 0% 20% 80% 
Is the availability of addiction treatment 
services adequate in your state? 
10% 24% 47% 20% 
In your state, is participation in treatment 
mandatory in cases of positive toxicology 
screen during pregnancy? 
0% 24% 47% 20% 
Does your state provide Medicaid 
coverage for opioid use disorder (OUD) 
treatment? 
60% 24% 16% 0% 
Does your state offer additional services 
which facilitate OUD treatment during 
pregnancy? 
32% 20% 44% 0% 
Does your state provide developmental 
follow up services for infants exposed to 
opioids during pregnancy? 
14% 42% 34% 10% 
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Table 5 
Qualitative Analysis: Current and Future Plans for Treatment of Opioid Use 
Disorder 
Themes Representative Quotes 
Increased 
availability of 
medication 
assisted 
treatment 
Allows all medication approved by FDA to be used in licensed 
narcotic treatment programs 
More liberal licensing for suboxone providers (PCP) 
Expansion of the number of OTPs and OBOTs with tripling of 
number of people in treatment  
 
Education and 
regulation of 
safe 
prescribing 
practices 
 
Recent laws passed affect prescription of opioids 
Clinical practice measures for safer opioid prescribing 
 
Increased 
availability of 
naloxone 
 
Naloxone standing orders 
increased Narcan availability to the pubic 
 
Increasing 
services in 
rural areas 
Pilot of expansion of MAT services in rural areas using 
advanced practice nurses 
Through grant funding office-based narcotic treatment programs 
will be available in rural xxxv (state) 
DBHS is looking at recruiting MAT providers in rural areas 
 
Increased 
availability of 
services for 
pregnant 
women & 
families 
Increasing targeted outreach services to engage women earlier 
in care 
Increasing the availability of intervention and treatment services 
for pregnant women 
Development of NAS peer recovery support specialists 
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Addition of Family Task Force 
Pilot treatment programs for mothers with children 
 
Increased 
funding & 
reimbursement 
for treatment 
services 
Obtained additional federal funds for medication assisted 
treatment 
Additional funding related to opioid treatment 
Increase in funding for all SUD services 
 
Addition of 
funding and 
availability for 
residential 
treatment 
Funding for and certification of recovery housing 
Approval of Medicaid waiver to pay for residential services 
Include coverage for adult residential and partial hospitalization 
programs 
 
Plans for 
education and 
prevention 
programs 
Increase education and prevention efforts 
Implement programs for the prevention … of opioid misuse 
Developed clinical guidelines to assist providers in care of 
pregnant women and infants 
 
Discussion 
This survey captures an interesting moment in time when policymakers and their 
constituents seem united in the opinion that opioid use disorder is a public health crisis 
and deserves attention and funding. Although there are many potential models related to 
SUD, each of these approaches has shortcomings. The multi-sourced model of addiction 
emphasizes the complexity of this problem and illustrates that a single strategy will not 
be sufficient to adequately address all the contributing factors (Kovac, 2013). A multi-
pronged approach which considers neurobiology, individuals, underlying issues, and 
social, historical, cultural and environment factors will have the greatest impact. The 
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trend toward interdisciplinary problem solving by planning committees and task forces 
indicates states are recognizing the importance of a diverse and comprehensive plan to 
address maternal opioid use and NAS. 
There is evidence in the survey results of continuing conflict in the United States 
on the view of substance use disorder as a criminal act or public health issue, with 20% 
indicating prosecution of maternal substance abuse is sometimes pursued. These punitive 
responses continue in some areas even though they have been shown to be costly and 
ineffective (Kovac, 2013; Paltrow & Flavin, 2013). This attitude may be driven by 
policymakers’ constituents who continue to see substance abuse as a criminal and moral 
issue, rather than as a chronic disease. However, respondents indicate policy and program 
changes in recent years emphasize the public health approach, addressing first safety, 
with increased naloxone availability and screening to identify those in need of treatment 
and second, increasing availability of effective treatment and funding the cost of 
treatment.  
Many states have undertaken needs assessments and research reviews, looking to 
evidence to assist in shaping their future policy and funding. There is a trend toward 
increases in testing and reporting, but many individuals feel their state lacks adequate 
services for referral to treatment once substance abuse has been identified. Many states 
are examining unique methods for addressing this in a safe and timely fashion, such as 
moving medication-assisted treatment to primary care and expanding licensure to PCPs 
and nurse practitioners. Several states reported they next hope to examine education and 
prevention. Although substance abuse is viewed as a chronic disease by the public health 
community, public opinion continues to be mixed with conflicts apparent in some 
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policies which reflect the continued view of substance use as a moral issue (Angelotta, 
Weiss, Angelotta, & Friedman, 2016). It is important to address these attitudes as they 
inhibit both the individual and public from an effective response. For the individual, 
continued social stigma associated with substance use and marginalization inhibits their 
use of resources and help-seeking.  For public health policy, the attitude will continue to 
interfere with the development and funding of substance use programs which are 
innovative and effective. Public health-oriented approaches with demonstrated 
effectiveness and which are widely available are essential for progress toward the state 
and federal goals related to opioid use disorder. 
Limitations 
There are several limitations to this study, the first of which is the 
representativeness of the sample. Self-directed sampling was utilized, soliciting particular 
representatives assigned as state contacts for both SAMHSA and the Child Welfare 
Gateway who the researchers felt might increase the likelihood they were interested and 
informed on the particular topic of the survey. Choosing potential participants from a 
public list presents several problems, the contact list may not be accurate and up to date, 
and the recipient may not be familiar with the topic areas. The demographic information 
was limited because the survey did not allow a free text answer for the question 
concerning professional credentials. Most of our respondents (65%) recorded “other”. 
The telephone interviews indicate many of the respondents in this category may be 
information, or public relations professionals, but the online survey was not constructed 
to obtain complete information in this area. 
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The decision to allow a public link and forwarding increased the number of 
respondents but credentials, identifying information, and demographic information were 
then entirely by self-report and may be inaccurate, and in some cases were missing 
making it difficult to determine exactly who participated.  Response bias is always a 
concern for survey research and there may be an imbalance of respondents who viewed 
their state response to opioid use disorder in either an overly positive or negative way. 
Respondents also may not feel comfortable providing answers that present themselves, or 
their state, in an unfavorable manner. 
The survey was sent to at least two and sometimes three representatives from the 
same state to increase the likelihood of obtaining information from a higher percentage of 
states. More than one response was received from some states and in some instances 
different answers were recorded from the same state. In two instances one respondent had 
left a question blank and another had answered. In these cases, the answers were used in 
the analysis. Two respondents had conflicting answers within the same state and those 
survey questions were dropped from the analysis. The ability to reach respondents is one 
challenge of surveys. Lack of accessibility to an online survey is a threat and there was a 
significant technical issue with one electronic follow up mailing, the personal link was 
not working correctly, and some participants could not access the survey. One respondent 
was kind enough to email and notify the researcher of the problem with the survey and 
provided an explanation of the technical difficulties, this technical issue may have 
discouraged and frustrated some potential respondents. 
Some of the survey question answer options may have been unclear and led to 
variations in data because respondents may be have interpreted them differently. For 
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example, the answer option “some of the time” may represent different amounts to 
different respondents.  There were also respondents who requested a response of “not 
applicable”, although we had purposively not included this as an option as we felt it was 
not an appropriate answer. However, another available option such as “unsure”, or “I do 
not know” may have been an accurate alternative option. 
The survey also represents a very limited snapshot of time for this problem. 
Opioid use disorder is an area which is currently receiving tremendous attention by 
public health officials, policymakers, and the public. Opinions, from all of these groups, 
are very fluid and can change on even a daily basis. There may be significant changes in 
plans for policies and services, even during the relatively brief time of survey collection 
and data analysis. There is also a predictable lag between development of policy and the 
offering of program services, so responses concerning plans or policy may not reflect 
actual availability of services. 
Conclusions 
Overwhelmingly, states have recently initiated new programs and the majority of 
states continue to plan for additional services for opioid dependency prevention and 
treatment. Potential problems were identified between the development of policy and the 
delivery of program services related to these policies, such as allocating funding and 
availability of OUD treatment providers and facilities. Although the recognition of the 
scope and severity of the problem was slow, the progression from policy statements to 
program implementation has been accomplished in a timely manner in many states. The 
responses indicate a trend toward expanding services, acknowledging evidence-based 
care, improving treatment for pregnant women, and for the general population with 
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opioid use disorder. Although many states have not addressed gender-related issues, 
including responsibility for children, increased need for social support and services, and 
greater incidence of comorbidities such as behavioral health issues, most have expanded 
services for pregnant women and heightened standards of care. 
Most public health programs recently enacted focus on short-term harm reduction 
which is an appropriate initial response, but these need to be followed by evidenced-
based long-term approaches to treating and preventing opioid use disorder and NAS. 
There are several maternal, infant, and environmental factors that have been identified in 
literature as possible contributors to the incidence and severity of symptoms of NAS, and 
subsequently to use of neonatal medication, length of stay, and hospital cost. Additional 
research studies examining the effects of these factors can guide both policy 
recommendations and clinical care. 
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CHAPTER FOUR: Factors Associated with the Need for Neonatal Medication 
Among Infants Born to Opioid Dependent Mothers 
Introduction 
Neonatal abstinence syndrome (NAS), the constellation of withdrawal symptoms 
experienced by neonates exposed to opioids prenatally, is a growing health problem 
affecting an estimated 23,580 infants per year (Ko, 2016) with an estimated cost of $720 
million annually (Patrick et al., 2012).  The number of women taking opioids during 
pregnancy increased five-fold between 2000 and 2009 (1.2 per 1000 live births to 5.6 per 
1000) (Patrick & Wu, 2015). Between 55% and 95% of infants prenatally exposed to 
opioids will experience serious physical manifestations of withdrawal requiring treatment 
with medication to control their symptoms (MacMullen, Dulski, & Blobaum, 2014). NAS 
is a complex problem with many potential contributing factors and complex clinical 
practices related to screening, treatment, and appropriate follow-up which have not been 
adequately explored. There are significant gaps in knowledge concerning many factors 
that may aggravate or ameliorate the illness course of infants with NAS.  
There are several factors that have been identified in literature as possible 
contributors to the onset and severity of symptoms of NAS and subsequently to use of 
neonatal medication, length of stay, and hospital cost. These are typically not the primary 
focus of most studies but are mentioned as possible confounding factors and have 
received minimal attention. These factors include maternal opioid use history (Desai et 
al., 2015; Jones et al., 2010; Patel et al., 2013; Welle-Strand, Skurtveit, Jones, et al., 
2013), exposure to other drugs (Cleary et al., 2013; Jansson et al., 2012; McQueen, 
Murphy-Oikonen, & Desaulniers, 2015,(Wikner et al., 2007; Winklbaur et al., 2008)), 
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maternal tobacco use (Chisolm et al., 2011; Jones et al., 2013), feeding method (Isemann, 
Meinzen-Derr, & Akinbi, 2011; McQueen, Murphy-Oikonen, Gerlach, & Montelpare, 
2011; O'Connor, Collett, Alto, & O'Brien, 2013; Welle-Strand, Skurtveit, Jansson, et al., 
2013), family or primary caregiver  involvement (Abrahams et al., 2007; Bagley, 
Wachman, Holland, & Brogly, 2014; Dumas et al., 2013; Hodgson & Abrahams, 2012), 
location of care (Grossman et al., 2017; Holmes et al., 2016; Loudin et al., 2017; Metz et 
al., 2011), non-pharmacologic/comfort measures (Maguire, 2014), and healthcare 
provider experience and use of standardized clinical care guidelines (Metz et al., 2011). 
Infant characteristics such as gestational age (Dabek, Poeschl, Englert, & Ruef, 2013; 
Dysart, Hsieh, Kaltenbach, & Greenspan, 2007; Liu, Jones, Murray, Cook, & Nanan, 
2010), birthweight (Kaltenbach et al., 2012; Liu et al., 2010), and sex (Holbrook & 
Kaltenbach, 2010; Jansson, Dipietro, Elko, & Velez, 2010; Unger et al., 2011) have also 
been recognized as factors associated with severity of NAS. A more thorough 
examination of such non-pharmacologic factors could direct future research and facilitate 
development of more innovative and effective interventions related to care delivery for 
NAS patients. The full conceptual model based on the review of literature of potential 
factors associated with incidence and severity of NAS and an abbreviated model used for 
this study are included in Appendix B. 
Maternal and infant screening and clinical care guidelines that have potential to 
decrease infant illness, medication needs, lengths of inpatient hospital stay, and hospital 
costs are priorities for this population. A single-center retrospective medical record 
review was undertaken to examine maternal, infant, and environmental factors which 
may be associated with severity of NAS, as measured by need for medication treatment, 
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in infants exposed to opioids prenatally. Specific research questions addressed in this 
study were: 1) what proportion of infants exposed to opioids prenatally require 
medication treatment for NAS? And 2) what maternal, infant, and environmental factors 
are associated with the need for neonatal medication treatment for NAS?  
Methods 
Design 
A retrospective review of electronic and paper medical records was conducted 
with a convenience sample of 204 infants born to mothers who used opioids during 
pregnancy from April 2011 to September 2017 at the clinical site of a large suburban 
Midwestern hospital. Initial descriptive statistics on incidence of infant drug exposure per 
number of live births was obtained by electronic medical record query of diagnoses codes 
of intrauterine drug exposure ICD-9 760.72 and ICD-10 P04.9 and maternal drug use 
complicating pregnancy ICD-9 648.43 and ICD-10 099.320. Eligibility criteria for 
inclusion in the next phase, the examination of related factors, was a diagnosis of NAS 
verified by a recorded ICD-9 code of 779.5 or, after 2015 ICD-10 code of P96.1, neonatal 
drug withdrawal or neonatal abstinence syndrome or treatment with morphine solution. 
Infants were excluded if further examination of the medical record did not indicate 
prenatal opioid exposure by maternal report or maternal or infant toxicology screen. 
Sample 
Approval was obtained from the Indiana University-Purdue University 
Indianapolis institutional review board as well as a statement of clinical cooperation from 
the health care facility’s administration. A retrospective review of electronic and paper 
medical records was conducted with a final sample of 204 confirmed cases of infants 
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born to mothers who used opioids during pregnancy and 121 who were subsequently 
diagnosed with NAS from April 2011 to September 2017 at the clinical site.  
Criteria for Inclusion/Exclusion 
• Diagnosis of maternal drug use verified by diagnosis code of intrauterine drug 
exposure: ICD-9 of 760.72 or after 2015, ICD-10 P04.9 or maternal drug use 
complicating pregnancy: ICD-9 of 648.31 or ICD-10 of P99.320. 
• Diagnosis of NAS verified by a recorded ICD-9 code of 779.5 or, after 2015 
ICD-10 code of P96.1, neonatal drug withdrawal or neonatal abstinence 
syndrome. 
• Infants were excluded if further review of the medical record did not indicate 
prenatal opioid exposure by maternal report or maternal or infant toxicology 
screen. 
The hospital in which the data for study of maternal, infant, and environmental 
factors affecting medication use and length of hospital stay was conducted has a 26-bed 
NICU and a 15-bed pediatric inpatient unit. The average daily census for the NICU is 15 
patients. There are 2-4 patients in the daily census with a diagnosis of NAS. During the 
time period for the study, the annual number of patients with the diagnosis varied from 17 
to 35. A survey of case management records for the facility over the past six years, using 
cases identified for this study indicated an average cost for infants with a diagnosis of 
NAS of $4238 per day when cared for in the NICU. Daily costs for infants transferred to 
the inpatient pediatric unit for weaning of medication after initial treatment in NICU was 
lower at $2852. The charge for newborn nursery/ post-partum days was much lower at 
about $750 per day. The excessive cost of inpatient care makes reducing length of stay a 
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priority, even 2-6 days results in a significant cost savings. There are other potential 
deleterious factors related to transfer of the newborn to the NICU such as separation from 
mother, difficulty maintaining breastfeeding, and interruption of maternal infant bonding 
(Brenneman & Price, 2014). 
In the clinical facility used for this study, standardized clinical screening and 
treatment guidelines were adopted in 2010 and then revised in 2014. The guidelines 
include a specific screening tool (modified Finnegan), primary treatment with morphine 
solution, and standard recommendations for adjunct therapy and weaning. These are all 
key factors to examine related to outcomes for NAS, but due to the use of these standard 
guidelines, there is not sufficient variability in the current sample to examine these 
factors.  
Data Collection/Construction of the Dataset 
After Institutional Review Board approval was obtained, medical records were 
queried from the Epic electronic charting system in a large Midwestern Hospital from 
April 2011 to September 2017. This timeframe was chosen as it corresponds with the 
introduction of an electronic medical record system in the health care facility which 
facilitates the extraction of data. Data were extracted both electronically and manually 
from the EPIC charting system. A data extraction algorithm was developed by an 
informatics specialist employed by the clinical facility. Two separate queries were 
conducted. The first query identified eligible infants from electronic medical records and 
the second query extracted data needed for the study. Both queries were piloted on a 
small group of patients prior to the full query to assess completeness and adequacy of 
data obtained and to establish a secure database. Medication use, Finnegan scores, and 
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length of stay, as well as possible covariates from maternal, infant and environmental 
factors (maternal opioid used, other drug use, tobacco use, infant gestational age, sex, and 
other medical complications, feeding method, location of care, and primary caregiver 
involvement) were obtained. Information was also collected concerning potential 
confounding variables, attending physician, infant health complications, and infant 
adjunct medication (phenobarbital and clonidine). Hospital costs were obtained by a 
query of the case management and utilization review database. The data were transferred 
by the informatics consultant from the electronic medical record (EMR) to an Excel 
spreadsheet, which served as the study database.  
A minimal amount of clinical records continued to be kept on paper charts after 
transition to the EMR system. These paper records included information about maternal 
prenatal history, neonatal drug withdrawal scores (modified Finnegan scores), and 
morphine dosing. This additional data were then added to the study database. After data 
collection was complete, data extracted from the EMR were de-identified and subject 
numbers were used to match electronic and paper records. The database was stored in a 
secure server (IU Box Health) which is password protected and HIPPA compliant. A 
copy of the data collection sheet is included in Appendix D. 
Data Cleaning 
The data were prepared for transfer to the statistical program in three phases. The 
original worksheet with data as extracted directly from the medical record was 
maintained as originally captured. A copy was created as an interim data sheet to 
complete and clean the original data. First, missing fields were identified and completed 
by accessing the individual’s paper records. Then, data were cleaned by removing any 
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elements which should not be transferred to the final dataset because they may impede 
the ability to run the analyses effectively or affect the quality of the statistical analysis, 
such as duplicate entries, out-of-range data, and extraneous characters. Each infant was 
assigned a unique identifier number based on name and medical record number to assist 
with identifying and eliminating any duplicate records. Fields were then recoded 
according to standardized values and coding suitable for analysis in SPSS (see Appendix 
E for additional information on coding). Parameters or reference ranges were set for 
fields with continuous or interval data to help in identifying out of range values which 
needed to be corrected. A third and final dataset was prepared and used for analyses.  
Data Analysis 
 Two hundred and sixty-one eligible subjects were originally identified by EMR 
query during the six-year period from April 2011 to September 2017. Subjects were 
initially identified by ICD-9 or 10 codes of intrauterine opioid exposure/ intrauterine drug 
exposure or neonatal abstinence syndrome/ neonatal drug withdrawal. On closer 
examination of the medical record, 57 or 28% did not meet inclusion criteria due to 
improper diagnostic coding in which examination of the medical record did not confirm 
neonatal intrauterine opioid exposure. Independent variables (maternal age, parity, 
insurer, reason for maternal opioid use, maternal opioid type, other maternal drug use, 
maternal tobacco use, infant’s sex, infant’s birthweight, infant’s gestational age, primary 
caregiver involvement, feeding method, and inpatient hospital unit for stay) were 
compared with outcome variable of initiation of infant treatment with morphine solution. 
All analyses were conducted using IBM SPSS statistical software package.  Exploratory 
analysis to visualize main characteristics was done using histograms and scatter plots and 
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descriptive statistics were performed to summarize characteristics. Associations between 
the independent variables and the outcomes of interest were then analyzed using chi-
square test of association, independent samples t-test, analysis of variance, and logistic 
regression.  
Results 
Demographics of Sample 
The average maternal age ranged from 17 to 45 years with a mean of 27.5 years. 
The sample consisted of 17% primiparous and 83% multiparous mothers. The reasons for 
maternal opioid use were categorized as illicit use (48%), prescription use (12%), and 
opioid use disorder (OUD) treatment (40%). The types of opioid used by mothers were 
methadone (24%), buprenorphine (21%), heroin (9%), other opioid analgesics (26%), and 
unspecified opiate (20%).  Sixty-eight per cent of mothers reported current tobacco use 
and 32% were not using tobacco. Some of the women included in the non-tobacco use 
group had stopped smoking during this pregnancy. In 83% of mothers there were no 
other health complications described in the prenatal record, 7% had other behavioral 
health diagnosis such as schizophrenia, depression, post-traumatic stress disorder, and 
bipolar disorder. Three percent had a diagnosis of chronic pain, 0.5% had other 
neurological diagnosis, such as a seizure disorder, 1% had another diagnosis related to 
metabolic disease, and 5% had a variety of other diagnoses. The infants had gestational 
ages ranging from 28 to 41 weeks with mean of 37.2 and median of 38 weeks. Male 
infants compromised 60% of sample and females 40%. Infant weights ranged from 1.23 
to 4.29 kilograms with a mean of 2.82 kg.  
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Research Question 1. What proportion of infants exposed to opioids prenatally 
require medication treatment for NAS?    
Of the 204 neonates who were exposed to opioids prenatally, 121 (59%) 
developed symptoms of NAS requiring neonatal medication treatment with morphine 
solution. The use of non-pharmacologic comfort measures during care was recorded in 
96% of all infants.   
Research Question 2: What maternal, infant, and environmental factors are 
associated with the need for neonatal medication treatment for NAS? 
Maternal Factors 
Associations between neonatal medication treatment and maternal factors of race, 
parity, type of payment (insurer), source of mother’s opioid use (illicit use, prescription 
use, or opioid use disorder treatment), primary type of opioid used (methadone, 
buprenorphine, heroin, other opioid analgesics-which included codeine, hydrocodone, 
oxycodone, or opiate unspecified from toxicology screen), tobacco use (yes/ no), and use 
of benzodiazepines (yes/no) were examined.  The need for neonatal medication treatment 
for NAS was significantly associated with mother’s race χ2 (2) = 12.008, p = .002, source 
of mother’s opioid use, χ2 (2) = 8.523, p = .014, primary type of opioid used, χ2 (4) = 
27.520, p = .001), tobacco use, χ2 (1) = 5.148, p = .023 and use of benzodiazepines, χ2 (1) 
= 10.158, p = .001. Mother’s age, parity, and type of payment were not associated with 
the need for neonatal medication treatment. However, there were a large amount of 
missing data for the factors of parity and type of payment (insurer), 59% and 85% of 
cases respectively were missing this information. 
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Data were collected on additional medications mothers were taking during 
pregnancy. Sixty mothers (45%) were taking medication in addition to opioids based on 
prenatal history or toxicology screening results (information available on 181 mothers or 
89% of sample). There were a total of 24 different medications from seven categories 
(benzodiazepines, barbiturates, selective serotonin re-uptake inhibitors, stimulants, and 
others). The most common additional medication was a benzodiazepine (n=27). Maternal 
use of benzodiazepines was associated with an increased need for neonatal treatment with 
morphine solution, χ2(1) = 8.702, p =.003. There were not a sufficient number of 
occurrences to determine the association of the other additional medication categories 
with need for neonatal medication treatment. Table 6 summarizes maternal factors, 
which were associated with the need for neonatal morphine treatment. 
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Table 6 
Maternal Factors Associated with Need for Neonatal Medication Treatment 
Maternal 
Factors 
Neonates 
who 
required 
medication 
Neonates 
who did 
not require 
medication 
Statistic Value p-value 
Source of 
Opioid Use: 
Illicit 
Prescription 
Opioid 
Dependence 
Treatment 
 
N =110 
 
49 (.56)* 
9 (.41) 
 
52 (.72) 
N = 83 
 
39 (.44) 
13 (.59 
 
20 (.28) 
x2 (2) 8.523 .014 
Primary Type 
of Opioid 
Used: 
Methadone 
Buprenorphine 
Heroin 
Other Opioid 
Analgesic** 
Unspecified 
Opiate 
 
N = 112 
 
 
40 (.89) 
21 (.55) 
13 (.76) 
 
19 (.40) 
 
19 (.53) 
N = 73 
 
 
5 (.06) 
17 (.45) 
4 (.24) 
 
29 (.60) 
 
17 (.47) 
x2 (4) 27.52 .001 
Use of 
Tobacco: 
Yes 
No 
 
N = 107 
 
78 (.70) 
29 (.52) 
N = 61 
 
34 (.30) 
27 (.48) 
x2 (1) 5.148 .023 
 
Use of 
benzodiazepine 
Yes 
No 
 
N = 111 
 
22 (.88) 
89 (.57) 
N = 70 
 
3 (.12) 
67 (.43) 
x2 (1) 10.158 .001 
Race: 
White 
Black 
N = 120 
113 (.64) 
7 (.29) 
N = 81 
64 (.36) 
17 (.71) 
x2 (1) 12.008 .002 
*Proportion of infants needing treatment versus those who did not 
** includes codeine, hydrocodone, and oxycodone 
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Infant Factors 
Infants requiring medication treatment for NAS had significantly higher 
gestational ages (37.7 weeks vs 36.4 weeks; p = < .001). There was no association found 
between infant’s sex, infant’s weight, or presence of other health complications.   
Environmental Factors 
The need for medication treatment for NAS was significantly associated with 
feeding method (χ2(1) = 11.693, p = .003) and with primary caregiver involvement. More 
infants who were exclusively formula fed required neonatal medication treatment than 
infants receiving breastmilk, either exclusively or in combination with formula.  
However, information about feeding method was missing in 59% of cases.  
 Primary caregiver involvement, measured by percentage of the total hospital days 
when mother or other designated primary caregiver spent at the infant’s bedside, was 
associated with the need for medication treatment. Infants who required medication 
treatment for NAS had a lower percentage of their hospital stay where their primary 
caregiver (usually mother) was present at the bedside (mean = 57% vs 74% of hospital 
days/length of stay; p < .001). A summary of infant and environmental factors associated 
the need for neonatal morphine medication is included in Table 7. 
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Table 7 
Infant and Environmental Factors Associated with Need for Neonatal Medication 
Treatment 
Infant & 
Environmental 
Factors 
Neonates 
who 
required 
medication 
Neonates 
who did not 
require 
medication 
Statistic Value p-value 
Infant 
Gestational 
Age 
Mean 
SD 
N = 121 
 
 
37.7 
1.550 
N = 83 
 
 
36.4 
2.929 
t-test 3.406 .001 
Mother’s time 
at bedside (%) 
57% 
.3059 
74% 
.2647 
t-test -3.834 < .001 
Breastmilk 
Feeding 
Yes 
No 
 
 
34.9% 
65.6% 
 
 
57.9% 
42.1% 
x2 11.693 .003 
 
 
Regression Analysis 
A binomial logistic regression was performed to ascertain the effects of mother’s 
race, mother’s reason for opioid use, mother’s opioid type, maternal tobacco use, 
maternal use of benzodiazepine, infant gestational age, and percentage of visitation time 
by primary caregiver during infant’s hospital stay on the likelihood that the infant needed 
medication treatment. Linearity of the continuous variables with respect to the logit of the 
dependent variable was assessed via the Box-Tidwell (1962) procedure. A Bonferroni 
correction was applied using all nine terms in the model resulting in statistical 
significance being accepted when p < .00556 (Tabachnick & Fidell, 2014). Based on this 
assessment, the two continuous independent variables, infant’s gestational age and 
mother’s percentage of days at the bedside, were found to be linearly related to the logit 
of the dependent variable. The logistic regression model was statistically significant, χ2 
(11) = 42.922, p < .001. The model explained 41.2 % (Nagelkerke R2) of the variance in 
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and correctly classified 76.5% of cases. Sensitivity was 83.8%, specificity was 64.4%, 
positive predictive value was 79.5% and negative predictive value was 70.7%. Of the 
seven predictor variables, only three were statistically significant predictors of need for 
medication treatment for NAS (see Table 4-4). Higher gestational age was associated 
with an increased likelihood of needing neonatal medication treatment. The type of 
maternal opioid used was a predictor, with buprenorphine use decreasing the likelihood 
of need for neonatal medication treatment. A higher percentage of days during the 
hospital stay the primary caregiver/mother was present at the infant’s bedside decreased 
the likelihood of medication treatment. 
Strengths and Limitations 
Strengths of this study include that it is one of the few studies to accurately 
estimate the proportion of infants who were exposed to opioids prenatally who went on to 
require neonatal medication treatment.  In addition, clinical guidelines used to guide care 
in the hospital setting controlled for several important variables, such as selection of 
medication, criteria for weaning, and preparation of caregivers.  This provided 
consistency on these factors between subjects and throughout the timeline of data 
collection strengthening the comparisons between groups. Third, this study was guided 
by a strong evidence-based conceptual framework. Few studies in this area are guided by 
theory or frameworks, making it difficult to understand the full complement of factors 
that influence the need for medication treatment for NAS. A conceptual framework 
provides a solid foundation for many aspects of the study including identifying the 
variables, guiding the literature review, formulating the research questions, and directing 
the methods and analysis. It provides a consistent context and rationale to clearly identify 
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relationships (Meleis, 2011). To minimize potential bias, the specific inclusion and 
exclusion criteria were identified before any EMR query was developed. The researcher 
met with the informatics specialist to provide information about the query and supplied 
the conceptual model and operational definitions of the variables prior to the 
development of the electronic query. Once the EMR query was completed detailed 
records were kept throughout the evaluation of inclusion/exclusion review for potential 
subjects, as well as during the data cleaning process. Specific definitions, precise research 
questions, and a detailed plan prior to the beginning of abstraction helped to increase the 
potential quality of the information. The study was conducted in a single health care 
setting, which increases consistency in identification of subjects and in clinical care, 
however this limits generalizability. 
Several limitations to this study should be noted. Retrospective medical record 
review studies have several inherent limitations including the potential for incomplete 
documentation due to information that was unrecoverable or unrecorded, difficulty 
interpreting information found in the documents due to inconsistent abbreviations or 
acronyms, problems with verification of information, variance in the quality of 
information recorded by individual providers, and difficulty establishing cause and effect 
(Gearing, Mian, Barber, & Ickowicz, 2006). In this study, the prenatal care information 
was particularly incomplete. On the mother’s admission, information from the outpatient 
EMR system is transcribed by the nursing staff into the Epic EMR system used by the 
hospital. The completeness and consistency of what was transcribed was not assessed. 
This may have been the cause of the low number of mothers with other complicating 
health care diagnoses listed in the EMR. Specifically, the low behavioral health 
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complication rate of 7% is much lower than anticipated.  The literature indicates that this 
prevalence may be as high as 56% among all patients with prescription use/misuse or 
opioid use disorder (Han et al., 2017). Data were not originally collected for research 
purposes and consequently, are limited by incomplete or inaccurate data due to 
inconsistency in the quality and thoroughness of information across records.  
The retrospective, cross-sectional, single-group design limits the ability to 
determine cause and effect.  A cross-sectional design is helpful in determining prevalence 
and associations, but because the independent variables and outcomes were measured 
simultaneously it was not possible to determine the specific relationship between 
exposure variables and outcomes (Carlson & Morrison, 2009).  Using ICD-9 and ICD-10 
codes for initial screening was a potential limitation due to inconsistent use of the codes 
among various individual healthcare providers. Specific information could not be 
obtained about differences in coding between providers. It also creates a potential bias 
toward including more severely affected patients with NAS. Patients with milder 
symptoms and those, whose symptoms develop after the initial 2-3 day hospitalization 
and are identified on readmission, may not have been captured. There were two infants 
included in the study that were discharged within 2-3 days from birth and re-admitted in 
the first week of life for symptoms of NAS. These two infants received morphine 
treatment. There may be affected infants who were re-admitted to other facilities. Thus, 
the estimated proportion of infants who require treatment for NAS in our cohort may be 
lower than the actual frequency in the population at the facility.  The retrospective nature 
of the chart review over a 6-year period leads to inconsistencies in the clinical 
documentation which may have occurred due to changes in clinical practice over time. 
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There may have been better identification and greater utilization of coding for 
intrauterine drug exposure and NAS in more recent years due to increasing attention on 
topic, increased provider training, and heightened awareness. Therefore, increasing use of 
the ICD-10 code may not reflect a true increase in the number of affected patients. Much 
of the mother’s prenatal history was derived from the initial prenatal visit and admission 
patient interviews. Determining whether documentation of patient-reported information 
into the EMR was accurate and what information may have been lost or distorted in this 
process was not possible.  
Discussion 
The results of this study provide some interesting insights into factors which may 
affect the incidence and severity of neonatal abstinence syndrome. There were several 
factors which were shown to be associated with the initiation of medication treatment. 
Mother’s reason for opioid use, type of opioid used, use of tobacco, use of 
benzodiazepines, infant’s gestational age, feeding with breastmilk, and amount of time 
the primary caregiver spent at the infant’s bedside all were significantly associated with 
the initiation of medication. Although previous studies have not specifically examined 
need for neonatal medication treatment, these results are consistent with previous studies 
which identified factors of type of maternal medication (methadone versus 
buprenorphine), use of tobacco, and use of benzodiazepine with outcome variables of an 
increased peak neonatal medication dose, increased length of treatment, and increased 
hospital LOS (Chisolm et al., 2011; Pritham, 2009; Schindler et al., 2003; Seligman et al., 
2008). The findings of factors of infant’s gestational age (< 36 weeks) and the use of 
breastmilk or breastfeeding as factors which decrease need for neonatal medication is 
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also consistent with previous studies which used peak medication dose and length of 
hospital stay as outcome variables (Abdel-Latif et al., 2006; Dysart, Hsieh, Kaltenbach, 
& Greenspan, 2007; McQueen, Murphy-Oikonen, Gerlach, & Montelpare, 2011; 
Seligman et al., 2008; Welle-Strand et al., 2013). The variable of percentage of days the 
primary caregiver was present at the bedside was used as a proxy for maternal or primary 
caregiver involvement and was significant in reducing the number of infant’s who needed 
medication treatment. Although there is no direct comparison of this variable in previous 
studies, others have examined this factor in several diverse ways, such as rooming-in or 
parent care arrangements which have been shown to decrease need for neonatal 
medication and hospital length of stay (Abrahams et al., 2007; Grossman et al., 2017; 
Hodgson & Abrahams, 2012). 
There was a significant association between race and need for neonatal 
medication which has not been identified in previous studies. Infants of black mothers 
were less likely to need medication treatment. There was limited variability in the sample 
of infants exposed to opioids prenatally, 87% were white, 12% of mothers were black, 
and only 1% Hispanic. The distribution of opioid exposure itself is an interesting point 
but may be related more to the single facility design and the distribution in the facility’s 
patient population than reflective of the distribution of opioid use during pregnancy 
among races. 
Two factors which were associated with a decreased need for neonatal medication 
treatment were primary caregiver involvement and use of breastmilk feeding, even using 
very general measures for these variables in the current study. Studies with more precise 
measurement techniques for these variables are an important next step. A future study, 
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which collects information on both quality and quantity of time spent by primary 
caregiver would provide valuable information to guide both preparation of the family 
prenatally and design of the neonatal care environment. The ability to assess the impact 
of breastmilk feeding was very limited in this study due to the large amount of missing 
information, a better query, or a study which collects this information accurately 
prospectively with measures of quantity, could provide more useful information to help 
prepare mothers prenatally and direct clinical care of the infant. 
Several factors examined could be useful for identifying infants at risk and used 
to determine need for surveillance and anticipate potential need for medication such as 
mother’s reason for opioid use, infant’s gestational age, and sex, although they are not 
modifiable, and therefore not amenable to intervention. Several factors may be 
modifiable prenatally, such as type of opioid used, use of benzodiazepines, and use of 
tobacco.  Future prospective studies which manipulate these factors are needed. Variables 
related to the environment of care, such as encouraging participation by primary 
caregiver, and facilitating breastmilk feeding are additional modifiable factors that have 
potential to improve outcomes for these infants. Additional studies using a prospective 
design with thorough exploration of maternal history and documentation is needed to 
accurately assess the impact of the maternal factors. 
These results should be interpreted with caution because of the problems and 
limitations inherent in retrospective chart-review research, however, the results provide a 
starting point for researchers for further research based on the significant associations. 
These results can be used to inform future prospective research studies both descriptive 
and interventional which can direct care for both the mother and infant.  Plans of care are 
115 
needed that decrease hospital length of stay which will then decrease costs, as well as 
optimize developmental outcomes, maternal role adaptation, and decrease family 
disruption.  
Growing numbers of infants are experiencing NAS and the resources needed for 
both short and long-term complications are extensive. Current research with the aim of 
decreasing incidence and severity of NAS has many limitations including lack of a 
theoretical framework or conceptual model to guide design and intervention, lack of 
standardized measures for diagnosing and treating NAS, and largely retrospective 
designs. Future goals for research should include studies which address these 
shortcomings. Appropriate future aims are gaining knowledge about predicting NAS 
incidence and severity, developing evidence-based recommendations for optimal prenatal 
and neonatal care, and recognizing the importance of compassionate and holistic care for 
both the mother and infant.   
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CHAPTER FIVE: Discussion and Conclusions 
Introduction 
This chapter presents a summary of the three studies conducted to examine 
maternal opioid use and neonatal abstinence syndrome, followed by discussion and 
synthesis of the major findings. In addition, limitations of the studies, implications for 
future research, and conclusions will be presented.  
Significance of the Problem 
There are over 24,000 pregnancies estimated to be affected by opioid use each 
year (Whiteman et al., 2014). In 2012, almost 22,000 neonates per year were diagnosed 
with neonatal abstinence syndrome in the United States, translating to one neonate born 
every 30 minutes (Patrick, Davis, Lehmann, & Cooper, 2015). Health care costs related 
to maternal opioid use and NAS are estimated to be greater than $1.5 billion nationwide 
(Patrick et al., 2015).  
Summary of the Included Studies 
Risk factors that contribute to the incidence and severity of NAS have not been 
well established in the literature and research in this area has been problematic for several 
reasons. Some of the weaknesses of research to date include study design differences, 
lack of theoretical framework or conceptual model to guide design, inconsistency in 
definitions and measurement, constantly evolving clinical care practices, and variation in 
measurement of outcomes. In first undertaking a broad research mission in the area of 
NAS my original aims were focused on the clinical care of the infant after diagnosis. On 
closer examination of the issue this approach was too narrow to appreciably impact the 
problem. Research which included assessment and care of the mother, as well as health 
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systems and policies related to opioid use were essential for the ultimate aim of 
identifying, treating, and preventing NAS. 
Exploring the Experiences and Needs of Women and Mothers 
A qualitative approach offered insights into the personal experience of pregnant 
women and new mothers who use or misuse opioids and experienced fetal and infant 
loss. Eleven women with histories of prescription or illicit opioid use who experienced 
fetal or infant loss participated in the semi-structured telephone or in-person interview 
portion of the mortality case review. Thematic analysis was used to analyze interview 
data and identify themes. Five themes were identified related to the care experiences of 
participants throughout pregnancy and fetal/infant loss: Frustration and anger related to 
not being heard, feeling minimalized; Being overwhelmed with attempts to process and 
understand medical complications and outcomes; Profound sense of grief and coping 
with loss; Need to understand why and make difficult decisions; Placing blame and guilt 
over death. 
Especially striking was the mothers’ experience of not being heard or feeling 
undervalued which appeared in every interview. These findings suggest that women who 
use opioids and experience fetal/infant loss have complex care, educational, and 
emotional needs. When developing interventions for these women, it is important to 
address their unique and complex circumstances.  
Facilitating Prevention and Optimal Treatment of Maternal OUD and NAS through 
Health Policy 
The problem of maternal opioid use disorder and NAS cannot be fully addressed 
while focusing only on clinical care. Advocacy and policy development are essential 
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components to effective and comprehensive solutions. A non-experimental descriptive 
study using an electronic survey with telephone follow-up for non-respondents was used 
to assess current US States’ trends in policy development and public health practices 
related to maternal opioid use in pregnancy and treatment of NAS.  A 19-question survey 
instrument formatted in REDcap was distributed to a convenience sample of 145 
representatives from individual U.S. state departments of child welfare/ child and family 
services and representatives of state health departments in the divisions of substance 
abuse and mental health.  
Examining Factors Associated with Incidence and Severity of NAS in Infants 
Exposed to Opioids Prenatally 
A retrospective chart review was conducted for the purpose of examining factors 
associated with the incidence and severity of NAS as measured by the outcomes of need 
for initiation of neonatal medication among newborns born to opioid-dependent mothers. 
There were 204 infants born to mothers who used opioids during pregnancy. Data from 
April 2011 to September 2017 were collected from medical records of a large 
Midwestern hospital. Exploratory analysis and descriptive statistics were performed. 
Associations between independent variables and outcomes were examined using 
correlations, chi-square, t-tests, analyses of variance, and logistic regression. Of the 204 
neonates who were exposed to opioids prenatally, 121 (59%) developed symptoms of 
NAS requiring medication treatment with morphine. Factors were divided into three 
categories maternal (age, parity, race, reason for opioid use, type of opioid used, use of 
other drugs, and tobacco use), infant (gestational age, sex, and other health 
complications), and environment (hospital unit used for inpatient care, feeding method, 
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and primary caregiver involvement). The outcome measure was the need for neonatal 
medication treatment with morphine solution.  
Discussion and Synthesis of Major Findings 
The results of the descriptive qualitative study in the population of women who 
used opioids and experienced fetal or infant loss indicate the women who used opioids 
and experienced infant/fetal loss had complex needs which were often unmet. Of note, 
participants in our study repeatedly voiced concerns about not being heard, being 
ignored, and being undervalued. The participants’ perception was that caregivers who did 
not listen to them, minimized their feelings, and were unsupportive, contributed to their 
pain, guilt, and bereavement experience. For health care provider, projecting acceptance, 
accessibility, and readiness to listen is essential, as well as providing understandable 
medical information about the care provided and procedures performed is essential 
(Fleischer, Berg, Zimmermann, Wüste, & Behrens, 2009).  
Many participants in the study had difficulty understanding why devastating 
medical complications occurred for them and their infants and often felt the 
communication from health care providers was inadequate, incomplete, or difficult to 
understand. This problem of incomplete understanding may be caused partially by the 
stress and uncertainty of the situation itself, but also may reflect a lack of communication 
skills among health care providers (Pozzo, Brusati, & Cetin, 2010). Dealing with grief, 
guilt, and blame was an ongoing process for participants from the first time infant 
complications were identified through the infant’s death and months later.  
The findings in the survey of US state policies identifies common trends and 
differences in individual states’ responses to the opioid crisis. The majority of states have 
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recently initiated new programs to address opioid use and misuse and the majority are 
planning for additional programs to meet their states’ needs in the treatment and 
prevention of opioid use disorder. Some states are experiencing problems between the 
development of policies and the funding and delivery of program services. Although the 
recognition of the scope and severity of the problem was slow, the current progression 
from policy statements to program implementation has been accomplished in a timely 
manner in many states. There is evidence in the survey results of continuing conflicts in 
attitudes on substance use disorder as a criminal act as opposed to a public health issue 
and chronic disease, with 20% of states indicating prosecution of maternal substance 
abuse is sometimes pursued.  The trend toward interdisciplinary problem solving by 
planning committees and task forces indicates states are recognizing the importance of a 
diverse and comprehensive plan to address maternal opioid use and NAS. 
In the retrospective chart review which focused on clinical care of maternal opioid 
use and NAS, there were several significant associations between the factors examined 
and the outcome variable in the retrospective chart review. Neonates requiring morphine 
had significantly higher gestational ages than those who did not, infants also exposed to 
tobacco and benzodiazepines prenatally were at increased risk of needing medication 
treatment. The mother’s reason for opioid use and the type of opioid she used were also 
associated with differences in the proportion of infants who required medication 
treatment. Breastmilk feeding and increased primary caregiver involvement were also 
associated with a decrease in need for neonatal medication treatment.   
These three studies represent an inclusive approach to the research question of 
what factors are associated with increased severity of NAS. The mother’s experience and 
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her needs for complete care, clinical care issues for the mothers and infants, and policy 
decisions which ultimately affect the availability and funding of research are all 
components of comprehensive solutions. A variety of methods can balance the strengths 
and weaknesses of each approach to obtain reliable and robust results (Creswell & 
Creswell, 2017). Considering public health practices and policy is also a key component 
for this issue that determines availability and affordability of care for mothers and infants. 
Public health policy facilitates availability and accessibility of services and determines 
reimbursement for patients and providers. Clinical research informs providers and 
policymakers decisions on best practice guidelines and funding. The problem of opioid 
use in pregnancy is changing rapidly and becoming more complex, no single type of 
study can address all the components that contribute to the severity of the problem. 
Sharing information and resources between disciplines and investigating and interpreting 
the current needs of the population, the delivery of care, and the policy response is key to 
informed decisions in both individual clinical care and population health related to opioid 
use. Ongoing research in this area will continue to address the gaps in information for 
patients, health care providers, and policymakers. 
Limitations of the Studies 
There are important limitations to note in the included studies. The sample sizes 
were limited in all three of the studies. Studies in a larger sample size could have 
generated more accurate results. This is particularly important in the two quantitative 
studies as saturation was achieved on the major themes in the qualitative study, however 
a richer, more complete description of the mothers’ experience might have been achieved 
with a larger sample. The retrospective nature of the studies is problematic in an area 
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which is changing so quickly. There may be major differences in assessment and clinical 
care during the time period studied from the subjects in the earliest year to the latest.  
In both the studies using secondary data, Fetal Infant Mortality Review (FIMR) 
records and the retrospective EMR review, available data was collected for other 
purposes. In paper one, there are specific objectives of the FIMR review, to explore ways 
to decrease infant mortality, and the interview questions were constructed for this 
purpose. An independent study with interviews conducted specific to the research 
objective of documenting the mother’s lived experiences would enhance the quality of 
the insights generated. The study on associated factors utilized data initially collected for 
clinical purposes and this limited ability to explore certain variables because of 
inconsistent, incomplete, or ambiguous entry in the EMR.  
In the survey on US state policies, even though research objectives were 
formulated early and the survey was designed to meet these purposes, the inexperience of 
the researcher caused gaps in information and limited the sample. The formulated 
research aims, and objectives were too broad to capture the objectives accurately in the 
brief survey. In a future survey, with research aims and objectives narrowed perhaps to 
pregnant women only, the level of focus could be increased and results more specific. 
Literature review in the topic area of maternal opioid use and NAS is challenging 
because of the focus and urgency assigned to this particular problem and the amount of 
new material published each month. It is a contemporary and evolving research problem 
with frequent changes in assessment, clinical care, and policy. Parts of the literature 
review findings used as the foundation to formulate the research objectives in these 
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studies were outdated before the study was completed due to the abundant research 
conducted and published during the study time period.  
The scope and depth of discussions in these papers is compromised on many 
levels compared to the works of experienced scholars. The researcher’s expertise is 
extensive in clinical care of mothers and infants exposed to opioids prenatally, but very 
limited in conducting research and evaluating and communicating findings, particularly 
the areas of conclusions and limitations  
Implications for Future Research 
There are many aspects of the problem of opioid use in pregnancy and NAS 
which need continued systematic evaluation. Rather than focusing on any single factor, a 
collaborative and diverse research approach is most likely to produce viable solutions. 
Collaboration should start with those most affected by the issue, the mothers who use and 
misuse opioids and their families. Further qualitative research with this population is 
needed to gain a richer understanding of their needs, frustrations, facilitators and barriers 
to care, and underlying and motivations. Additional qualitative research in this population 
with interview and recruitment strategies guided by research questions specific to the life 
experience of pregnant women and mothers who use and misuse opioids will provide a 
more in-depth exploration than what can be achieved with a survey question approach, or 
open interview data originally collected to answer other research questions. Insight 
gained about beliefs, values, feelings, and motivations that underlie behaviors will 
provide a starting point to further research in prevention and clinical care strategies. 
The substantial increase in patients with the diagnosis of NAS has helped 
clinicians gain experience with the population. However, the rapidly increasing number 
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of patients caused frequent alterations and accommodations in the delivery of clinical 
care which may have interfered with the quality of research. The immediate clinical 
needs and lack of available resources necessitated protocols based on either clinical 
expert advice or poorly designed studies. Studies based on historical controls are difficult 
to interpret with guidelines constantly changing for both mother and infant. Instead of 
targeting specific factors, multiple parts of the care model often changed between the 
control patients and the intervention group making it difficult to compare and discern 
which factors contributed, and to what degree, to the differences in outcomes. 
Further research is needed to understand optimal treatment for both pregnant 
woman who use and misuse opioids and their infants. Factors which are associated with 
the incidence and severity of NAS that can be modified during prenatal care have been 
identified in this study.  These include medication chosen for opioid use disorder 
treatment, smoking cessation, and limited use of adjunct medications.  Interventions that 
are designed to alter these factors can be developed and implemented to improve 
management of the mother’s illness and neonatal outcomes. As the next step, these 
factors should be examined prospectively with attention to consistency and control of 
confounding variables.  Once associations with maternal and neonatal outcomes are 
established, promising interventions can be designed and tested.  
More research is required to develop consistent and reliable screening tools which 
are appropriate for infants throughout the course of treatment. Consistent screening is 
essential for determining incidence of NAS, as well as comparing the success of various 
treatment strategies. Developmentally appropriate screening tools which are reliable and 
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valid will improve the consistency of decisions to initiation medication and assist with 
weaning strategies. 
Many concepts that are included in the full conceptual model developed for this 
dissertation could not be examined in the included studies. Several factors in the model 
could not be explored due to limitations of retrospective chart review and no appropriate 
proxy for measurement. Particularly feeding method, primary caregiver involvement, and 
a rooming-in model of care are areas identified in the review of literature which show 
promise for improving short-term outcomes and should be prioritized for further study. 
There is a lack of studies designed to examine these factors thoroughly, and to limit the 
influence of other potentially confounding variables, such as variations in assessment tool 
and treatment guidelines. A prospective design which begins during pregnancy, rather 
than after the infant is born, including optimizing mother’s treatment, as well as 
preparation for parenthood and for care of her infant during observation and treatment of 
NAS, would be suited to answer questions on these factors and their relationship to short 
and intermediate outcomes. 
Other aspects of the model which were not assessed include an examination of 
maternal-infant attachment related to stress neurobiology in opioid dependence and the 
factors of infant temperament, maternal temperament, reactivity, and reciprocity (Schore, 
2001). A thorough examination of reliable and valid instruments to measure these 
variables in the population of affected mothers and infants would facilitate testing of the 
conceptual model. More research is also needed to understand the long-term outcomes 
included in the model, such as re-hospitalization, foster placement, developmental 
outcomes, neglect, abuse, and future addiction, due to the very limited timeframe 
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available for the current studies. Long-term follow up of families affected by opioid use 
and misuse is the only way to develop a complete understanding of the population at 
greatest risk and develop strategies to provide them with optimal care. The optimum goal 
of research on maternal opioid use in pregnancy and NAS is to reduce the burden of this 
problem on the individual, the healthcare system, and society. Future research conducted 
prospectively in a larger and more diverse sample is needed to examine the relationships 
between factors associated with incidence and severity of NAS and to assess their impact 
on the outcome variables.  
Conclusions 
Maternal use and misuse of opioids during pregnancy is a poorly understood 
cause of significant infant and maternal morbidity, currently there is a lack of sufficient 
evidence to determine optimal evaluation or treatment. Women who used opioids in 
pregnancy and experienced fetal and infant loss have complex emotional and clinical care 
needs. Health care providers have a responsibility to partner with women who use opioids 
in designing care and making treatment decisions that acknowledge their physical and 
emotional needs. Care providers should be sensitive to the needs of these women to help 
reduce their perception of stigmatization and increase their perception of being valued.   
Public health policy and management in the area of use and misuse of opioids is 
evolving to meet the demands of increased incidence and severity of this issue. U.S. 
states have initiated new programs and the majority of states continue to plan for 
additional services for opioid dependency prevention and treatment. There is evidence in 
the survey results of continuing conflict in the United States on the view of substance use 
disorder as a criminal act rather than a chronic illness and public health. Allocation of 
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funding and adequate availability of OUD treatment providers and facilities continue to 
be problematic in most states. The survey respondents indicate a trend toward expanding 
services, acknowledging evidence-based care, improving treatment for pregnant women, 
and for the general population with opioid use disorder. There continues to be gaps 
identified in gender-related issues, including responsibility for children, increased need 
for social support and services, and greater incidence of comorbidities such as behavioral 
health issues, most have expanded services for pregnant women and heightened standards 
of care.  
Clinical care of mothers who use opioids during pregnancy, and their neonates 
requires ongoing systematic research to determine optimal risk assessment, surveillance, 
and treatment. In the current study, several factors were shown to be associated with the 
initiation of medication treatment. Mother’s source of opioid use, primary type of opioid 
used, use of tobacco, use of benzodiazepines, infant’s gestational age, feeding with 
breastmilk, and amount of time the primary caregiver spent at the infant’s bedside all 
were significantly associated with the initiation of medication. These results should be 
interpreted with caution because of the problems and limitations inherent in retrospective 
chart-review research, however, the results provide a starting point for researchers for 
further descriptive and interventional studies based on the significant associations.  
Assessment of the individual experiences of women with opioid use disorder, 
development of health policies for prevention and treatment of opioid use disorder, and 
clinical research to support clinical decision-making for mother and infant are all required 
to adequately address the current problem of maternal opioid use during pregnancy and 
neonatal abstinence syndrome. An effective response to the epidemics of opioid use 
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during pregnancy and the incidence of NAS requires ongoing coordinated research and 
intervention in clinical care of mothers and infants, public health, and health policy. 
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Appendix B: Conceptual Models 
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Abbreviated Model of NAS: Treatment, Associated Factors, and Outcomes Adapted from Attachment Theory (Blowby) and 
Schore’s Regulation Theory 
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Appendix C: Conceptual and Operational Definitions 
 
Construct/ 
Variable 
Conceptual 
Definition 
Operational 
Definition 
Source of Data 
Field 
Intrauterin
e opioid 
exposure 
Exposure of fetus via 
placental circulation 
to opioids ingested 
by the mother during 
pregnancy (R. J. 
Desai et al., 2015). 
ICD-9/10 code 760.7/ 
099.32 or P04.4 and 
confirmed by review 
of maternal self-
report during prenatal 
history or positive 
urine toxicology 
screen during 
prenatal care or at 
admission for labor 
(Rishi J Desai, 
Hernandez-Diaz, 
Bateman, & 
Huybrechts, 2014; S. 
Patrick et al., 2015). 
Electronic medical 
record (EMR) 
review (Prenatal 
History and 
Neonate 
admission) 
NAS A constellation of 
symptoms associated 
with drug 
withdrawal in 
neonates exposed to 
drugs in-utero, most 
commonly opioids. 
NAS is characterized 
by symptoms in 
three categories 
central nervous 
system, autonomic, 
and gastrointestinal 
functioning (Lauren 
M Jansson & Velez, 
2012). 
ICD-9/10 code 
779.5/P96.1 and 
confirmed by review 
of record indicating 
prenatal opioid 
exposure and either 
initiation of neonatal 
MAT or Finnegan 
score > 8 (R. J. Desai 
et al., 2015; S. 
Patrick et al., 2015)}. 
Electronic medical 
record (EMR) 
review 
(medication 
administration and 
Finnegan score) 
Type of 
maternal 
opioid use 
(prescribed 
for MAT or 
other 
medical use 
or illicit 
opioid use) 
Opioid medications 
ingested by the 
mother either 
prescribed or illicit 
Medication self-
reported in prenatal 
history or results 
recovered by urine 
toxicology screen 
during prenatal care 
or at hospital 
admission. 
Electronic medical 
record (EMR) 
review (Prenatal 
Hx and laboratory 
results) 
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Other 
maternal 
drug use 
Other medications 
ingested by mother 
which may affect 
neonatal symptoms 
of withdrawal 
(benzodiazepines, 
barbiturates, 
selective serotonin 
reuptake inhibitors, 
caffeine) 
Medications self-
reported in prenatal 
history or results 
recovered by urine 
toxicology screen 
during prenatal care 
or at hospital 
admission. 
Electronic medical 
record (EMR) 
review 
(Prenatal Hx) 
Maternal 
tobacco use 
Mother’s continued 
cigarette smoking or 
use of nicotine 
patches throughout 
pregnancy 
Self-reported in 
prenatal history 
Electronic medical 
record (EMR) 
review 
(Prenatal Hx) 
Infant sex Infant sex as 
determined by 
physical examination 
at birth 
Recorded sex by 
healthcare provider 
on birth record 
Electronic medical 
record (EMR) 
review 
(Birth history) 
Infant 
birthweight 
Infant weight 
immediately 
following birth 
Birthweight in grams 
as recorded on the 
delivery summary/ 
birth record 
Electronic medical 
record (EMR) 
review 
(Birth history) 
Infant 
gestational 
age 
Number of 
completed weeks of 
gestation at birth 
(Battaglia & 
Lubchenco, 1967). 
Based on estimated 
date of delivery 
recorded in prenatal 
chart assigned by best 
obstetric estimate 
(first trimester 
ultrasound, last 
menstrual period, late 
prenatal ultrasound)  
Electronic medical 
record (EMR) 
review 
(Birth history) 
Infant 
complicatio
ns 
Other health 
complications 
experienced by 
neonate during initial 
hospitalization 
Diagnoses, other than 
those related to NAS, 
recorded in neonate’s 
chart during initial 
hospitalization. These 
may include, but are 
not limited to 
prematurity, 
congenital anomalies, 
and birth 
injuries/asphyxia (S. 
W. Patrick et al., 
2012). 
Electronic medical 
record (EMR) 
review 
(Neonate 
admission note 
and progress 
notes) 
Need for Use of an opioid Recorded dose of oral Electronic medical 
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neonatal 
morphine 
treatment 
medication to treat 
and control 
symptoms of opioid 
dependence and 
withdrawal (Lauren 
M Jansson & Velez, 
2012) 
morphine solution to 
infant. 
record (EMR) 
review 
(medication 
administration hx) 
Peak Dose 
of Neonatal 
opioid 
medication 
Maximum morphine 
dose administered 
(David A Osborn et 
al., 2010) 
Highest morphine 
dose in mg/kg/day 
with administration 
recorded in EMR 
(Colombini et al., 
2008) 
EMR review 
nursing medication 
administration 
record 
Use of 
Neonatal 
Adjunct 
Medication 
Other medication 
used to assist in 
control of NAS 
symptoms, such as 
phenobarbital or 
clonidine 
(Colombini et al., 
2008) 
Medication 
administration 
recorded of 
phenobarbital, 
clonidine, or other 
medication which is 
indicated in physician 
progress note as 
being used for the 
purpose of adjunct 
therapy to neonatal 
opioid medication 
Electronic medical 
record (EMR) 
review 
(medication 
administration hx 
and physician 
progress note) 
Primary 
Caregiver 
involvemen
t 
Amount of neonate’s 
care which was 
provided by a 
primary caregiver 
(mother, family 
member, foster 
parent) during the 
neonate’s inpatient 
stay 
Percentage of time 
infant was 
hospitalized that 
primary caregiver 
(mother, father, foster 
parent) was recorded 
at bedside (number of 
days of mother visits 
/ total hospital stay) 
Electronic medical 
record (EMR) 
review 
(nursing 
flowsheet) 
Feeding 
Method 
Type of feeding 
method and 
substance 
Feeding methods and 
type recorded during 
hospital stay feeding 
with exclusive 
breastmilk, exclusive 
formula or  
combination of 
breastmilk and 
formula(Okan, Ozdil, 
Bulbul, Yapici, & 
Nuhoglu, 2010; 
Welle-Strand, 
Electronic medical 
record (EMR) 
review 
(nursing 
flowsheet) 
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Skurtveit, Jansson, 
Bakstad, Bjarkø, et 
al., 2013) 
Unit of 
Care 
Location of 
neonate’s room 
during inpatient stay 
Total number of days 
of neonate’s inpatient 
stay in each unit: 
post-partum/ NBN, 
neonatal intensive 
care unit, and 
pediatric unit 
(Grossman et al., 
2017; Loudin et al., 
2017) 
Electronic medical 
record (EMR) 
review 
(hospital room 
number) 
Finnegan 
Score 
An observation scale 
dividing symptoms 
in three broad 
categories of 
neurological, 
metabolic, and 
gastrointestinal used 
to quantify the 
severity of NAS 
symptoms (K. C. 
D'Apolito, 2014; L. 
P. Finnegan, R. E. 
Kron, et al., 1975). 
Highest modified 
Finnegan score 
recorded during 
hospitalization and 
day of life of highest 
Finnegan score (K. C. 
D'Apolito, 2014) 
Electronic medical 
record (EMR) 
review 
(Finnegan score 
NAS flowsheet) 
Hospital 
LOS 
Total number of 
days neonate 
remained an 
inpatient after birth 
Number of days from 
admission at birth to 
discharge to home or 
foster care (S. W. 
Patrick et al., 2012) 
Electronic medical 
record (EMR) 
review 
Hospital 
Cost 
Total cost of 
neonate’s initial 
hospital stay 
Total cost in dollars 
billed to neonate by 
hospital for inpatient 
stay (S. W. Patrick et 
al., 2012) 
Case Management 
Record Review 
Calculated 
Hospital 
Cost 
Total cost of infant’s 
hospital stay 
calculated based on 
average daily cost 
for infants with 
diagnosis of NAS for 
newborn nursery, 
pediatrics and 
neonatal intensive 
care unit. 
Total in dollars 
calculated form 
averages supplied by 
the hospital’s case 
management 
department and 
compared to infants 
with actual cost to 
determine correlation 
and accuracy 
Case management 
and hospital 
administration 
records; 
calculations by 
SPSS 
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Appendix D: Data Collection Sheet  
Factors related to Severity of NAS: Data Collection Tool 
Subject No.___________    Date ______________ 
Maternal 
• Mother’s Name __________________ 
• Mother’s MRN___________________ 
• Maternal age: _____ years 
• Maternal race: Caus / Black / Hispanic / Burmese / Other 
• Marital status: Married/ Single / Divorced / Separated  
• Employed: Full time / Part time / Student / Unemployed / Disabled 
• Gravida (#pregnancies): ____ 
• Parity (#live births):______ 
• Insurer:  Medicaid / Private Insurance/ self-pay 
• Opioid use diagnoses: illicit / prescription / opioid dependence disorder treatment 
• Type of opioid used:  methadone / buprenorphine / heroin / other opioid analgesic 
/ opiate unspecified 
• Other maternal drug use: benzodiazepine / barbiturate / SSRI / other______ 
• Tobacco use: yes/ no 
Infant 
• Infant’s Name_____________________ 
• Infant’s MRN______________________ 
• Infant’s DOB______________________ 
• Gestational age: ___   weeks____ days 
• Gender: male/ female 
• Weight : ______ grams 
• Feeding Method:  exclusive breastfeeding/ exclusive bottle feeding/ breast and 
bottle/ exclusive breastmilk from bottle/ bottle feeding with formula 
• Infant health complications: prematurity/ respiratory distress / hypoglycemia/ 
/congenital anomalies/ sepsis/ other ________ 
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Enviroment/ Treatment 
• Peak Finnegan score:_______ DOL#: _______ 
• Peak morphine dose: _______ DOL#:_______ 
• Adjunct Medication: phenobarbital / clonidine / other____________ 
• Number of days in NICU : ______ 
• Number of days in Pediatric Unit: ______ 
• Number of days attending physician #1: _______ 
• Number of days attending physician #2: _______ 
• Number of days other attending physician : _______ 
• Number of days of parent visitation: __________ 
• Length of hospital stay: ______ days 
• Proportion of hospital stay primary caregiver at bedside (days of visitation/ total 
hospital stay: ___________ 
• Total Hospital charges #: $_____________ 
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Appendix E: Codebook NAS Factors Analysis 
Scott_Codebook_NASFactors 
 
Variable Label Variable Values Coding 
Subject # Assigned 
Subject # 
1-204 1-204 
BABY NAME Infant name Identifying 
information 
 
BABY MRN Infant medical 
record number 
Identifying 
information 
 
Baby DOB Infant date of 
birth 
Identifying 
information 
 
ADMIT_DT Infant admit 
date 
Identifying 
information 
 
YEAR Year of 
Admission 
2011-2017 2011, 2012, 
2013, 2014, 
2015, 2016, 
2017 
BABY DX 1 Infant 
diagnosis 
related to 
maternal drug 
use 
Intrauterine opioid 
exposure; 
maternal drug 
abuse; 
intrauterine drug 
exposure 
ICD 9; 10 codes 
search criteria 
BABY DX 2 Infant 
diagnosis 
related to 
withdrawal 
symptoms 
Neonatal 
abstinence 
syndrome; 
neonatal drug 
withdrawal; 
newborn affected 
by maternal drug 
use 
ICD 9; 10 codes 
search criteria 
BABY OTHER DX (r) Other infant 
health 
complications 
Other health 
complications 
including 
prematurity; 
respiratory (RDS, 
TTNB, Mec 
Aspiration, 
PPHN); 
congenital 
anomalies (cleft 
lip and palate, 
1- Prematur
ity 
2- Respirat
ory 
3- Congenit
al Anomalies 
4- Other 
0- None 
 140 
 
undescended 
testes, hearing 
loss); Other ( 
SVT, SGA, 
jaundice, 
perinatal 
asphyxia, 
suspected sepsis) 
BABYOtherHealthY_N Other health 
diagnosis for 
infant  
Yes or no 1- Yes 
2- No 
MOM_AGE Maternal Age number in years # yrs 
Insurer (r) Insurer Medicaid/ 
Private/self-pay 
1-Medicaid  
2-Private  
3-self-pay 
MOM Race (r) Maternal Race Caucasian; Black; 
Hispanic; other 
1=Caus 
2=Black 
3=Hispanic 
4=other 
Marital Marital Status Single; married; 
divorced 
1=single;  
2=married;  
3=divorced 
Gravida Gravida number of 
pregnancies 
# pregnancies 
Para Para Number of live 
births 
# births 
MOM Parity (r) Maternal Parity Primiparous or 
multiparous 
mother 
1- Primip 
2- multip 
MOM DRUG USE DX (r) Source of 
maternal 
opioid use  
Illicit Use; 
Prescription Use 
(Rx); Treatment 
for Opioid 
Dependence (Tx) 
1-illicit  
2-prescription 
3- treatment 
 
MOM DX Type (r) Other health 
care diagnosis 
for mother 
None or 
Behavioral 
Health: Bipolar, 
depression, 
schizophrenia, 
anxiety, PTSD; 
1-Behavioral 
Health 
2-Chronic Pain 
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Chronic Pain: 
Trauma, motor 
vehicle accident, 
fibromyalgia; 
Neurological: 
brain tumor; 
seizure disorder; 
Metabolic: 
hypothyroidism, 
diabetes; Other: 
HTN, asthma, 
Hep C positive 
3-Neurological 
4-Metabolic 
5- other 
0- None 
MOMTOBACCO Maternal use 
of tobacco 
during 
pregnancy per 
prenatal 
records 
Never; Yes; No; 
Quit during 
pregnancy 
1-never, 2-quit, -
3-yes, 4-no 
3TOBACCOYN (r) Maternal Use 
during 
pregnancy  
Yes or No 1-Yes  
2-No 
MOM Primary Opioid (r) Maternal 
Opioid most 
used 
Methadone; 
buprenorphine; 
heroin; other 
opioid analgesics 
(hydrocodone, 
oxycodone, 
codeine, 
tramadol, 
morphine);  
opiate not 
specified 
(toxicology 
screen) 
Coding by 
Group  
1-methadone  
2-buprenorphine  
3-heroin  
4- Other 
opioid anlagesic  
5- Opiate 
unspecified 
(toxicology 
screen) 
 
MOM other opioid Any other 
occasional 
maternal 
opioids used  
Including 
Methadone; 
buprenorphine; 
codeine, other 
opioid analgesics 
(hydrocodone, 
oxycodone, 
tramadol);  
Morphine; heroin; 
opiate not 
specified 
(toxicology 
Text string list of 
opioids 
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screen) 
MOM other opioidYNr Additional 
opioids used 
either by 
maternal 
history or 
toxicology 
screen 
Including 
Methadone; 
buprenorphine; 
codeine, other 
opioid analgesics 
(hydrocodone, 
oxycodone, 
tramadol);  
Morphine; heroin; 
opiate not 
specified 
(toxicology 
screen) 
1-yes 
2-no 
MOM other drugs (#1 and 
#2) 
Other maternal 
drugs taken 
during 
pregnancy 
Barbiturate; 
benzodiazepine; 
SSRI; Stimulants 
( cocaine, 
methamphetamin
e, amphetamine), 
THC, other 
(labetalol, proton 
pump inhibitors, 
muscle relaxants, 
anti=convulsants) 
List of drugs/ 
medication 
MOMDrugTyper2 Other drug by 
class 
Barbiturate, 
benzodiazepine, 
SSRI, stimulants, 
THC, other 
1-Barbiturate;  
2-
benzodiazepine; 
3-SSRI; 
4-Stimulants 
5- THC  
6-other 
0-None 
MOMBenzoY_N Benzodiazepin
e use by 
maternal hx or 
by urine 
toxicology 
screen 
Yes or no 1 Yes 
2 No 
BABY_GA Infant’s 
gestational 
age at delivery 
in completed 
weeks 
Gestational age in 
weeks 
# for GA 
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BABY SEX Infant’s sex male, female 1- male 
2-female  
BABY WEIGHT KG Infant’s weight 
at birth 
Weight in 
kilograms 
# kg 
PEAK FINNEGAN SCORE Highest 
Finnegan 
score recorded 
Score in whole 
numbers 1-22 
# score 
Morphine Y/N Infant 
Treatment with 
oral morphine 
solution 
Morphine solution 
started for the 
treatment of NAS 
symptoms 
1- Yes 
2- No 
MS Peak/ KG Highest dose 
of morphine 
solution in mg 
per Kg 
# in mg/kg/dose # in mg/kg/dose 
MS Peak MG/dose Highest dose 
of morphine 
solution in mg 
per dose 
# mg/dose # mg/dose 
MS Peak MG/Day Highest dose 
of morphine 
solution in mg 
per day 
# total mg/day # total mg/day 
Addtl TX Meds #1- #2 Additional 
infants 
medications 
used for 
treatment of 
withdrawal 
None, 
Phenobarbital, 
clonidine, Ativan 
0-None 
1-Phenobarb 
2 Clonidine 
3- Ativan 
Addtl TX MedsY_N Additional 
infants 
medications 
used for 
treatment of 
withdrawal 
Given yes or no 0-No 
1-Yes 
 
Infant_Meds1 
 
Additional 
infant 
medications 
for treatment 
of other 
diagnosis 
List other 
medications not 
related to NAS 
treatment 
 
Infant_Meds 2 Additional 
infant 
medications 
for treatment 
of other 
diagnosis 
List other 
medications not 
related to NAS 
treatment 
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Infant_MedsR 
 
Additional 
infant 
medications 
for treatment 
of other 
diagnosis 
Other 
medications not 
related to NAS 
treatment yes or 
no 
1- Yes 
2-No 
FDG (r) Infant feeding 
methods 
Exclusive breast 
feeding; formula 
feeding; 
combination of 
breast and 
formula feeding 
1- Breast 
2- formula 
3-breast/formula 
NON-MED COMFORT Use of non-
medication 
comfort 
measures  
Use of non-
medication 
comfort measures 
including 
swaddling, low 
light, low 
stimulation, 
rocking bed, 
pacifier 
1- Yes 
2- No 
Transfer Infant born at 
facility or 
transferred in 
Yes (outborn 
transferred); No 
(inborn) 
1- Yes 
2- no 
 
NBN LOS (HRS) Length of stay 
in newborn 
nursery by 
hours 
Number of hours 
in NBN 
# in hours 
PEDIATRICS LOS (HRS) Length of stay 
on pediatric 
unit in hours 
Number of hours 
on pediatric unit 
# in hours 
PEDS/NBN LOS (Days) Length of stay 
in newborn 
nursery and 
Pediatric unit 
in days 
Number of days 
on newborn 
nursery and 
pediatrics 
combined 
# in days 
NICU LOS (HRS) Length of stay 
in neonatal 
intensive care 
unit in hours 
Number of hours 
on NICU 
# in hours 
NICU LOS 1 (DAYS) Length of stay 
in neonatal 
intensive care 
unit 1st 
admission in 
days 
Number of days 
in NICU on 1st 
admission 
# in days 
NICU LOS 2 (DAYS) Length of stay 
in neonatal 
intensive care 
Number of days 
in NICU on 2nd 
admission 
# in days 
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unit 1st 
admission in 
days 
NICU Total (Days) Total length of 
stay in 
neonatal 
intensive care 
unit in days 
Number of days 
in NICU 
combined 1st and 
2nd admission 
# in days 
HOSPITAL LOS (HRS) Total hospital 
length of stay 
in hours 
Number in hours 
of hospital stay 
# in hours 
HOSPITAL LOS (DAYS) Total hospital 
length of stay 
in days 
Number in days 
of hospital stay 
# in days 
@# OF DAYS MOM AT 
BEDSIDE 
Number of 
days during 
stay mother 
was present at 
bedside 
Number in days 
mother was 
recorded at 
bedside 
# in days 
MOMSTAY Percentage of 
total stay 
mother was 
present at 
bedside 
Amount of time 
mother was at 
beside as a 
percent of the 
total hospital stay 
% of days 
MOMSTAYr Proportion of 
total Hospital 
Stay Mom was 
recorded at 
bedside 
Fraction of 
hospital stay 
mother was at 
bedside 
 
 #Days Mom at 
bedside/ 
#Hospital LOS in 
days 
Provider #1 Days with 
attending 
physician- 
Durbin 
Number of days 
attending was 
physician 1 
# of days 
Provider #2 Days with 
attending 
physician- 
Guilfoy 
Number of days 
attending was 
physician 2 
# of days 
Provider #3 Days with 
attending 
physician- 
Winchester 
Number of days 
attending was 
physician 3 
# of days 
OTHER MD Days with 
attending 
physician- 
Other 
Number of days 
attending was 
physician 4 
# of days 
Hospital Cost $ Cost of 
hospital stay 
for this 
admission, 
Cost of hospital 
stay in dollars 
# in dollars 
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hospital billing 
only (does not 
include fees 
for 
professional 
services) 
Calculated Hospital Cost Calculated 
cost of hospital 
stay in dollars 
Cost of hospital 
stay for this 
admission, 
calculated from 
identified patients 
(actual cost) and 
de-identified 
patients cost 
(average cost for 
diagnosis of NAS 
in newborn 
nursery, NICU, 
and pediatric 
ward) 
# in dollars 
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